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Abstract

Human immunodeficiency syndrome (HIV-1) has infected over 75 million people and over 35
million have succumbed to virus related illnesses. Despite access to a variety of antiretroviral
therapy (ART) options, ART programs have been disproportionally spread in the world with lowand middle-income countries (LMICs) facing challenges to access the most potent ART options.
With less potent ART remaining in use in LMICs, HIV-1 drug resistance (HIVDR) presents a
growing challenge in LMICs. Since approval of the first-generation integrase strand transfer
inhibitor (INSTIs), Raltegravir (RAL) in 2007, INSTIs remain the best choice as a backbone of
ART. Access to second generation INSTIs, Dolutegravir (DTG) and bictegravir (BIC) in LMICs
is based on need and not on a full evaluation of the effectiveness of these treatments in patients
infected with non-B HIV-1 subtypes. To address this challenge of limited INSTIs associated
HIVDR data in non-B HIV subtypes, we first screened for the presence of INSTIs associated drug
resistance mutations (DRMs) in ART naïve and experienced patients in Uganda using Sanger and
Illumina sequencing. In Uganda, 47% of patients failing on RAL carry resistance to RAL-and
elvitegravir (EVG), and only 4% harbor resistant virus to DTG. A panel of recombinant viruses
from patient-derived HIV-1 integrases carrying resistant mutations was created and tested for
susceptibility to a panel of INSTIs: EVG, RAL, DTG, BIC, and CAB. The virus carrying N155H
or Y143R/S was susceptible to DTG, BIC, and CAB but highly resistant to RAL and EVG (>50fold change). Two patients, one with E138A/G140A/Q148R/G163R and one with
E138K/G140A/S147G/Q148K, displayed the highest reported resistance to RAL, EVG (FC,
>1000) and even DTG (FC, >100), BIC (FC, 60->100), and CAB (FC, 429->1000). All viruses
had impaired replication fitness and <50% reduction in integration capacity. We further
determined potential novel polymorphisms associated with INSTI resistance in HIV-1 subtype A
and D using simple vector machine analysis. The identified I208L and I203M, did not show
reduced susceptibility to RAL or DTG with 1.3-1.8-fold and 1-1.4-fold observed, respectively.
Further investigation is required to determine how these novel mutations influence susceptibility
to INSTIs in HIV-1 subtype A and D infected patients.
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Summary for Lay Audience
Human immunodeficiency syndrome virus type 1 (HIV-1) is the causative agent for Acquired
immunodeficiency syndrome (AIDS) which is characterized by rapid depletion of CD4+ T cells
which eventually results in emergence of opportunistic infections. HIV-1 like other retroviruses,
hijack host DNA machinery to be able to replicate and cause havoc in the infected individual.
Because of high replication rate and numerous errors during replication, there are diverse strains
of HIV-1 circulating in world population which are commonly referred to as subtypes, circulating
recombinant forms, and unique recombinant forms. The non-B HIV-1 subtypes are predominantly
in low- and middle-income countries (LMICs) and account for up to ~ 90% of HIV-1 infections.
The antiretroviral therapy (ART) has tremendously improved the lives of individuals infected with
HIV-1 and discovery of an even more potent class of ART, the integrase strand transfer inhibitors
(INSTIs) has further improved HIV-1 treatment outcomes. Despite these advances, research of
HIV-1 drug resistance associated with INSTIs has historically been done in HIV-1 subtype B virus
which is predominant in high-income countries. With improved access to INSTIs by HIV-1
patients in LMICs, there is urgent need to assess susceptibility of HIV-1 non-B strains to INSTIs
and also discover novel potential pathways to resistance in these strains. From a cohort of HIV-1
infected patients in Uganda, we show that prolonged virological failure on INSTI, raltegravir, leads
to accumulation of drug resistance mutations which confer resistance to all currently available
INSTIs. Novel mutations in the HIV-1 integrase gene which show no impact on INSTIs
susceptibility by themselves, may act as secondary mutations to other drug resistance mutations
outside HIV-1 integrase gene which merits further investigation.
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Chapter 1

1 Introduction
1.1

HIV-1

The human immunodeficiency virus type 1 (HIV-1) belongs to a subgroup of retroviruses which
infects humans and was first recognized in 1981 among a group of homosexual mean in the US
(1,2). In 1982, a resident doctor in the East African country of Uganda started seeing patients
with major clinical manifestations of severe weight loss and diarrhea among heterosexual
individuals (3). This was a kick start for global awareness campaigns of a strange new disease
called GRID (gay-related immunodeficiency disease) in the US and SLIM disease in East Africa
(Slim being related to emaciation of immunodeficient patients). HIV-1 was later discovered (1983)
as the causative agent for Acquired Immunodeficiency syndrome (AIDS) (formerly GRID and
SLIM) (4–6) which is characterized by severe depletion of CD4+ T cells leading to susceptibility
to numerous opportunistic infections and cancers (7–9). If left untreated, the average time of
survival is about 9-10 years depending on the virulence of infecting HIV-1 strain. The current
literature indicates that HIV-1 was introduced into humans between 1920-1940 (10). Based on
phylogenetic analysis, HIV-1 is classified as HIV-1 based on the zoonotic transmission to humans
from simian immunodeficiency virus (SIV) from chimpanzee (SIVcpz) and gorilla (SIVgor) in
West Central Africa, and HIV-2, based on the transmission from West Africa sooty mangabeys
(Cercocebus atys, SIVsmm) (11,12). HIV-1 was first isolated in 1983 and HIV-2 in 1986, and both
spread and diversified exponentially to create numerous subtypes that are circulating today.

1.2

HIV-1 particle and genome

HIV-1 is roughly spherical with a diameter of ~100nm-150nm and two identical single strands of
RNA enclosed in the viral core (Fig. 1). HIV-1 has a total of 15 proteins from three major open
reading frames, gag, pol, and envelope. The outer membrane proteins are translated from env open
reading frame and they include highly glycosylated surface protein (SU, gp120) and
transmembrane (TM, gp41) glycoproteins for attachment and fusing to host cell. From outside to
inside, there is outer core membrane matrix (p17, MA) protein, capsid (p24, CA) protein and
1

nucleocapsid (p7, NC) protein that is tightly bound to genomic RNA strands (Fig. 1). Functional
viral enzymes are coded by the pol open reading frame and they include, protease (p12, PR),
reverse transcriptase (p66, RT), RNase H (the C-terminal p15 of RT p66) and integrase (p32, IN).
Rev (RNA splicing regulator), and Tat (transactivator protein), act as regulatory proteins
controlling RNA transcription and metabolism. Accessory genes, Vpu (viral protein unique), Vif
(viral infectivity factor), Vpr (viral protein r), and Nef (negative regulatory factor), play critical
roles in viral pathogenesis, replication and budding of the virus among a host of other regulatory
functions during HIV-1 lifecycle or to avoid host restriction factors (13,14). The genomic RNA is
flanked on both ends by identical long terminal repeats (LTRs) sequences with 5' LTR acting as
promoter site and 3′ LTR having polyadenylation signal. HIV-1 and HIV-2 have similar genome
structure except that Vpx is encoded in HIV-2 in place of Vpu found in HIV-1 (15).

Figure 1. HIV-1 particle. At the center of HIV-1 mature virion, there are two copies of viral RNA
tightly associated with nucleocapsid protein and copies of reverse transcriptase and integrase viral
enzymes. These are encapsulated in cone-shaped capsid protein which is also surrounded by
protease enzyme and matrix protein. The outer membrane consists of host-derived cell membrane
and includes transmembrane glycoprotein (gp41) which anchors surface glycoprotein (gp120).

2

1.2.1

Structural proteins

Gag is expressed in the form of a 55-kDa precursor, Pr55Gag and is the major structural component
of HIV-1. The Pr55Gag polyprotein is cleaved by HIV-1 protease to structural proteins p17 matrix
(MA), p24 capsid (CA), p7 nucleocapsid (NC), spacer protein1, spacer protein 2, and p6 proteins
(16,17) (Fig. 2).
CA (p24) is a cone-shaped protein which surrounds the two strands of viral genome and viral
proteins. It is mainly involved in maturation of virions and virus assembly processes. CA is made
of two domains, N-terminal core domain (NTD, 1-145) and C-terminal dimerization domain
(CTD, 151-231). The NTD is highly helical due to secondary structure of 7 alpha helices and 2 βhairpin, in addition to exposed loop which acts as binding site for cyclophilin A (18). Whereas,
NTD is implicated in maturation of virions and incorporation of cyclophilin A into the virion, CTD
has been shown to be involved in recruitment of Gag-pol (Pr160gag-pol) precursor which eventually
facilitate incorporation of viral proteins IN, RT and PR (19). The CTD is also involved in Gag
oligomerization (20,21). Despite NTD being a core domain for CA, induced mutations in this
domain generally have no effect on HIV-1 virion production, whereas mutations in CTD cause
significant loss of virion particle assembly and release by proviral DNAs (22).
NC (p7) is typically bound to genomic RNA in the HIV-1 particle core. It contains two zinc fingerlike motifs (Cysteine-Histidine boxes) which are highly conserved in retroviruses and each box
coordinates a zinc ion. p7 is involved in packaging of genomic RNA and segments of the protein
may facilitate assembly and release of viral capsid particles (23).
MA (p17) is a protein of 128 amino acids made up of 5-α helices and mixed β-sheet. It forms the
N-terminal end of Pr55Gag precursor protein. MA forms a core domain of mainly α -helices and
three-stranded β-sheet while the C-terminus of the protein comprises an α-helix that connects MA
and CA. The protein plays a critical role in intracellular targeting of polyproteins (24) including
targeting Gag precursor to the site of viral assembly on the plasma membrane, and incorporation
of Env glycoprotein into the virions. MA also targets the preintegration complex (PIC) to the
nucleus by providing a nuclear localisation signal.

3

HIV-1 p1 also known as spacer peptide 2 (sp2) is a protein derived from cleavage of Pr55Gag and
is located at C-terminus of Gag between NC and p6 (Fig. 2). It is made up of 16 amino acids with
two highly conserved proline residues, Pro-439 and Pro-445 and substitution to leucine decreases
infectivity and reduces stability of RNA (25). It is crucial for Gag and Pol incorporation into virus
particles (26).
HIV-1 p2, also known as spacer peptide 1 (sp1), is a 14 amino acid peptide that is found between
the CTD of CA and NTD of NC proteins (Fig. 2). p2 plays a significant role in CA assembly and
HIV-1 infectivity (27–29). Deletion of p2 results in decreased ordered assembly and infectivity
which results in “bent” core structures in virus particles produced. (27–29). Gag constructs lacking
p2 are only able to form tubular and conical shapes but not spherical viral particles (30).
Ribonucleoprotein formation of genomic RNA and condensation of CA core has been shown to
be influenced by proteolytic processing of p2 from NC. CA-p2 cleavage during late viral
processing enables CA shape by modulating CA-CA interactions.
HIV-1 p6 is a 52 amino acid protein that is important in formation of infectious viruses and could
be categorized as regulatory versus structural protein. P6 aids the process of HIV-1 particle
maturation by incorporation of Vpr into virus particles (31) and supports budding off of HIV-1
virion from host cell membrane (32). It has been shown to interact with Vpr and cyclophilin A
(33). HIV-1 p6 is also involved in regulation of CA processing and virus core (34), and MHCclass 1 presentation of Gag (35).

4

Figure 2. HIV-1 genome structural organization. HIV-1 is made up of 9719 base pairs in total
with three major open reading frames of gag, pol, and env. HIV-1 genome is franked with similar
sequences in 5′ long terminal repeat and 3′ long terminal repeat regions which are important for
regulatory functions such as transcription and polyadenylation.
Pol: The proteolytic processing of Pr160gag-pol polyprotein by HIV-1 protease yields structural
proteins, MA, CA and Pol and catalytic enzymes RT, PR, RNase H, and IN (36,37) (Fig. 2 and 3).
Gag-Pol precursor is a product of fusion of Gag and Pol polyproteins from -1 translational
frameshift which happens at UUA leucine codon near 5′ end of overlap region between Gag and
Pol. The ribosomal frameshift signal consists of “slippery” sequence U UUU UUA and upstream
ACAA tetraloop and this ensures 5% of -1 Pol open reading frame and 95% Gag alone products
(38,39).
Reverse transcriptase: The mature form of HIV-1-RT is an asymmetric heterodimer enzyme
containing a 66 and 51 kDa protein produced and possibly self assembled following the cleavage
of gag-pol polyprotein by HIV-1 protease during virion maturation. In each HIV-1 particle, there
are about 50 p66/p51 RT molecules (40). Only one (p66) of two subunits contains a functional
polymerase and RNase H domains (41). Despite sequence homology between the p66 and p51
subunits, polymerase has a different structure between the two subdomains with p66 forming a
large active-site cleft and p51 exhibiting an inactive closed morphology. The p66 polymerase
active site has a catalytic amino acid triad (Asp 110, Asp 185 and Asp 186) in the “palm”
subdomain, which is similar and conserved in many reverse transcriptase enzymes and other RNA
polymerases (41–43). When RT binds to a primer-template nucleic acid duplex the catalytic triad
in palm is positioned “over” the 3′-OH of the primer terminus and catalyzes the nucleophilic attack
on the incoming nucleoside triphosphate releasing a diphosphate and forming a covalent bond with
5

primer terminus and this new nucleoside monophosphate. As such p66 is involved in catalytic
activities and p51 in structural roles of HIV-1-RT (41,43). HIV-1 RT catalyses reverse
transcription of genomic RNA. The C-terminus of the p66 subunit of RT forms RNase H domain
(441-560) which degrades the RNA genome except for the PPTs (44). The full process of HIV-1
reverse transcription is described in section 1.3.3.
Protease is a 99 amino acid aspartyl protease which cleaves the Gag and Gag-Pol precursors
during viral assembly to form structural and functional enzymes (45) (Fig. 3). The initial
processing is initiated by activated protease releasing itself from Gag-Pol precursor (46). It then
cleaves Gag-pol and Gag polyproteins into functional enzymes, RT, PR, IN and structural proteins,
matrix (MA), capsid (CA), nucleocapsid (NC), and proteins p1, p2 and p6 (45). It is only functional
as a dimer with only one active site which consists of two identical subunits with a two-fold (C2)
symmetry.
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Figure 3. HIV-1 Pr55Gag and Pr160gag-pol polyprotein cleavage by HIV-1 PR. The polyproteins
Pr55Gag and Pr160gag-pol from transcription of provirus are cleaved by HIV-1 PR enzyme late during
assembly and maturation of new virions. Pr55Gag is proteolytically cleaved by HIV-1 PR in orderly
manner with first cleavage happening between p2 and NC followed by MA and CA then p1 and
p6, NC and p1, and finally CA gets cleaved from p2. Pr160gag-pol polyprotein from ribosomal
frameshift contains region with transframe locus which encodes p6 and a transframe protein
covalently linked to N-terminus of HIV-1 PR. Pr160gag-pol gets cleaved into gag structural proteins
of MA, CA, P2, NC, P6 and pol proteins, PR, RTp51, RTp15 and IN.
Integrase: HIV-1 integrase (HIV-1 IN) is a 32 kDa protein produced from gag-pol polyprotein
cleavage by HIV-1 protease gene and about 40-100 integrase molecules are packaged in each HIV1 virion. HIV-1 IN is involved in a number of viral steps of reverse transcription (47), nuclear
import of PIC (48,49), and integration of cDNA into host chromosome (50). The process of HIV1 integration into host chromatin is a two-step process of 3' processing and subsequent strand
transfer process both mediated by HIV-1 IN. In 3' processing, HIV-1 IN dimer binds to each end
of the newly synthesized linear viral DNA (vDNA) and cleaves the two nucleotides (GT) from
each 3′ end which leaves conserved CA dinucleotide at terminus and exposes hydroxyl group
(CAOH) (51,52). The cleaved vDNA is a component of the PIC that translocates into the nucleus
for subsequent strand transfer process. Details of this HIV-1 integrations process are described in
sections 1.3.4, 1.3.5 and 1.3.6.
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HIV-1 IN is composed of 288 amino acids and 3 domains, NTD (NH2-) (1-49), catalytic core
domain (50-212)-CCD, and CTD (213-288) (COOH-) (53) (Fig. 4). HIV-1 IN is relatively
conserved compared to RT and PR HIV-1 enzymes, with well-defined cytotoxic T lymphocyte
epitopes of n=11, compared to PR, n=7 and RT, n=41 (54). All the three domains of HIV-1 IN are
required for 3′ processing and strand transfer processes (55,56). However, disintegration can solely
be carried out by CCD (56,57). When strand transfer product is added to a protein mixture of
mutated NTD and mutated CTD both with active site, it was shown that 3′ processing and strand
transfer only occur after complementation with a protein with active site mutants which shows that
HIV-1 IN functions as a multimer (58). In solution, HIV-1 IN forms dimers (59–62) and tetramers
(61,62), and each domain taken separately can also form dimers: the same CCD+CTD and
CCD+NTD. The active form of HIV-1 IN during integration is shown to be a tetramer upon
interaction with the 3′ and 5′ ends of vDNA (63,64) (Fig. 4).

Figure 4. The intasome complex of HIV-1 IN, vDNA and target DNA. The active form of HIV1 IN when bound to 5′ and 3′ ends of vDNA is a tetramer as shown by four HIV-1 IN monomers
colored (sky blue, limon, cyan, and pink). The vDNA is depicted in orange and target DNA, hot
pink. The image was generated using Pymol from cryo-electron microscopy structure (PDB ID,
5U1C) (65).
8

The NTD structure has been solved for both HIV-1 and HIV-2 using nuclear magnetic resonance
spectroscopy and it shows a domain with a bundle of 3 α-helices that are stabilised by Zn2+ (66,67).
The isolated NTD is folded and only becomes a dimer when zinc ions are present (66,67). The
NTD of HIV-1 like all other retroviruses has a pair of highly conserved His and Cys residues (HHCC) that forms a zinc finger (68). Despite having a different structure than the canonical zinc
fingers, the HH-CC motif of HIV-1 IN binds zinc (69,70) which allows NTD folding,
multimerization, and enhancement of enzymatic catalytic activity (70). There is less effect on
disintegration and impairment of 3′ processing and DNA joining by mutations induced in HH-CC
motif of NTD (60,71–74). Mutations in HH-CC motif reduce ability of HIV-1 IN to bind zinc (57).
However, integrase lacking HH-CC motif are still able to recognise the CA/GT at the end of viral
DNA but cannot catalyze the 3′ processing activity (60).
The crystal structure of CCD shows a α/β structure consisting of a 5-stranded β-sheet and 6-α
helices numbered 1-6 (Fig. 5). The α4 contains residues Y143 and Q148 which directly bind
terminal ends of vDNA (75). Between α5 and α6, there is a flexible finger-like loop of glycine
rich sequence of about 12 residues (F185-A196) in HIV-1 (Fig. 5). The loop is stabilised by
connections for example a salt bridge between R187 and E198 in HIV-1 has been shown to support
enzymatic activity, conformational structure rearrangement of IN on binding DNA, nuclear
localisation, stabilising tetramerization, and viral infectivity. The CCD domain is relatively
resistant to proteolysis (71) and binds ends of vDNA via residue Q148. The Q148 lies within a
flexible loop of residues 140GIPYNPQSQG149 that is disordered in most integrase crystal structures
but suggested to become ordered upon DNA binding and is involved in stabilising the 5′-end of
vDNA (75,76). The interaction between Q148 residue and 5′-C at the end of vDNA enables
efficient strand-transfer process by HIV-1 IN (77). The domain has a highly conserved motif of
acidic residues, D64, D116, and E152 (D,D-35-E) motif present in all retroviral integrases and
transposases. This motif embedded in a RNase H fold protein is used to bind metallic cationic
cofactors in all retroviruses, retrotransposon integrase proteins, and some prokaryotic transposases
(71,74,78,79), and they are in a similar position in ribonuclease H (76). The D,D-35-E enables
enzymatic activity by binding to at least one divalent metal cofactor Mg2+ or Mn2+ (80–83) and is
also implicated in nuclear import (48,84). Within the CCD, the active site is contained within
amino acids 50-212, as evident from recombinant peptide encoding this segment being sufficient
to promote disintegration and introducing even conservative mutations at any of the catalytic D64,
9

D116, and E152 residues results in abrogation of catalytic activity (71,73,74). Despite CCD
containing the catalytic site for the enzyme, NTD and CTD are indispensable for 3′ processing and
strand transfer processes (85). In CCD, a 13-amino acid sequence

161

IIGQVRDQAEHLK173

located outside the catalytic triad motif but around a surface exposed loop connecting α4 and α5
helices has been shown to have karyophilic property (86).

Figure 5. The structural organization of HIV-1 integrase. A) The N-terminal domain consists
of 3α-helices with a zinc finger-like motif of 2-His and 2-Cys amino acids for coordinating zinc
ions. The catalytic core domain is made up of 6 α-helices and 5-stranded β-sheet with highly
conserved residues D16, D116 and E152 for coordinating magnesium ions required for catalytic
activity of the enzyme. The C-terminal domain is least conserved with an SH3-fold structure. B)
The crystal structure of HIV-1 IN for antiretroviral therapy naïve patient sample ‘GS221’ was
predicted using template d1wfa (99.9% confidence) for NTD, d1c6vx (100% confidence) for CTD
and d1hyva (100% confidence) for CCD in PHYR2 (87). The α-helices are shown in green, β
strands in magenta, the finger-like loop between α5 and α6 of CCD is shown in orange and divalent
metal coordinating residues of NTD and CCD shown in blue. The structures were visualized and
analyzed in UCSF Chimera (88).
The CTD is least conserved among all retroviral integrases and binds DNA non-specifically. Based
on NMR spectroscopy, the solution structure of CTD domain forms a homodimer of five β-strands
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which make two antiparallel β sheets (68,89). The overall folding topology of CTD is closely
similar to that of Src-homology 3 (SH3-fold) (68,89,90); though there have been variations in CTD
interfaces in IN crystal structures containing CTD domain (91). When CTD is joined to CCD, it
forms a monomeric structure (91). The structure of full-length HIV-1 IN with all three domains
has been elusive due to the natural tendency to form large aggregates under test conditions. But
the structure of double domains of CTD/CCD for HIV-1, SIV and RSV (91–93), and NTD/CCD
has been solved. Sequence fragment of minimal region of CTD (220-270) is adequate for DNA
binding (94) and residues between 245-270 make interactions with bases A (4) and T (5) of vDNA
end (75,95). Mutation of CTD basic residue K264 in HIV-1 results in a significant decrease in
DNA binding and catalytic activity (94). Mutating residues Leu 241 and Leu 242 to alanine impairs
dimerization which significantly decrease catalysis activity (96). CTD may be critical in stabilising
interaction of HIV-1 IN and vDNA by aligning DNA to fit in position that allows proper binding
of viral terminal ends. In support of this observation, CTD is involved in 3’ processing but not in
disintegration process (97). CTD also provides a karyophilic property of IN by having a bipartite
NLS of amino acids 211 KELQKQITK219 and 261PRRKAK266 which are recognised by karyopherinα (48). To function properly, HIV-1 IN associates with a number of cellular proteins which act as
catalytic cofactors for integration processes. High mobility group protein A1 (HMGA1) and barrier
to autointegration factor (BAF) appear to directly interact with DNA substrate whereas, lens
epithelium-derived growth factor/transcription coactivator p75 (LEDGF/p75), EED and HSP have
been shown to directly interact with HIV-1 IN.
Env: HIV-1 env gene is about 2.5 kb and is translated into 850 amino acids. HIV-1 env is first
produced as precursor glycoprotein gp160 that undergoes a number of stages during its maturation
including, formation of disulfide bonds, extensive glycosylation, cleavage by furin-like proteases,
transport to cell membrane, and package into HIV-1 particle (98). Gp160 undergoes glycosylation
in the endoplasmic reticulum and subsequently gets cleaved by cellular furin-protease in golgi
apparatus, producing surface glycoprotein gp120 (~ 480 amino acids) and transmembrane
glycoprotein gp41 (~ 345 amino acids). Gp120 has five conserved domains (C1, C2, C3, C4 and
C5) and five variable domains (V1, V2, V3, V4, and V5). HIV-1 gp41 consists of seven domains,
N-terminal fusion peptide, heptad repeat 1 (HR1), disulfide loop, HR2, membrane proximal
ectodomain region, transmembrane and cytoplasmic tail (99). A trimer of heterodimers from three
gp120s and gp41s form envelope spike protein (100). During HIV-1 entry, gp120 of envelope
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spike protein that is ~ 50% carbohydrate, recognises and binds to primary receptor CD4 (101)
which induces conformational changes in gp120 and allows recognition of C-C chemokine
receptor type 5 (CCR5) or C-X-C chemokine receptor type 4 (CXCR4) (102). This triggers
conformational change of gp41 which triggers heptad repeats HR1 and HR2 to form a 6-helical
bundle which creates a pore to allow fusion with host cell plasma membrane and delivery of viral
genome into the cytoplasm of host cell (103).

1.2.2

Accessory proteins

HIV-1 Nef: It is a multifunctional 27-kd myristoylated protein that is encoded by a single exon
that extends into the 3’ LTR of primate retroviruses. After packaging in virions, Nef is cleaved by
HIV-1 protease during maturation (104,105). It is the first protein to be produced to sufficient
levels inside an infected cell (106). Although Nef is predominantly localised in the cytoplasm and
associated with the plasma membrane via the myristoyl residue, it has also been found in the
nucleus in some studies. It is implicated in increasing the infectivity of the virus. In early phases
of HIV-1 infection, Nef downregulates CD4 from the cell surface by endocytic pathways involving
clathrin and AP2 (107–109) and eventually degraded in lysosomes (110,111). Downregulation of
CD4 is crucial because accumulation of CD4 on cell surface prevents Env incorporation and
budding (112,113). Nef is also implicated in downregulation of MHC-1 molecules from cell
surface by rapid internalisation and degradation in endosomal vesicles (114), which inhibits lysis
by cytotoxic CD8+ T cells and for viral spread and disease progression in vivo. Defective Nef has
been observed in HIV-1-infected long term progressors, (115) indicating its role in maintaining
high viral loads in infected individuals. Nef increases viral infectivity in both lymphocytes and
macrophages (116) and relative infectivity of virus particles in Nef (+) compared to Nef depleted
virus has been shown to be 3-to10-fold higher (117).
HIV-1 Vpu: viral protein U, is a 16-kDa of 81-amino acid that is expressed late in HIV-1 life
cycle and is coded by an open reading frame between the first exon of tat and env genes (118,119).
Vpu is a product of Rev-dependent bicistronic mRNA which also encodes env showing their
coordination in HIV-1 infection (120). Vpu is unique to HIV-1, and its closest homologs are in
SIV from chimpanzee (SIVcpx) and SIV from rhesus mona monkeys (Cercopithecus mona;
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SIVmon), SIV from greater spot-nosed monkey (Cercopithecus nictitans; SIVgsn), SIV from
mustached

monkey

(Cercopithecus

cephus;

SIVmus),

SIV

from

Dent’s

mona

monkey(Cercopithecus mona denti; SIVden) and SIV from gorilla (Cercopithecus Gorilla gorilla;
SIVgor) (121–126). There is no similar protein in either HIV-2 nor other related SIVs, SIV from
sooty mangabey (SIVsmm) and SIV from rhesus macaques (SIVmac) (118,119). It is implicated
in degradation of CD4 molecules by mediating the proteasomal degradation of newly synthesized
CD4 molecules in endoplasmic reticulum (127). It also enhances virion release from plasma
membrane of HIV-1 infected cells (119,128) by antagonizing interferon-regulated host restriction
factor-tetherin which directly cross links virions on host cell surface (129–131) .
HIV-1 Vpr: the viral protein R (Vpr) is a 14-kDa protein of 96-amino acid that is incorporated
into the virion with around 100 copies of Vpr copies present in each virion (132). The incorporation
of Vpr in virions is mediated by specific interaction with carboxyl-terminal region of Pr55Gag (133).
Vpr is involved in binding of PIC to importins and nucleoporins to promote nuclear import of
HIV-1 into non-diving cells (134,135), and activation of HIV-1 LTR through binding to sp1 (136)
or primarily through sequences of -278 to -176 of HIV-1 LTR (137). Vpr is also involved in
preventing infected cells from passing through mitosis by arresting them in G2 phase (G2 cell
arrest) through interactions with a DDB1 and Cullin4A-containing ubiquitin ligase complex (138–
142) and direct and indirect promotion of T-cell dysfunction. Vpr induces T-cell apoptosis through
inhibition of NF-kB activity (143), but it is also involved in inducing the NF-kB activity by
phosphorylation and degradation of IkB (144). In HIV-2, G2 cell arrest is still carried out by Vpr
and protein Vpx (close sequence homology to Vpr) is involved in PIC nuclear import (145,146).
Interaction of Vpr with cellular Uracil-DNA glycosylase, a protein implicated in DNA repair
process (removes uracil from synthesized DNA) influences in vivo mutation rate (147).
HIV-1 Vif: Viral infectivity factor is a 23 kDa protein that is incorporated in virions (148) and
exists in both membrane-associated and soluble cytosolic forms. Vif is required during late stage
of infection and promotes viral infectivity by 10-1000 fold (149–152). Vif protein also antagonizes
the activity of Apolipoprotein B mRNA Editing Enzyme Catalytic Subunit 3G (APOBEC3G)
enzyme which redirects it by ubiquitination to degradation in the proteasome (153–155) through
recruitment of Cullin CUL5, elongins B and C, and Rbx1 to form ubiquitin ligase complex which
induces APOBEC3G degradation (156).
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1.2.3

Regulatory proteins

HIV-1 Rev: is a 19 kDa protein made up of 116 amino acids that is critical for regulation of HIV1 protein expression. It is a product of completely spliced mRNA transcript. It functions as a
tetramer and a nuclear localisation signal encoded by the protein allows its localisation in the
nucleus. Rev sequence has an arginine-rich sequence on amino-terminal domain which acts as a
nuclear localisation signal (157–160) and RNA-binding domain (157,161–165). The flanking
sequences on both sides are required for multimerization (163–165). The leucine-rich carboxyl
terminal domain of Rev (158,164,166) exhibits nuclear export signals (167–169). It is involved in
nuclear export of intron-containing ∼ 9 kb-unspliced (Gag and pol) and ∼ 4-kb incompletely
spliced (Env) transcripts into the cytoplasm for translation or packaging into new virions (170–
172). HIV-1 Rev response element (RRE) found in Env region of unspliced and partially spliced
mRNAs is required for Rev function. Rev in the presence of RRE increases levels of both unspliced
(Gag) and partially spliced (Env) mRNAs (173) and decreases the amount of mRNAs targeted for
splicing. In early (Rev independent) stage, ∼ 2-kb mRNA transcripts which encode Tat, Nef, and
Rev proteins accumulate in the cytoplasm, and importation of Rev into the nucleus allows binding
to RRE of ∼ 9 kb and ∼ 4-kb transcripts which enables their nuclear export out of nucleus in late
Rev-dependent stage. In absence of Rev, late genes, Gag, Pol, Env, Vpr, Vpu and Vif are localised
in the nucleus and cannot be translated.
HIV-1 Tat: Reverse transcription of provirus DNA is regulated by HIV-1 trans activator protein,
Tat, which enhances the process of reverse transcription by binding to the cis-acting stem loop
element in the 5’ end of HIV-1 LTR encompassing nucleotides +1 and +59 known as TAR (174).
TAR is made up of the first ~60 nucleotides of nascent RNA transcript 5’ end LTR promoter and
acts as a binding site for Tat and assembly site for a large number of transcriptional elongation
factors. TAR sequence has a region of highly conserved 3-nucleotide pyrimidine bulge that binds
Tat and 6-nucleotide loop for binding positive transcriptional elongation factor P-TEFb (175). The
binding of Tat to TAR region, recruits P-TEFb (cyclin T1/ cyclin dependent kinase 9) to TAR
region. With Tat bound to TAR, pTEFb recruits TATA box binding protein to the promoter region
and CDK9 phosphorylates the C-terminal domain of RNA polymerase II which increases
processivity of RNA polymerase. In absence of Tat, transcription initiates but only short transcripts
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within TAR (between positions +55 and +59) are produced due to early termination by RNA
polymerase II enzyme (176).

1.3

Overview of HIV-1 life cycle

HIV-1 undergoes several steps in a life cycle that only lasts 24-48 hours. Each step is crucial for
effective viral replication and this has allowed the discovery of different antiviral compounds
which target different stages to halt HIV-1 viral replication (Fig. 6). HIV-1 uses a number of viral
and cellular proteins during its replication to produce nine open reading frames which code for 15
proteins. Please note that this review will focus on HIV-1 reverse transcription, protease
processing, and integration which are the primary targets for the current and most effective
antiretrovirals. Other steps in the lifecycle of HIV-1 are not described in detail.

Figure 6. HIV-1 replication life cycle. 1) HIV-1 surface glycoprotein gp120 binds to host cell
through mainly CD4+ receptor. 2) Fusion with host cell membrane occurs after a change in
conformation of gp120 to expose gp41 transmembrane glycoprotein. 3) HIV-1 core uncoats inside
the cytoplasm to release reverse transcription complex where genomic RNA is reverse transcribed.
15

4) HIV-1 genomic RNA is reverse transcribed by reverse transcriptase enzyme into double
stranded DNA. 5) Dinucleotide ‘GT’ of synthesized viral DNA is cleaved at conserved CA site on
U3 and U5 of 3′ end within the preintegration complex (PIC) by HIV-1 IN. 6) The nuclear
localization signal of PIC components Vpr and matrix allows its importation through nuclear pore
into the cell nucleus. 7) The exposed hydroxyl group on cleaved 3′ ends cut through host DNA
and viral DNA integrates into host chromatin. 8) When infected cell is activated, the provirus acts
as a template for transcription of viral RNAs. 9) Spliced and unspliced viral RNAs are exported
out of nucleus to cytoplasm for translation. 10) Viral proteins and genomic RNA assemble on
plasma membrane. 11) The immature virion buds off cell membrane. 12) HIV-1 virion undergoes
maturation under HIV-1 protease accompanied by structural changes of virion proteins to form a
mature infectious HIV-1 virion.

1.3.1

HIV-1 binding and fusion

The first stage of HIV-1 infection is binding or attachment coordinated by surface envelope
glycoprotein. HIV-1 env is around 400 kDa in size and trimeric in structure (trimers of gp120/gp41
complexes). Through coordinated events, the viral envelope glycoprotein attaches to its primary
cellular CD4+ receptor and subsequently to CXCR4 or CCR5 chemokine co-receptors. HIV-1
receptor CD4+ marker is a member of the immunoglobulin superfamily that is expressed on cells
including helper and regulatory T cells, CD4 T cells, macrophages, monocytes, and dendritic cells
(177). The Van der waal forces and hydrogen bonds stabilise the complex of gp120-CD4 through
interaction between the negatively charged gp120 pocket and positively charged CD4 receptor.
The amino acid Phe 43 on CD4 receptor has been implicated in increasing the binding affinity of
gp120 to CD4 receptor by 23%. The binding of gp120 to CD4 receptor triggers a change in
conformation of gp120 which enables interaction with coreceptors, CCR5 (178) or CXCR4 (179).
HIV-1 tropism is defined by the type of coreceptor usage during infection; CCR5 binding viruses
(M-tropic) (178) CXCR4 (T-tropic) (179) and CCR5-CXCR4 (dual-tropic) (180). It has been
shown that CCR5 mainly expressed on surface of macrophages is preferred during early infection
and CXCR4 is largely preferred during late phase of HIV-1 infection. On binding of gp120 to its
coreceptor CCR5 or CXCR4, triggers conformational change of transmembrane protein gp41.
gp41 consists of fusion protein and N-terminal heptad repeat (HR) 1 and C-terminal HR2 regions.
The fusion protein has hydrophobic glycine-rich residues which facilitate penetration of HIV-1
virion into target cell membrane (181). After binding of gp120 to its coreceptor, fusion protein is
inserted into target cell membrane which triggers interaction between HR1 and HR2 regions to
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form 6-helix structure which leads to formation of a fusion pore through which HIV-1 capsid enters
into cytoplasm of CD4+ cell (181).

1.3.2

Uncoating

After successful viral attachment and fusion, the cone-shaped viral capsid (CA) dissembles in the
cytoplasm during the process of uncoating (182). The CA encompasses genomic RNA, viral and
cellular proteins (50) and around 1500 CA molecules that oligomerize through interactions
between their N-and C-terminals. Despite the timing of uncoating being not properly explained,
the limited presence of CA molecules in the reverse transcription complex indicates early
occurrence of uncoating (182). In support of this view, defects in viral core leads to impaired steps
like reverse transcription (183–185). The viral core stability is critical for the uncoating as it affects
the ability of HIV-1 to infect non-dividing cells (186) and nuclear import of PIC to the nucleus
(187). The IN is among viral proteins facilitating CA uncoating (188). Host factors are also
involved in uncoating of the viral core; TRIM5α impairs the process through increased output of
uncoating (189,190) and recognition of CA lattice by TRIM5α activates innate immune signaling
pathways (191). Cyclophilin A promotes uncoating of viral core (192,193) and interaction between
cyclophilin A and CA leads to specific increase in infectivity in some cell lines (194–196). Host
factors are also known to facilitate the shedding of the CA protein to release the two singlestranded viral RNA copies and accessory proteins inside the cell cytoplasm. Inside the cytoplasm,
the viral single-stranded RNA must undergo reverse transcription to complementary DNA (cDNA)
to facilitate viral replication. The viral reverse transcriptase enzyme and cellular factors are
required for the process of reverse transcription to occur.

1.3.3

Reverse transcription

After viral entry into the host cell cytoplasm, the HIV-1 core slowly disassociates to reduce spatial
constraints and allow for infusion of dNTPs into a PIC in which reverse transcription of the
genomic RNA occurs. The host tRNALys,3 primer already packaged and bound to genomic viral
RNA (vRNA) anneals at its 18 nucleotide 3′ end to the primer binding site (PBS) found ~180
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nucleotide from 5′ end of vRNA. The stability of vRNA and tRNALys3 complex is mediated by
complex, extended base pairing interactions that are likely facilitated and then stabilized by the
nucleocapsid protein (197,198). The minus-strand cDNA is initiated from tRNALys3 and becomes
the first product of reverse transcription (minus strand strong stop DNA). RNaseH degrades the
RNA portion of the newly formed RNA/DNA hybrid and releases the minus strand strong stop
DNA. The complementarity repeat (R) of sequences at 5′ end of minus-strand strong stop DNA
and 3′ of vRNA allows minus strand DNA to hybridize 3′ end of one of two vRNAs in HIV-1
particle and continue the synthesis of full-length minus-strand DNA, a process known as first
template switch. During the minus strand DNA synthesis, the RNAse H activity of RT degrades
the genomic RNA in RNA-DNA hybrid but retains a RNase H-resistant, highly conserved purine
rich-polypurine tract (PPT) at the 3′ of genomic RNA and PPT acts as a primer for synthesis of the
plus-strand DNA synthesis. The synthesis of positive-strand DNA is initiated at PPT and proceeds
to the end of HIV-1 genome and it also copies the first 18 nucleotides of tRNALys3 primer which
becomes a substrate for RNaseH once it has been copied to DNA. HIV-1 cleaves tRNA from 3′
end leaving a single A ribonucleotide at 5′ end of minus-strand. The 18 nucleotides copied from
tRNALys3 are complementary to the 18 nucleotides at the 3′ end of minus-strand DNA copied from
the pbs. The two complementary sequences anneal which allows synthesis of both positive and
minus-strands to ends of templates completing proviral double-stranded DNA. This process is
summarized in Figure 7.
The synthesized proviral vDNA becomes the specific substrate for the PIC. The PIC consists of
viral proteins, RT, IN, matrix and Vpr (199–201) and ever increasing number of host proteins
including, BAF, EED, HMGA1, p300, and LEDGF/p75, and HRP-2 (202).
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Figure 7. HIV-1 reverse transcription. HIV-1 is a retrovirus with two copies of viral RNA which
are reverse transcribed into double-stranded DNA for integration into human genome. A) In the
first step of reverse transcription, human tRNAlys3 binds to the complementary sequence on pbs
region of 5′ of viral RNA. The binding of tRNAlys3 at pbs initiates synthesis of minus -strand DNA.
B) The complementarity repeat (R) of sequences at 5′ end of minus-strand strong stop DNA and
3′ of vRNA allows minus strand DNA to hybridize 3′ end of one of two vRNAs. C) The binding
at the R allows synthesis of full-length minus-strand DNA. In the process, the original viral RNA
template is degraded by RNaseH except for the RNaseH-resistant highly conserved purine richpolypurine tract (PPT) at the 3′ of genomic RNA which subsequently acts as a primer for synthesis
of the plus-strand DNA synthesis. D) The synthesis of positive-strand by RT is initiated at PPT
and proceeds to the 5′ end of viral genome including 18 nucleotide sequence of tRNAlys3. E) The
complementarity of tRNAlys3 sequence allows annealing of positive strand on pbs. F) The
annealing of two complementary sequences allows synthesis of both positive and minus-strands
to generate proviral double-stranded DNA.

1.3.4

3′ processing of terminal vDNA sequences

The HIV-1 IN recognizes and binds to short specific sequences (12-20 bp) on both 3′ ends of viral
LTRs. This high-order nucleoprotein complex of linear vDNA and HIV-1 IN known as intasome
mediates integration of HIV-1 into target DNA. Reverse transcription of genomic RNA by reverse
transcriptase results a blunt-ended vDNA duplex with terminal sequences 5′-ACTGCAGT-3′. The
‘TGCA’ repeat is conserved in all retroviruses, retrotransposons, and in some prokaryotic DNA
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transposable elements. During 3′ processing which occurs in the cytoplasm (203), and in PIC
(204), HIV-1 IN catalyzes the cleavage of dinucleotide (GT) from both 3′ ends of vDNA at
conserved CA and exposed CAOH-3′ acts as nucleophiles for cleavage of target DNA later during
strand transfer process in the nucleus (51,52) (Fig. 8).

Figure 8. HIV-1 3′ processing and strand transfer processes. HIV-1 integrates into the host
chromatin in a two-step process involving cleavage of dinucleotide ‘GT’ at conserved CA site of
3′ LTR of HIV-1. The HIV-1 integrase remains bound to cleaved viral DNA which is translocated
into the nucleus in pre integration complex. During strand transfer, the exposed hydroxyl act as
nucleophiles and cut through phosphodiester bond of the phosphate at 5′ end of host DNA in
staggered fashion creating 5-base pair insertion. The lone CA is removed and cut DNA ligated by
cellular proteins which completes integration process.

1.3.5

Import of PIC into nucleus

The HIV-1 PIC is formed after viral core uncoating and formation of cDNA from reverse
transcription of viral RNA. The HIV-1 PIC has karyophilic properties which it inherits from three
of its components, HIV-1 Gag matrix (205,206), Vpr (207), and IN (48). In addition, PIC
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associated cellular proteins, barrier-to-autointegration factor (BAF), HRP-2, and LEDGF/p75
contain the nuclear localization signals (NLS) which allow active transport of PIC via nuclear pore
(less than 40 kDa) into the cell nucleus. The karyophilic property of the HIV-1 PIC accounts in
part for the ability of HIV-1 to infect both terminally differentiated macrophages and G2-and Sphase arrested cells (206,208). The MA has a stretch of highly conserved amino acids, Gly-LysLys-Lys-Tyr-Lys (209), which is recognized by importin/karyopherin proteins (205,210). Indeed,
a synthetic peptide containing putative NLSs of MA acted as nuclear import signal when combined
with bovine serum albumin contrary to abolished nuclear import when the peptide was conjugated
to wheat-germ agglutinin, an inhibitor of nuclear pore-mediated import heterologous protein invitro (205). The phosphorylation of carboxyl-terminal tyrosine residue of matrix protein may be
required for direct nuclear export of PIC (211). Nuclear import of PIC is further facilitated by
several importins which transport proteins with NLS through nuclear pore. Importins, Imp7 (212),
Impα1 (48,213), Impα3 (49,214), and Transportin 3(TNP03) directly bind to HIV-1 IN in cells in
interphase to promote nuclear import of PIC (215,216). Nucleoporins, Nup153 interacts and
facilitate import of HIV-1 Vpr (217) and HIV-1 IN (218), whereas Nup358 specifically binds to
HIV-1 Rev and enables cDNA nuclear import (219). The role of HIV-1 Vpr for nuclear import of
PIC may be stimulated by heat shock protein 70 (Hsp70) (220). In dividing cells, the HIV-1 PIC
targets disassociation of cell nuclear membrane during mitosis to enter nucleus during interphase
stage by signal mediated and energy dependent import through nuclear pore (208,221,222).

1.3.6

Strand transfer-integration

Once inside the nucleus, the PIC is tethered to host DNA by several cellular proteins including
LEDGF/p75, BAF, Integrase interactor 1 (INI-1), and high mobility group protein A1 (HMGA1).
The most well characterized of these is LEDGF/p75 (223–226). LEDGF/p75 is a 530 amino acid
protein that acts as a transcriptional factor and a survival factor encouraging cell growth by
preventing stress-induced cell death. LEDGF/p75 is localized to the nucleus where it is found in
tight association with chromosomes (227), and its nuclear abundance perfectly matches that of
HIV-1 IN (228). The close contact of LEDGF/p75 with chromosomes helps to tether PIC to highly
transcribing regions of cellular DNA (229,230). The role of LEDGF/p75 in HIV-1 integration is
further demonstrated by its up-regulation in HIV-1-infected cells (231) and increased strand21

transfer activity exhibited by recombinant HIV-1 IN in the presence of recombinant LEDGF/p75
in vitro (228). In addition to tethering PIC to chromatin, LEDGF/p75 increases the HIV-1 IN halflife by preventing its ubiquitination and degradation by proteasomes (232).
BAF is an 89 amino acid protein that bridges DNA molecules in a nucleoprotein complex by
binding double stranded DNA. BAF is recruited in PIC (233) and has been implicated in
orientating the PIC to chromatin (234–237). BAF also prevents autointegration of cDNA before
integration (238). Lamina-associated polypeptide 2 alpha (LAP2alpha) is also involved in
positioning PIC to chromatin by interacting with BAF (236). PIC associated HMGA1 protein has
been implicated in facilitating DNA unwinding, supercoiling and bending. HMGA1 shows no
interaction with HIV-1 IN but may facilitate HIV-1 integration by bringing vDNA ends together
and into close contact with HIV-1 IN. INI-1 is a 385 amino acid protein that interacts with HIV-1
IN and activates HIV-1 LTR by synergizing with tat and p300/CBP at 5′ HIV-1 LTR.
In the nucleus and following dinucleotide cleavage/processing of the 3′ of vDNA, integratable
vDNA associated with the PIC will mediate proviral DNA integration into the host genome. The
IN bound to exposed 3′-OH ends of vDNA now cuts the host DNA by breaking down a pair of the
phosphodiester bonds via nucleophilic attack by the reactive 3′-OH of vDNA (Fig.7). The host
DNA cuts occurs simultaneously at both strands in a staggered fashion typically at position
separated by 5 base pairs between the two opposite ends of insertion, exposing the 5′ phosphate
end of host DNA that is ligated to the 3′-OH of the vRNA (239). After strand transfer, the vDNA
and host DNA junctions have a 5 base pair sequence gap on the leading and lagging DNA strand
in addition to 2 base pairs on 5′ of vDNA that remain unpaired. In the subsequent step of HIV-1
integration, the host cellular enzymes remove 5′ dinucleotide (CA) ‘flaps’ on vDNA and catalyze
the filling of the gaps to complete integration process (240,241). The PIC is dissembled within
minutes following joining of vDNA 3′ ends to the target DNA which results in an irreversible
process of proviral integration. The cleavage of host DNA mediated by HIV-1 IN and ligation of
vDNA and host DNA doesn’t require exogenous energy source. In addition to 3′ processing and
strand transfer activities, HIV-1 IN can cleave integrated vDNA from host DNA in vitro in process
termed disintegration and this can be accomplished in absence of either NTD or CTD (242–245).
As described above and possibly related to LEDGF/p75 binding, HIV-1 proviral DNA is
preferentially integrated into host DNA in regions of high transcription activity, which is believed
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to facilitate virus infection and transmission (231). The provirus serves as a template for
transcription into mRNAs in a process catalyzed by host RNA polymerase II or goes into
transcriptionally inactive phase called latency. The latency phase is characterized by
transcriptionally silent cells which don’t produce virions (246).
Not all proviral DNA circularizes and associates with PIC/IN as a substrate for proviral DNA
integration. Unintegrated extrachromosomal vDNA can also be found as linear (3′ processed
cDNA) and circularized DNA unintegrated forms inside the cell nucleus (Fig. 9). The circularized
DNAs have covalently closed DNA circles with either single LTR sequence or two LTR sequences
commonly referred to as 1-LTR circles and 2-LTR circles respectively. The 1-LTR circles are
formed earlier than 2-LTR circles (247), and occur in most abundance compared to other forms of
unintegrated DNA with the ratio of 2-LTRs to 1-LTRs circles ranging from 0.16-0.43 (248). The
1-LTRs circles are products of homologous recombination between two flanked HIV-1 LTRs
(248) or circularization due to defective reverse transcription (249). About 90% of 1-LTR circles
are products of homologous recombination which occurs after nuclear import and are commonly
found inside the nucleus (248). Approximately 10% of the total 1-LTR circles population is found
in the cytoplasm, and these are products of defective reverse transcription (247). Cellular
nucleases, RAD50, MRE11, and NBS1 have also been implicated in formation of 1-LTR circles
(248,250). Another fate of unintegrated linear viral DNA, is autointegration which happens when
HIV-1 IN mediates 3′ processing of cDNA LTR ends which attack sites within viral DNA (selfintegration), resulting in circularized forms of rearranged or incomplete vDNA genomes (251)
(Fig. 9).
The 2-LTR circles are products of non-homologous end joining (NHEJ) pathway (252) and
autointegration process, and they are exclusively formed inside the nucleus (247). The host NHEJ
components are involved in double-strand DNA break repair during the G0, G1 and early phase of
the cell cycle as a protective strategy towards presence of viral ssDNA. The NHEJ pathway
involves binding and holding of ends of broken DNA by DNA-dependent serine/threonine protein
kinase (DNA-PK) consisting of autoimmune antigen ku and DNA-PK catalytic subunit (DNAPKs). With ku guiding DNA-PKs to cut DNA ends, ligase 4/XRCC4/XLF performs the ligation
reaction (253,254). In absence of compatible DNA ends for ligation, Artemis nuclease often trims
the ends to facilitate ligation by polymerases (255). The role of NHEJ components to the formation
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of 2-LTRs is shown by decreased abundance of 2-LTRs when Ku, ligase 4 or XRCC4 are
inactivated and modest reduction is observed upon inhibition of DNA-PKcs (248,256). Two LTR
circularized DNA forms can still mediate HIV-1 mRNA transcription (257), production of Tat and
Nef proteins (258), and are found at higher frequency in macrophages and resting CD4+T cells
(259).

Figure 9. Unintegrated forms of HIV-1 DNA. The translocated cleaved viral DNA has two fates
in the nucleus; successful integration into the host DNA to form a provirus or failed integration
which is characterized by mainly two forms of circulating DNA-1 LTR circle or 2-LTR circle. The
larger portion of 1-LTR circles (90%) is found in the nucleus and the rest is in the cytoplasm. 2LTR circles are exclusively found in the nucleus. Another fate of unintegrated linear cDNA is
autointegration due processed 3′ ends of reverse transcripts cleaving sites within viral DNA
resulting into truncated and internally rearranged autointegrants. The majority of unintegrated viral
DNA is degraded by various host DNA repair and restriction factors.
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1.3.7

Transcription, nuclear export of nascent RNA, translation and virus
assembly

Transcription of provirus is regulated by the promoter region of HIV-1 5′ LTR which contains
crucial DNA binding sites; two NFkB sites, three Sp1 sites, and a TATA box. Upon stimulation
of CD4+ T cell, NFAT and NFkB are activated and recruited to the promoter region of nascent
RNA transcripts. This leads to recruitment of Tat to the promoter region which trans-activates
HIV-1 mRNAs expression by interacting with Trans acting response element (TAR) of 5′ HIV-1
LTR. Tat binding on TAR stabilizes TFIID/TFIIA complex on the TATA box and facilitates
recruitment of TATA-binding protein, and a cellular P-TEFb and CTD kinases to the HIV-1
promoter. These kinases include CDK family of CDK2, CDK7, CDK8, CDK9, and CDK11. PTEFb is a heterodimer protein made up of cyclin-dependent kinase 9 (CDK9) and its regulatory
partner cyclin T1. The human cyclin T1 mediates interaction between P-TEFb and Tat (260). In
presence of Tat, CDK9 phosphorylates the CTD domain of RNA pol II which increases
processivity of elongating RNA polymerase II (261). In the absence of Tat, only serine 2 of
heptapeptide repeats is phosphorylated by CDK9 and serine 5 by a component of TFIIH, CDK7
(261). Tat also interacts with transcriptional cofactors including sp1, cyclinE/cdk2, TFIIH, Tip60,
polymerase II and transcription activators p/CAF and CBP/p300. In the absence of Tat, the rate of
HIV-1 transcription initiation is not affected but no elongation of mRNA transcripts is observed
beyond +59 position due to pausing by RNA pol II (176).
Alternative splicing of HIV-1 mRNA leads to 47 different RNA species. Depending on extent of
splicing, there are three categories of HIV-1 RNA transcribed from provirus: 1) partially spliced
RNA, which are ≈ 4 kb length transcripts of Vpu, Env, one exon Tat, Vpr and Vif; 2) completely
spliced, ≈ 2 kb transcripts of Tat, Rev, Nef; 3) unspliced RNA, genomic RNA for packaging, Gag,
and Gag-Pol polyproteins. In the early phase of nuclear export, 9 kb mRNA transcripts are spliced
to 2 kb RNAs which are exported via normal mRNA pathway and are translated to produce Tat,
Rev, and Nef. After translation, Rev is imported back to the nucleus via its nuclear localization
signal(169,262). In the late phase of nuclear export, Rev binds partially spliced and unspliced
mRNAs at Rev Response element (RRE) located in env coding region before splicing, and exports
these unspliced or partially spliced messages out of the nucleus to cytoplasm. The leucine rich
nuclear export signal of Rev enables recruitment of Crm1 protein to mediate this
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nucleocytoplasmic export. To facilitate nuclear export of cargo, Rev also recruits nucleoporins,
Nup98 and Nup124 in rev-Crm1 controlled export (263). The partially spliced and completely
spliced RNAs are shuttled to the ribosome in the cytoplasm for translation into various viral
proteins.
The Env and Vpu proteins which are coded by the same mRNA transcript are translated on rough
endoplasmic reticulum (RER). The Env proteins are glycosylated as they translocate through
membrane of RER, and they are cleaved by Furin protease to produce SU gp120 and
transmembrane protein gp41 in the Golgi apparatus, and then transported to the plasma membrane.
At budding site (cell membrane), the intracellular tail of the transmembrane Env gp41 interacts
with MA region of the Gag and Gag-Pol precursor proteins. Gag also binds, interacts with, and
packages other components into a newly formed core. These include (264,265) cellular proteins,
ICAM-1, HLA-II, cyclophilin A, actin-binding proteins, lysyl tRNAs-synthetase, and ubiquitin
(266). HIV-1 Gag preferentially binds and incorporates/encapsidates two copies of the genomic
HIV-1 RNA while the Gag-Pol is involved in the preferential packaging and placement of the
tRNALys3 on the genomic RNA. During assembly, Env protein, PR, RT and IN viral enzymes are
incorporated into the immature virion. The HIV-1 particle later buds off of the cell surface as an
immature virion mediated by the host endosomal sorting complexes required for transport
(ESCRT) machinery.

1.3.8

Maturation of viral proteins

Maturation of HIV-1 particle occurs simultaneously with or immediately after budding from the
cell surface and is triggered by proteolytic cleavage of Gag and Gag-Pol precursor proteins by
HIV-1 PR. During virion maturation, the PR subunit in the Gag-Pol precursor autocleaves itself
out and proceeds to cleave the rest of Gag-Pol and Gag polyproteins at twelve different sites into
mature structural MA, CA, NC, P6, small spacer peptides p1 and p2, and catalytic enzymes PR,
RT, and IN (45). This cleavage at these different sites occurs sequentially and at different rates
with e.g. the first cleavage occurring between spacer peptide p2 and NC and intermediate cleavage
occurring between CA/MA and p1/p6 sites, and final cleavage at the NC/p1 and CA/p2 sites
(16,27,267–270). The fully processed structural and catalytic enzymes get dramatically rearranged
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within the viral particles to form the mature viral particles. Following its release from the Gag-Pol
polyprotein, CA forms hexameric lattice that forms the conical viral core containing viral RNA
genome, mature NC, RT, and IN proteins (Fig 1). The sequential maturation process of Gag and
Gag-Pol is described in Figure 3.

1.4

Antiretroviral therapy

The first report of a new deadly disease found in men who have sex with men in 1981 and then
among hemophiliacs and intravenous drug users in the USA (2,271,272) led to the rapid search for
a drug to block this unknown disease. The discovery that AIDS was caused by HIV-1 in 1983
then led to the rapid testing of nucleoside analogs that had been shown to inhibit avian and murine
retroviruses. Among the nucleoside analog class, only acyclovir, an acyclic nucleoside analogue
against herpes simplex was approved for therapy by the FDA and was the only effective antiviral
agent available on market (273,274).
3'-azido-3'-deoxythymidine (AZT), first synthesized in 1964, was the leading agent among
nucleoside reverse transcriptase inhibitors (NRTIs) (275,276) and was rapidly approved in 1987
(Fig. 10) for HIV-1 treatment after undergoing a small exploratory study (277) and a double blindplacebo controlled trial. Drug resistance quickly emerged in patients taking AZT (278). In
subsequent years, more NRTIs were available for HIV-1 treatment including didanosine (2',3'dideoxyinosine) (279) and zalcitabine (2',3'-dideoxycytidine) (280) which allowed comparison of
dual NRTIs to monotherapy. Better outcomes in antiretroviral therapy (ART) naïve patients were
recorded with dual nucleoside analog therapy (281–284) which paved a way for triple therapyhighly active antiretroviral therapy (HAART) in 1996 after a number of studies including ACTG
320 which showed adding two new drugs (indinavir (IDV) and lamivudine (3TC) with AZT in
AZT experienced patients was more effective than adding a single drug (285). HAART
combinations differ in each geographical location and largely attributed to the disproportional
ability to access the most potent antiretroviral drugs for the most effective treatment regimens by
countries of different economic means. This inequality for HIV-1 treatments across the globe
remains today after 25 year of effective HAART, now referred to as combined ART (cART).
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Currently, there are over 34 individual and 23 HIV-1 drug combinations approved by Food and
Drug Authority (FDA) for therapeutic treatment and one ART combination for HIV-1 prevention
(Fig. 10). Over the years, cART have become more potent, formulated in a single daily pill, are
easier to tolerate with few adverse events, and high barrier to drug resistance, all of which has
improved treatment outcomes. These new formulations include fixed dose combinations which
contain two or more drugs from two or more drug classes in a single tablet. Long acting injectables
which are dosed once per week or month are tolerable and improve adherence to ART (US national
library of medicine). These may include long acting injectable, cabotegravir/rilpivirine (in late
phase III clinical trial), dapivirine within a vaginal ring, and tenofovir alafenamide as a subdermal
implant (286–288) (289). ART regimens reduce viral replication by targeting different stages of
HIV-1 life cycle.

28

Figure 10. FDA approved HIV-1 treatment drugs and combinations. A) Regimens approved
for HIV-1 treatment, in blue, nucleoside reverse transcriptase inhibitors; orange, non-nucleoside
reverse transcriptase inhibitors; green, protease inhibitors; red, integrase inhibitors; yellow,
pharmacokinetic enhancer; brown, post attachment inhibitors; and black, fusion inhibitors. B)
Brand names of fixed-dose tablets with drug abbreviations. In blue, combinations consisting of
reverse transcriptase inhibitors; green, combinations of protease inhibitors; black, combinations
with more than one class of ART.
There are mainly 5 classes of ART; reverse transcriptase inhibitors target reverse transcription
step, protease inhibitors target cleavage of polyprotein gag-pol and gag by protease, integrase
inhibitors target strand transfer step, fusion inhibitors target fusion of gp41 onto host cell
membrane, and binding inhibitors target HIV-1 coreceptor CCR5. Along with a novel long acting
anti-CD4 monoclonal antibody, Ibalizumab, new agents targeting capsid assembly, glycoprotein
120 attachment, Rev-dependent mRNA expression, present alternative pathways to viral
replication inhibition.
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1.4.1
1.4.1.1

Classes of ART and mode of action
HIV-1 integrase strand transfer inhibitors

HIV-1 integrase strand transfer inhibitors (INSTIs) target HIV-1 IN to stop viral replication. HIV1 IN catalyses HIV-1 integration by 3′ endonucleolytic processing of vDNA ends in the cytoplasm
and strand transfer process in the cell nucleus where vDNA is covalently linked to cellular DNA.
The discovery of integrase inhibitors depended on screening compounds using assays where
recombinant HIV-1 IN catalyzed the first step of dinucleotide cleavage on the end of viral DNA
and/or the strand transfer reaction. The safety of HIV-1 IN is largely based on the fact that the host
does not produce an enzyme with this type of endonucleolytic processing and strand transfer event.
After this enzymatic assay screen, an effective IN inhibitor had to meet four basic preclinical
development criteria in cell culture: (1) efficacy in vitro that was comparable to blocking HIV-1
replication in tissue culture (also suggesting cell penetration by the drug) (290–293), (2)
accumulation of 2-LTRs and reduced integration into host chromosome (290,292,294), (3) with
dose escalation experiments, the emergence of drug resistant viruses with mutations in integrase
(290,293,294), and confirmation that the presence of DRMs in recombinant IN showed reduced
susceptibility to the inhibitor in vitro (290,294).
The two strategies considered in development of HIV-1 IN inhibitors were; binding to free
unbound HIV-1 IN or to HIV-1 IN-vDNA complex. Both strategies were attempted, however, the
high stability of HIV-1 IN-vDNA complex characterised by slow catalytic activity makes it
difficult for HIV-1 IN inhibitors to bind free HIV-1 IN (295). The complex of HIV-1 IN CCD and
shionogi inhibitor 1-(5-chloroindol-3-yl)-3-hydroxy-3-(2H-tetrazol-5-yl)-propenone-5CITEP,
formed a platform for design of HIV-1 IN inhibitors. The 5CITEP inhibitor binds centrally
between D-D-35-E motif and forms hydrogen bonds with residues Thr 66, Gln 148, Asn 155, Lys
156, and Lys 159 (296) (Fig. 11). Some of these residues Lys-156, Lys-159, and Gln-148 are
involved in vDNA binding (297,298). 5CITEP does not chelate cationic ions at the active site but
tends to mimic DNA substrate/IN interaction and therefore seems to prevent binding of the second
divalent cation by occupying the DNA-substrate binding site that inhibits the formation of HIV-1
IN/DNA complex (296,299) (Fig.11). The assays to identify ligands that bind to HIV-1 IN-vDNA
complex led to the discovery of first INSTIs, diketo acids L-731,988 and L-708,906 (290).
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Figure 11. The HIV-1 IN CCD and 5CITEP complex. The crystal structure (PDB ID 1QS4)
(296) shows three HIV-1 IN CCD monomers with HIV-1 IN inhibitor, 5CITEP (red) binding to
one of the CCD monomers. The three catalytic residues (D64, D116 and E152) are depicted in
blue and magnesium ion (green) being coordinated by D64, and D116 residues in presence of four
water molecules (cyan). The HIV-IN residues which form hydrogen bond with 5CITEP inhibitor
are shown in black.

Following this initial discovery and preclinical development of HIV-1 IN inhibitors at Merck, most
INSTIs in development and all those approved for treatment target HIV-1 IN protein by
specifically inhibiting strand transfer process not 3′ processing (300–304). HIV-1 IN requires a
metallic cationic cofactor to be active and these are coordinated by a triad of acidic residues called
DDE motif (D64, D116, and E152) in the catalytic domain of HIV-1 IN. INSTIs target the Mg2+
chelating groups due to the fact that Mg2+ is a cofactor required in vivo and is less tolerant to
sequence variations in LTRs (305), and several mutations affect IN activity in Mg2+ dependent
assays for instance mutations in zinc coordinating motif, HHCC of N-domain of HIV-1 IN (306).
After successful cDNA synthesis by HIV-1 RT, IN recognises specific sequences at either end of
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vDNA to form stable complexes with LTR DNAs (PIC). The confirmation change as a result of
HIV-1 IN binding to vDNA allows the binding of INSTIs (307).
INSTIs bind to the CCD domain on IN, involved in chelated Mg2+, and compete with host DNA
substrate (307). They typically bind to IN/DNA complex close to 3′ end of vDNA in the enzyme
and thus inhibits binding of donor DNA to the target host DNA (300,308) (Fig. 12).

Figure 12. The crystal structure of DTG bound to prototype foamy virus integrase and
vDNA. The structure shows DTG binding at active site of CCD of PFV IN with catalysis residues
D128 (HIV-1, D64), D185 (HIV-1, D116) and E221 (HIV-1, E152) depicted in blue and divalent
Mg2+ shown in yellow. DTG is shown in red binding to 3′ end of PFV vDNA. The common INSTIs
associated resistance residues, Y212 (Y143, HIV-1), N224 (N155, HIV-1), and S217 (Q148/G140,
HIV-1) are shown in magenta. The image was made in Pymol using x-ray crystallography structure
(PDB ID 3S3M) (308).

For the INSTIs compounds to be active pharmacophores, they must have a chemical group of three
oxygen atoms in same geometric plane and halogenated phenyl group in their chemical structure
(Fig.13). The halobenzyl moiety fit within a tight catalytic pocket of HIV-1 IN made available
after 3′ processing, and interact with G:C proceeding the terminal adenine of 3′ HIV-1 LTR viral
end, and with residues 145 and 146 of HIV-1 IN. This interaction results in displacement of the
reactive adenine (309,310) and eventually of 3′ hydroxy group from the active site which
inactivates the intasome and stabilises the HIV-1 IN-vDNA complex. The stability of HIV-1 IN-
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vDNA complex due to displaced 3′ hydroxy group is further elucidated by increased rate of
association of INSTIs binding to HIV-1 IN-vDNA complex on deletion of this adenine base (311).
The three oxygen atoms of β-hydroxy ketone moiety chelate divalent cations within the catalytic
pocket which impedes catalytic triad D-D-35-E from participating in strand-transfer process (312–
315).
Raltegravir (RAL), formerly known as MK-0518, was the first INSTI to be approved by the FDA
in 2007 (316,317), followed by elvitegravir (EVG) (JTK-303/GS-9137) in 2012, dolutegravir
(DTG) in 2013 (S/GSK1349572), bictegravir (BIC) (GS-9883) in 2018 and cabotegravir (CAB)
formerly S/GSK 1265744 or GSK 744 in 2021. Both first generation INSTIs, RAL and EVG are
effective against WT HIV-1 but the genetic barrier to drug resistance was less than that observed
with the second generation of INSTIs (DTG, BIC and CAB). DTG and BIC remains effective in
the presence of some HIV-1 resistant to RAL and EVG (318,319). The structural differences
between DTG and RAL or EVG may explain high potency seen with DTG. Contrary to EVG/RAL,
the chelating motif of DTG is located on a tri-cyclic scaffold (319,320). The linker region joining
metal chelating motif to halogenated group of DTG is further extended compared to RAL and
EVG (308) (Fig.13) which allows deeper access into the pocket vacated by displaced vDNA
allowing a closer interaction with vDNA. In addition, presence of RAL/EVG resistant viruses,
DTG can adjust its position and conformation in response to structural changes at the IN active
site.
INSTIs, BIC, and CAB, are the latest second generation INSTIs. BIC a structural analog of DTG
was approved in 2018 as a fixed-dose combination of BIC/FTC/ tenofovir alafenamide (TAF) in
ART naïve and suppressed patients (<50 copies/ml) (321). BIC is a potent, un-boosted, once daily
INSTI, with higher in vitro barrier to resistance against RAL and EVG and with a few drug-drug
interactions. CAB is another analog of DTG from a class of carbamoyl pyridones that has recently
been approved by FDA and European Union as long-acting injectable, CAB/rilpivirine for use in
HIV patients with undetectable viral loads, stable on current ART, and no drug resistance. 9–11 The
unique physicochemical and pharmacokinetic properties of the CAB formulation allows its use as
a single-daily tablet or long-acting nanosuspension for monthly or quarterly via subcutaneous or
intramuscular administration. CAB was recently approved as a fixed-dose long-acting injectable
combination of CAB plus the NNRTI rilpivirine after successful clinical trials in HIV infected
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individuals.

12,13

. BIC and CAB are structurally and chemically similar to DTG both having tri-

cyclic central pharmacophore, though metal-chelating scaffold for CAB is 5-membered (more
rigid) compared to 6-membered ring (more flexible) for DTG (Fig.13) (325). Overall, BIC seems
to be more effective than either CAB or DTG which may be explained by further flexibility of
oxazepine ring allowing accommodation to structural changes of IN active site in presence of
resistant mutations.

Figure 13. HIV-1 integrase strand transfer inhibitors (INSTIs). Currently, there are two groups
of INSTIs, the first generation (RAL and EVG) and second generation INSTIs (DTG, BIC, CAB).
All currently approved INSTIs are characterized by three coplanar oxygen group for chelating
magnesium ions at active site of HIV-1 IN and halogenated benzyl group which seats in pocket
left by cleaved ‘GT’ dinucleotide and eventually displacing the terminal adenosine of 3′ end of
viral DNA to terminate integration process. 1) Elvitegravir, 2) Raltegravir, 3) dolutegravir, 4)
cabotegravir, and 5) bictegravir. The coplanar oxygen atoms are highlighted in red and green circle
highlights extended linker a common feature to all second generation INSTIs. MarvinSketch was
used to draw and display chemical structures, MarvinSketch v20.11 ChemAxon
(http://www.chemaxon.com).

34

1.4.1.2

Nucleoside reverse transcriptase inhibitors

HIV-1 reverse transcriptase catalyses reverse transcription of viral RNA into complementary
DNA. Nucleoside reverse transcriptase inhibitors (NRTIs) halt viral replication by inhibiting
reverse transcription. NRTIs bind to a hydrophobic pocket away from RT active site and exert
inhibition by competitive inhibition, where modified nucleotide (nucleoside triphosphates) lacking
3′-hydroxyl group on deoxyribose moiety compete with natural deoxynucleotide for incorporation
into new strand of DNA (326). Inside the cell, the NRTIs are activated by phosphorylation of
deoxyribose moiety by cellular kinase enzymes into active metabolite triphosphates (327–329).
When modified deoxynucleotides are incorporated, the incoming deoxynucleotides cannot form
5′-3′ phosphodiester bond required to extend DNA chain (330). The chain termination stops
formation of DNA synthesis which halts viral replication (326). The NRTIs have been screened to
have highly selective incorporation into the HIV-1 RT over the normal host DNA synthesis to
minimize drug toxicity and side effects.

1.4.1.3

Non-nucleoside reverse transcriptase inhibitors

The non-nucleoside reverse transcriptase inhibitors (NNRTIs) do not compete with HIV-1 RT for
incorporation of normal deoxynucleotides but bind directly to a pocket near the active site of HIV1 RT enzyme (41,331). A NNRTI hydrophobic RT complex forms only in the presence of NNRTIs
(332,333) and the NNRTIs causes conformational change of substrate-binding site which impairs
RT enzyme polymerisation (41,334). The NNRTIs make contacts with hydrophilic residues, K101,
K103, S105, D192, E224, and E138; and hydrophobic residues, Y181M Y188, F227, W229, and
Y232 (335). The approved NNRTIs for treatment and their abbreviated names in the subsequent
text are listed in figure 10.

1.4.1.4

Protease inhibitors

The HIV-1 protease enzyme is relatively small (11 kDa). It is a homodimer of two identical
symmetrical subunits of 99 amino acids. It has two mobile flaps which form a cleft, the middle of
which is the substrate binding site while the bottom of cleft is the enzyme active site. The
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polyproteins Gag-Pol and Gag from translation of mRNA by ribosome are cleaved by HIV-1
protease enzyme into viral enzymes, RT, PR and IN and structural proteins of matrix, capsid,
nucleocapsid, p1, p2 and p6 respectively (336,337) as described in sections 1.2.1 and 1.3.8. The
protease inhibitors inhibit PR activity through interaction between hydroxyl group of inhibitor and
carboxyl group of PR active site residues, Asp 25 and Asp 25’ contacting relatively conserved
residues Asp 29, Asp 30, Gly 27 and Gly 48 of PR enzyme. This prevents cleavage of Gag-pol and
Gag polyproteins which results in formation of immature non-infectious virion particles (338). The
PIs are potent regimens with high genetic barrier to resistance but to inhibit fast metabolism and
to increase drug’s intracellular half-lives, they need to be co-administered with pharmacokinetic
enhancers. Ritonavir is a protease inhibitor and also a pharmacokinetic enhancer now commonly
used to inhibit cytochrome P450 3A4 isoenzyme to increase the intracellular half-lives of protease
inhibitors as well as many drugs used for treatment of various diseases (339,340). Cobicistat
(Tybost -GS 9350) is an inhibitor designed to specifically inhibit the cytochrome P450 3A
(CYP3A) isoforms including CYP3A4 subtype. Low dose Cobicistat increases systemic exposure
and ultimately reduces adverse side effects of atazanavir (ATV), darunavir (DRV), tenofovir
(TDF), EVG, and other antiretroviral agents used in treatment of HIV-1. It has also been shown
that Cobicistat increases intestinal adsorption of substrates including ATV, DRV and TDF (341).
The first PI, saquinavir, was approved by FDA in 1995. The approved PIs for treatment and their
abbreviated names in the subsequent text are shown on figure 10.

1.4.1.5

Fusion inhibitors

The HIV-1 envelope consists of surface membrane gp120 and transmembrane protein gp41 which
anchors the HIV-1 on to the target cell surface. The binding of gp120 to CD4 receptor triggers
disassociation of gp120 from gp41 and gp41 undergoes a conformational change which allows
fusion of viral and cellular membranes (342). The essential role of gp41 in anchoring HIV-1 to the
cell surface makes it a target for inhibition. The gp41 is predicted to have two hydrophobic helices
termed ‘heptad repeat’ sequences, HR1 and HR2 that are positioned at the base of HIV-1 env
trimer. The two heptad repeat domains, HR1 and HR2, interact to form a stable six-helical bundle
of N helices (interior trimeric coiled coil) and trimeric C helices (342,343) and this interaction
between HR1 and HR2 induces membrane fusion (344).
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Analysis of gp41 using x-ray structure shows a small pocket in conserved hydrophobic groove of
N-peptide bound to isoleucine, tryptophan, and 3 hydrophobic residues which makes it attractive
to entry inhibitors (342,345). A non-pocket binding peptide, T-20 is the only fusion inhibitor
approved by FDA. T-20 is a synthetic peptide of 36-amino-acid peptide corresponding to Cterminal HR2 sequence of gp41 (181). T-20 disrupts interaction between HR1 and HR2 which
disrupts formation of 6-helix bundle required for membrane fusion (181). T-20 has shown potency
in patient studies (346,347), and has similar viral inhibition to that of reverse transcriptase and PI
(346). However, T-20 is more affected by resistance compared to binding-pocket analogues (348).
Mutations against T-20 are known to reduce viral replication fitness (349,350) and result in
hypersensitivity to neutralising of monoclonal antibodies targeting gp41 (349). Resistance
mutations against T-20 include, G36DEVS, V38EAMG, Q40H, N43DKS, I37V, N42T, L44M,
and L45M (Stanford HIV-1 database, IAS-USA). Resistance mutations to synthetic peptide DP178
early version of T-20 cluster more in first heptad repeat (HR1) than other regions of gp41.

1.4.1.6

HIV-1 coreceptor antagonists

HIV-1 entry into the CD4+ cells requires binding to chemokine receptors CCR5 (178,351) or
CXCR4. CCR5 is expressed by lymphocytes, astrocytes, brain microglia, neurons, capillary
endothelial cells, epithelium, vascular smooth muscle, fibroblasts, and subpopulations of
monocytes (352). The ligands for CCR5 include, macrophage inflammatory protein 1 (MIP-1),α,
MIP-1β, RANTES, and HIV-1 gp120 (353,354). CXCR4 is constitutively expressed by lymphatic
tissues, spleen, thymus, small intestines and brain (355). The critical role of coreceptors to
effective HIV-1 infection is underscored by observation that peripheral blood mononuclear cells
(PBMCs) isolated from individuals deficient of CCR5 are not infected by HIV-1 (356–360).
Naturally occurring point mutations don’t reduce HIV-1 infection (361), but CCR5 missing 32
base pairs (CCR5∆32) leads to resistance to HIV-1. Individuals homozygous for CCR5 deletion
mutation (CCR5∆32) are resistant to HIV-1 (359,360) and heterozygous individuals for CCR5∆32
may be protected from numerous abnormalities including, AIDS associated lymphoma (362,363),
multiple sclerosis (364–366), rheumatoid arthritis (367,368) and Crohn’s disease (369).
Individuals with heterozygous CCR5∆32 also show reduced HIV-1 entry and replication in CD4+
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T cells (358). The CCR5∆32 allele frequencies is around 0%-14% across Eurasia but absent in
individuals with Asian or African origin (359,370,371).
CCR5 antagonists bind to a hydrophobic pocket formed by transmembrane helices of CCR5 (372).
This allosteric interaction results into locks the receptor into a conformation that is unrecognisable
by HIV-1 Env (373). There are four CCR5 analogues which have shown potency as CCR5
antagonists; maraviroc, aplaviroc, vicriviroc, and leronlimab (PRO 140). Maraviroc was approved
in 2007 (374,375), Vicriviroc was not filed for FDA approval following a successful phase III
clinical trial, Aplaviroc was discontinued due to severe liver toxicities (376), and Leronlimab is a
monoclonal antibody that binds to CCR5 receptor on the CD4+ T cells that has emerged as
treatment following clinical trials.
Maraviroc is recommended in treatment experienced patients infected with CCR5 usage viruses.
Use of CCR5 antagonist in patients infected with CCR5/CXCR4 dual tropic viruses may
encourage emergence of CXCR4 virus and rapid virological failure. Therefore, it becomes
paramount to screen patients with HIV-1 showing even minimal usage of the CXCR4 coreceptor
before prescription of MVC, a CCR5 antagonist. Resistance to CCR5 antagonists is mainly
through 3 mechanisms; ability of HIV-1 Env to bind CCR5 bound to MVC (377,378), selection of
CXCR4 by originally CCR5 viruses (379,380), and increased affinity of CD4 resulting in HIV-1
remain bound to cell surface in a confirmation to engage CCR5 when MVC dissociates (based on
its on-off binding). Generally, most mutations against CCR5 occur in V3 loop of gp120 (Maraviroc
Viiv healthcare) though resistance mutations have also been observed in gp41 (381). Serial passage
assays show selection of resistant mutations, T316A, V323I in V3 loop, contrary to resistant
mutations against aplaviroc which preferentially cluster in C1-5, V1, V3 of gp120 and in gp41
protein. The CCR5 antagonist functions by binding to CCR5 which leads to conformational change
in coreceptor, in particular, the second extracellular loop (ECL2) which terminates binding to V3
loop of HIV-1 gp120 (382,383). Some inhibitors like aplaviroc bind directly to ECL2. The CXCR4
antagonists halt HIV-1 entry by inhibiting interaction between CD4-gp120 complex with ECL2
region of CXCR4. Resistance emerging through enhanced CD4 interactions is conferred by the
N425K mutation in the CD4 binding pocket in gp120. This mutation provides a gain in replicative
fitness but never emerges in patients with or without MVC treatment which may relate to exposing
gp120 epitope inducing neutralizing antibodies which in turn eliminate this mutated virus (384).
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1.5

HIV-1 drug resistance

HIV-1 drug resistance (HIVDR) is characterized by active viral replication in presence of ART,
and it is the major reason for treatment failure (385). All currently available drugs for treatment of
HIV-1 can select for HIVDR with first generation inhibitors more susceptible to HIVDR compared
to newer generation of inhibitors. There are a number of factors which can lead to development of
HIVDR; poor drug levels in patients taking the prescription but subtherapeutic blood drug levels
is related to poor drug absorption, drug-drug interaction or possible genetic polymorphisms
impacting drug metabolism. Emergence of drug resistance is rare in patients adherent to the drug
regimen and the latter factors appear a low frequency in the patient population. Instead, HIVDR
is primarily related to poor treatment adherence (Fig. 14) due to fatigue in maintaining life-long
daily treatment, drug stock outs, taking “holidays” from drug treatment, avoiding the stigma or
hiding treatments from others, and taking wrong dosages.

Figure 14. The role of patient adherence to ART. 1) Adequate adherence to ART (>90%) allows
viral suppression within first 3 months of starting ART in most patients. 2) Suppressed viral load
inhibits selection of drug resistant variants in presence of ART. 3) Patients starting ART and not
adequately adhering to ART (<90%) experience immunodeficiency rapid viral replication. 4) High
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viral replication in presence of suboptimal drug dosage leads to preferential selection drug resistant
variants in presence of ART.

The HIV-1 mechanism(s) behind the emergence of drug resistance is rather simple compared to
the sociodemographic and physiological factors that set the stage for treatment failure. Compared
to all other RNA and DNA polymerases in nature, HIV-1 RT has one of the highest
misincorporation rates of nucleotides and does not possess repair mechanism such that replication
of each HIV-1 genome can have been 1 and 10 mutations. With a turnover rate of approximately
a billion HIV-1 particles/day within an infected individual, nearly every possible mutation
encoding for a replication competent virus emerges every day. The survival of each mutant HIV1 strain forming a swarm of clones or “quasispecies” is based on the replicative fitness of each
strain. Under drug selective pressure, the strain with a specific mutation conferring reduced
susceptibility to the drug is immediately selected in the population. In general, the current
generation of antiretroviral drugs select for HIV-1 mutants with low replicative fitness and of very
low frequencies in the quasispecies of a patient. Alternatively, the mutations conferring resistance
are lower in the “fitness valley” and require multiple compensatory mutations to emerge for
effective drug resistance and treatment failure.

1.5.1
1.5.1.1

Mode of resistance to HIV-1 inhibitors
Resistance to entry inhibitors

Though sparsely used compared to other classes of ART, the clinical use of entry inhibitors has
led to emergence of resistance to these inhibitors mainly through a coreceptor shift from CCR5 to
CXCR4, and changes in the viral envelope which allows viral replication to continue in presence
of inhibitors. HIV-1 resistance mutations against CCR5 antagonists are scattered in different
regions of gp120 including V2, V3, C2 and C4 (386–388). Resistance mutations to many CXCR4
antagonists have been observed on V3 domain of gp120; however, mutations against SDF-1α
analogue in V1, V2, C2, and 5 amino acids deletion in V4 loop of gp120 have also been observed
in resistance selection assay (389). No coreceptor usage switch from CXCR4 to CCR5 been
observed with CXCR4 antagonists (389).
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1.5.1.2

Resistance to NRTIs

Resistance to NRTIs mainly occurs in two ways; discrimination and excision pathways (326).
During discrimination pathway, the HIV-1 RT enzyme affinity to bind to NRTIs is decreased due
to mutations in the N-terminal domain of polymerase while retaining the ability to recognise
natural deoxynucleoside triphosphate (dNTP) substrate e.g. RT mutations M184V and V75T. In
another form of discrimination, there is a decrease in rate of incorporation of analogue over natural
nucleotides, e.g. K65R, K70E, L74V, and Q151M. In the second mechanism to NRTIs resistance,
the incorporated chain terminating analogues get excised from the 3′-terminus after it has been
added into the viral DNA through pyrophospholysis. This allows DNA chain elongation to
continue resulting in viral replication. The mutations may affect phosphorolytic activity of RT
overcoming activity of NRTIs in a process called primer unblocking. The mutations which
enhance loss of phosphorolytic activity of RT include those against thymidine analogues, AZT
and d4T (stavudine), exhibit this form of antagonism; D67N, K70R, L210W, T215Y/F, K219E/Q.

1.5.1.3

Resistance to NNRTIs

The NNRTIs inhibit viral replication by non-competitive inhibition; where analogues bind the p66
subunit of HIV-1 RT at a hydrophobic pocket near active site of RT which terminates elongation
of DNA chain. The mutations result in conformational changes of the binding pocket through
disruption of specific contacts between inhibitor and binding pocket, e.g. K103N, K101N;
disruption of interactions inside pocket e.g. Y181C, Y188L; and overall conformational change of
pocket e.g. G190E which makes a steric bulk in the pocket leaving no space for NNRTI binding.
NNRTIs mutations, K103N against nevirapine (NVP), and efavirenz (EFV); and Y181C, against
NVP, EFV, rilpivirine (RPV), and etravirine (ETR) are the most commonly selected in treated
patients (390–392). HIV-2 and half the isolates of HIV-1 group O are intrinsically resistant to most
NNRTIs (393). The drug resistance mutations observed in patients failing NNRTIs regimen all
reside in the NNRTI binding pocket. NNRTIs have better tolerability profiles than NRTIs, but
have lower genetic barrier to resistance since a single mutation in HIV-1 RT hydrophobic pocket
confers high resistance to most NNRTIs with minimal or no impact on replicative fitness.
Resistance to NNRTIs usually emerges rapidly in case of incomplete viral suppression or when
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administered as monotherapy which suggests that pre-existing mutations are quickly selected
under NNRTIs pressure (394–397). Again, since mutations conferring NNRTI resistance don’t
cause substantial loss to viral replication fitness (392,398), NNRTI resistant HIV-1 remain
detectable in patient’s viral population many years after stopping a failing NNRTI-based treatment
regimen. Non-subtype B viruses may be intrinsically more resistant to NNRTIs due to pre-existing
background polymorphisms (399,400). Paradoxically, NRTIs resistance mutations for example, at
codons 118, 208, and 215 were shown to cause hypersensitivity to NVP, EFV and DLV (401).

1.5.1.4

Resistance to PIs

The symmetrical structure of HIV-1 PR is crucial for efficient binding of PIs into the substratebinding site. The resistance to PIs is a result of mutations near the substrate-binding cleft of an
enzyme which cause a conformational change, thus preventing the binding of PIs directly or
indirectly leading to resistance (402–405). Most primary PI resistance mutations (e.g. V82A, I50V,
G48V, I84V) are located near the enzyme active site. The mutations in the substrate-binding site
of PR enzyme also affect the binding of normal substrates-Gag-pol and Gag polyproteins which
affects the normal processing of immature proteins, resulting in impaired viral replication capacity
(406–408). The loss in viral replication capacity (RC) is usually compensated by emergence of
compensatory mutations which increase resistance to PIs (409–411) and restores the RC (410–
412). Thus, mutations in the PR cleavage sites within the Gag and Gag-Pol precursor proteins may
act as compensatory mutations to ensure normal PR-mediated processing and HIV-1 core
formation (337,408,413–415). The resistance mutation against one particular PI usually affects
nearly all other first-generation PIs due to similar chemical structures and the substrate binding
site in PR.
Mutations in HIV-1 Gag located in close proximity to, but not within the canonical seven amino
acids of cleavage sites have been associated with evolution of HIV-1 PR resistance mutations, for
instance mutation I47V downstream of the NC/sp2 cleavage site, and P453L downstream of the
sp2/p6 site (416,417). The mutations in HIV-1 Gag cleavage sites have also been shown to reduce
susceptibility to HIV-1 PIs. The presence of NC/p1 cleavage site substitutions, K436E and/or
I437T/V conferred resistance to LPV (lopinavir), ATV, tipranavir and amprenavir in vitro (418).
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1.5.1.5

Resistance to INSTIs

Resistance to INSTIs occurs mainly through mechanisms involving conformational change of
HIV-1 IN affecting the binding of INSTIs, charge effects, loss of stabilising IN and INSTIs
interactions, and steric hindrance. The residues involved in INSTIs resistance are highly conserved
in HIV-1 IN protein. The common resistance pathways to RAL and EVG observed in vivo and in
vitro are commonly seen at positions N155, Q148, Y143, and E138 of HIV-1 IN (Fig. 15). Second
generation INSTIs, DTG and BIC are commonly associated with mutations at positions R263 and
Q148 in combination with other mutations. Resistance mutations at position Q148 are also
associated with CAB, the long-acting derivative of DTG. Most of the residues involved in
resistance are in proximity of surface α4 helix of CCD (Fig. 15) and some make direct contact with
INSTIs. Thus, the binding of INSTIs to the HIV-1 IN-DNA complex and crucial connections by
these residues within the complex may explain the occurrence of these mutations in HIV-1 IN.

HIV-1 drug resistance to RAL portrays three major mutation pathways, Y143R/C, Q148R/K/H
and N155H (419). Mutations, N155H and Q148H/K/R confer 10-fold and 25-fold resistance to
RAL respectively (420). Other mutations against RAL observed in vivo include: L74M, E92Q,
E138K, G140S/A and G163R (420). The mutation Y143H/C/R is specific to RAL (421,422) and
F121Y is selected by RAL only in-vitro. Drug resistance to EVG occurs mainly through primary
mutations, T66A/I/K, E92Q, N155H, S147G, and Q148H/K/R and G140S/A/C (423–425).
Mutations S147G confers resistance exclusively to EVG. Secondary mutations conferring
resistance to EVG include: H51Y, Q195K, Q146P, E138K/A/T, and G118R, (425,426) with
F121Y, P145S, Q146P, and R263K reducing EVG susceptibility in vitro. Mutations T66I and
E92Q reduce susceptibility to EVG by >30-fold and Q146P, S147G, H51Y, Q95K, and E157Q by
<10-fold (426).
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Figure 15.The common INSTIs DRMs in different domains of HIV-1 IN. A) In the CCD, the
majority of INSTIs associated DRMs (red) are observed in proximity to the three catalytic triad
residues of IN active site (blue) and surface α4 helix (cyan). B) Residue R263 in CTD that is
commonly associated with DTG resistance. C) Currently no INSTIs associated mutations been
observed in NTD of HIV-1 IN.

Mutations Y143R/C, Q148R/K/H and N155H are located within the CCD and in close
juxtaposition to the catalytic triad of D64, D116 and E152 in CCD. Though Y143 lies slightly
outside the catalytic pocket, Q148 is located close to the DDE residues and N155 is surrounded by
D64 and E152 residues. In the co-crystal structures, there is no direct contact observed between
residues Q148 and N155 with bound INSTIs (Fig. 12). However, owing to their critical position
in active site, substitutions at these positions may trigger a conformational change within the
catalytic pocket which impairs INSTIs binding (310). The α4 helix residues Y143 and Q148 make
crosslinks with 3-processing site CA GT3’/5’ ACTG of U5 and U3 of HIV-1 LTR and may confer
resistance by facilitating accurate positioning of target and vDNA substrates. The small and
flexible amino acid G140 has been shown to accommodate movement of the His side chain at
position Q148 enabling INSTIs to bind with a less significant conformation change of IN. This
probably explains the increased resistance seen with Q148H+G140S/A compared to single Q148H
(310). Further still, the presence of bulky Lys or Arg in Q148K/R disrupts the active site which
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impairs binding of INSTIs. Disruption of the His-phosphate interaction by INSTIs may explain
resistance at residue N155 (310). The resistance associated with Y143 may be due to direct
interaction with the oxadiazole group and phenol ring of bound RAL forming face-to-face π π
stacking interaction that is abrogated when this residue is mutated (310,427). INSTIs, EVG, DTG,
BIC and CAB which don’t have an oxadiazole group are not much affected by substitutions at
Y143 position. The residues E92 and F121 are located close to bound EVG which may explain
resistance at these positions. The primary resistance mutations to EVG are scattered around the
catalytic triad surrounded by secondary mutations. Residues G118 and S153 associated with DTG
resistance, are in close proximity to catalytic triad residues D116 and E152 respectively. G118R
may confer resistance by altering geometry of catalytic triad affecting INSTI chelation of divalent
cations in active site (428) or through causing steric hindrance to drug binding due to bulky
arginine compared to glycine residue (308). R263K is located far from active site and reduce DTG
susceptibility by reducing on vDNA binding (429).
Contrary to EVG and RAL, DTG possess a higher resistance barrier (430,431) and is generally
less affected by mutations known to cause cross resistance in RAL and EVG (432,433). DTG
selects a rare R263K mutation in vitro (434) and in vivo (435) but at a cost of reduced RC
(319,429,435) and ultimately impaired infectivity (436). Other resistance mutations associated
with resistance to DTG have also been found in both patients failing EVG and RAL-based
treatments and in vitro assays at positions F121, S153, G118, and E138 (319,429).
Resistance mutations R263K, G118R, H51Y and E138K confer low level resistance to DTG in
vitro (429,437). These mutations alone or combined with secondary mutations do impair RC. A
combination of R263K and mutations at positions 143 and 148, leads to a drastic reduction of
enzyme activity (434). R263K can tolerate the presence of two mutations, E92Q and N155H of all
other mutations associated with RAL and EVG (436). In the presence of R263K or G118R and
secondary mutations, H51Y, M50I, and E138K, the RC is significantly impaired or not restored
(434,438,439). R263K mutation has influence also on accessory mutations to N155H pathway
under DTG pressure. Despite viruses containing N155H and R263K in presence of DTG causing
low level resistance against DTG, surprisingly, no change in resistance level against DTG is
observed when R263K/N155H is added to L74M, E92Q, T97A, E157Q and G163R, common
secondary mutations to N155H in patients failing RAL/EVG treatment (440). A combination of
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S153F/R263K mutations shows >100-fold resistance to DTG, RAL, EVG, BIC, and CAB in vitro
(441). However, emergence of S153F and R263K as minority variants does not seem to translate
into virological failure in a patient on DTG treatment over 24 weeks (441).
Clinical trials, SINGLE (DTG/3TC/abacavir (ABC) vs TDF/FTC/EFV) (442), FLAMINGO (once
daily DTG vs ritonavir boosted DRV)(443), and SPRING-1 and 2 ([once daily DTG versus EFV
and twice-daily RAL respectively] drugs given with coformulated TDF/FTC or ABC/3TC) (444)
assessed efficacy of DTG-based regimens in ART naïve patients, and no emerging DTG resistance
was observed in patients given DTG-based regimens. In highly ART experienced patients with IN
resistant virus to RAL and EVG, DTG (50mg) twice daily showed efficacy with 69% of patients
achieving HIV RNA <50 copies/ml at week 24 but Q148HRK+ ≥ 2 mutations reduced odds of
achieving HIV-1 RNA <50 copies/mL by 96% (318). In a study which compared once daily DTG
versus twice daily RAL in ART experienced but INSTIs naïve patients (SAILING study), no
emerging resistance mutations with genotypic and phenotypic resistance to RAL or DTG was
observed in DTG arm but RAL-associated genotypic resistance emerged in 42% patients with
virological failure taking twice daily 400mg RAL (435). Nevertheless, there are case reports and
clinical studies reporting cases of DTG resistance. A case report shows virologic failure in an ART
naïve patient on DTG/FTC/TDF and rifampicin and failure was associated with reduced DTG drug
levels based on interactions with rifampicin (445). In this patient, virologic failure coincided with
the emergence of R263K and E157Q in IN and the M184I in RT, i.e. conferring resistance to FTC
(445). Another case report reported a patient on TDF/3TC/DTG regimen who had virologic failure
associated with I151V, G163R, and Q148K in IN and M184V in RT (446). In ART experienced
but INSTIs naïve patients in the SAILING study and a retrospective cohort study (DTG vs RAL
vs EVG), DTG resistance has been observed with IN T66I and R263K mutations emerging DTGbased arm (435,447). In HIV-1 infected patients, high RNA copies >100,000 copies/ml, CD4 T
cell of < 200 cells/ul, adherence <80% (416), and coinfection with Mycobacterium tuberculosis
(420), have been shown to be risk factors to emergence of DTG resistance. Despite these anecdotal
cases, emergence of DTG resistance is rare following initiation of a new DTG-based cART among
treatment experience patients and extremely rare in treatment naïve taking DTG-based cART.
These observations, the high genetic barrier for DTG resistance, and the low replicative fitness of
DTG-resistant HIV-1 prompted the field to consider use of DTG in monotherapy. DTG resistance
rapidly emerged in ART experienced, virologically suppressed patients (who were INSTI naïve)
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when switched to DTG monotherapy. DTG resistance was conferred by Q148H/R (3-patients),
N155H (3-patients), G118R (2-patients), S230R (2-patients) and R263K (1-patient) (448,449).
Interestingly, INSTIs mutations against DTG may have an inhibitory effect on NRTIs and NNRTIs
mutations. The presence of H51Y/R263K delays the emergence of NNRTI resistance mutation,
V106A by 5 weeks while R263K delays NRTI resistance mutation, M184V/I by 2 weeks (450).
Emergence of NNRTI resistance (Y181C) required more viral passages and a delay between 15 to
25 weeks when comparing wild type HIV-1 versus HIV-1 harboring INSTI resistance mutations
G118R, H51Y/G118R (450). The emergence of V106A mutation was delayed from week 6 to 25
weeks in viruses carrying H51Y/R263K vs wild type in presence of NVP. With 3TC, there was
delay in emergence of M184I to week 25 in presence of H51Y/R263K mutations (450). In addition,
presence of the INSTI-resistance mutations, R263K with either the NRTI resistance mutations,
M184V/I or K65R mutations further reduce viral replicative capacity of the viruses with any one
of these mutations alone (451). The R263K mutation progressively reduces HIV-1 integration
(452) and there is no detectable levels of integrated HIV-1 DNA in cell culture assays in presence
of R263K/H51Y and M184I/V, L74V, K103N, E138K (451). Together, these observations may
explain why cases of DTG failure with NRTI resistance mutation is rare, i.e. DTG resistant
mutations cannot emerge or are slow to emerge due to additive reduction in replicative fitness.
These observations also indicate impaired capacity of HIV-1 to develop resistance mutations in
different genes at the same time under drug pressure. Combination of mutations in RT and IN
genes also seem to interfere with interaction between these two genes leading to reduced RC. HIV1 IN mutations being pleiotropic, they have been described upon multiple viral steps including
reverse transcription. HIV-1 INSTI drug resistant mutations have been found in all three domains
of HIV-1 IN enzyme (453) and disruption of binding residues of RT on HIV-1 IN led to
downregulation in synthesis of cDNA (454). Interestingly, presence of RT mutations M184I/V or
K65R impair the emergence of DRMs against DTG but not EVG or RAL (455).
BIC has resistance pathway involving R263K, S153F/F, H51Y, Q146L in cell culture (456,457),
and Q148H. BIC generally retains activity against mutations T97A, T66I, E92G/Q, Y143R,
Q148H/K/R, Q148H/G140S, and N155H, conferring resistance to EVG, RAL (458,459), and DTG
associated mutations, G118R, R263K, H51Y/R263K (459). In phase 3 clinical trials investing
efficacy of single-tablet regimen BIC/FTC/TAF compared to DTG regimens in ART naïve
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patients, no emerging resistance to BIC was observed in any of the study patients (460,461). In
GS-US-380-4030 study investigating efficacy of single-tablet regimen BIC/FTC/TAF in
virologically suppressed patients with documented or suspected NRTI resistance, no emerging
resistance to BIC was reported in the study (462).
CAB an analog of DTG shows activity in presence of RAL, EVG, and DTG mutations, Y143R,
N155H, T66I, E92Q, H51Y and E138K/R263K with EC50 of <5 nM (458), and Q148H/K/R,
G140S/Q148H/K/R, (FC <7) (463). The oral formulation of CAB demonstrated a higher genetic
barrier to resistance than RAL and EVG (absence of mutations at residues, 138, 140, 148, and 155
) in a first time-in-human and phase IIa study involving healthy and HIV infected individuals
(464). The long-acting CAB has also shown activity in vitro in viruses from ART naïve patients
(mean EC50 FC, 0.91) and those harboring dual N155H/E92Q (4-fold) and Q148H/G140S (11fold) mutations in a panel of subtype B, A1, D, C, and recombinant AE recombinant viruses (465).
In a randomized, phase 2b, open-label clinical trial of ART naïve patients investigating
intramuscular CAB, resistance mutation Q148R emerged in one of the three patients who
experienced virological failure (286), and Q148R has also been observed in patient failing -oral
CAB (325). So far, long-acting injectable CAB has been tested in two phase III clinical trials,
FLAIR and ATLAS. In these trials investigating non-inferiority of monthly CAB+RPV compared
to current oral regimens, there was no emergence of resistance FLAIR study (466) and N155H
mutation which reduced CAB susceptibility by 2.7-fold was observed in ATLAS study (289). In
LATTE-2 trial comparing infectable CAB/RPV and oral CAB/3TC/ABC, R269R/G and Q148R
emerged in 2 patients with protocol-defined virological failure in CAB/RPV arm and only Q148R
showed phenotypic resistance to CAB (286). Overall, BIC, CAB, and DTG have higher genetic
barrier to resistance than EVG and RAL, but DTG and BIC show broader efficacy against resistant
viruses compared to CAB (457,459).

1.6

HIV-1 subtypes and recombinants

The HIV-1 epidemic is a result of zoonotic viral transmission of SIV from nonhuman primates to
humans mainly in regions of Western and Central Africa. Transmission from lentiviral strains,
SIVcpz (chimpanzees) and SIVgor (gorilla) resulted in HIV-1 groups M&N and groups O&P,
respectively. With HIV-1 groups O and P, SIVgor may have passed into chimpanzees prior to the
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jump to humans. HIV-2 originated from SIVsmm (Sooty mangabey). The high error prone HIV-1
RT and high turnover of HIV-1 virions within infected humans ultimately resulted into high
genetic diversity of HIV-1 circulating worldwide. HIV-1 is mainly divided into 4 main groups,
group M (major), O (Outlier), N (non M, non-O) and N (11). Group M is the most widely
distributed and is further divided into 9 subtypes: A-D, F-H, J and K (11). Globally, subtype C
accounts to the majority of HIV-1 infections (48%), subtype A (12%), subtype B (11%),
CRF02_AG (8%), CRF01_AE (5%), G (5%) and D (2%) of HIV-1 infections (467). HIV-1
subtype A is predominant in regions of Eastern Africa (468), Asia and other former Soviet Union
countries (469). HIV-1 subtype C is commonly found in Southern Africa, Eastern Africa, Brazil,
China, and India and has been increasing in regions of Brazil, Southwest China, Malaysia,
Scotland, and Uruguay. HIV-1 subtype B predominates in regions of North America (470), South
America (471), Australia (472), Europe (473), Middle East and Northern Africa (474). Subtype F
is mainly in regions of Eastern Europe and southern America. Subtypes E, G, H, J, and K are
mainly in countries of Central and West Africa. It is important to note that all of these HIV-1
subtypes had their origins in the Congo Basin, likely due to an unreported emergence of HIV-1
infections following the “opening” of this tropical rainforest region with Colonist expansion into
this region following the turn of the 19th century.
HIV-1 like all retroviruses has two copies of genomic RNA (diploid) on which RT can jump
between strands during reverse transcription to complete the proviral DNA (see section 1.3.3). In
cases of dual or super infection by two different HIV-1 strains within an individual human, these
two HIV-1 strains can dually infect a cell and produce a heterodiploid virus (a copy of an RNA
genome from both strains) which can then lead to recombinant HIV-1. Thus co-circulation of
different HIV-1 subtypes in the same geographical region will eventually lead to stable circulating
and unique recombinant forms (CRFs and URFs). A strain is recognized as CRF if it is isolated
from at least two unrelated individuals, fully sequenced and plays a role in HIV-1 pandemic. The
unique recombinant form (URFs) result from a mixture of subtypes found only in one HIV-1
infected individual (475). Approximately 20% of group M viruses found in the epidemic are not
“pure” subtypes but are recombinant forms (476). These recombinations are widely distributed in
regions of Western Africa and Asia with 101 CRFs identified as of 2020 (https://www.HIV1.lanl.gov/content/sequence/HIV-1/CRFs/CRFs.html).
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Originally known as subtype E, CRF01_AE, has subtype A genes and subtype E env, circulates in
South-East Asia and accounts to >80% HIV-1 infections in Thailand and 5% globally.
CRF01_AE/B is mainly found in Thailand, Georgia, and Malaysia. The CRF02_AG, which is
commonly found in Western Africa, accounts for 60% HIV-1 infections in Cameroon and nearly
5% of global HIV-1 infections. The former subtype I now classified as the CRF04_cpx, a subtype
A/G/H/K recombinant (477,478)(479), accounts for 2-10% of HIV-1 infection in Greece (480),
Cyprus and Mediterranean regions. CRF06_cpx from parental fragments of subtypes A, G, J, and
K is responsible for infections mainly in Burkina Faso and Mali; and CRF07_BC, and CRF08_BC
are the dominant HIV-1 forms in China (12, 13-Bertha 2008). CRF09_cpx from subtypes A, C
and D accounts for most HIV-1 infections in Senegal. Intermixed recombinant forms have also
been isolated with CRF18_cpx/CRF19_cpx isolated in Cuba, CRF06_cpx/A in Estonia and
CRF11_cpx/B in Switzerland.
The high degree of diversity between group M and O has not hindered occurrence of homologous
recombination between the two groups with patients carrying intergroup M and O replicative
competent (481). Recombination between HIV-1 and HIV-2 types has not yet been documented
probably because of wide diversity between the two groups, however, patients infected with HIV2 can subsequently be infected with HIV-1 (482).
HIV-1 Groups O, N, and P all appeared within or in the vicinity of Cameroon and never attained
the same foothold in the human population as HIV-1 group M. There is less than reported
infections with N and P while HIV-1 group O is responsible for ~50,000 infections worldwide.
HIV-2 strain shows low infectivity characterized by low viral loads and slow disease progression
in humans and this may explain its limited circulation/expansion in areas of Western Africa.

1.6.1

HIV-1 subtypes and drug resistance

Patients respond similarly to ART treatment irrespective of the HIV-1 subtype (483–485),
however, HIV-1 subtype may still influence ART outcomes and emergence of HIVDR. For
instance, despite susceptibility of HIV-1 subtype C and B strain-derived IN enzymes to the current
approved INSTIs, there is different treatment outcomes in patients infected with subtypes B and C
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infections on INSTIs (486). There is also less chance of subtype B viruses developing resistance
against DTG compared to subtype A/G and C viruses (429). HIVDR against NRTIs and PIs has
been shown to occur more frequent in subtype B compared to subtype C (26% vs 8% and 54% vs
23%) respectively. Faster emergence of HIVDR to NRTIs and PIs in subtype B vs C has been
shown in ART naïve and experienced patients (487). In Uganda, ART drug resistance and
treatment failure is more prevalent in subtype D compared to subtype A or subtype C infected
patients (488). The variability of INs at amino acid level between different HIV-1 subtypes is
relatively low ~8-12% however, higher entropy scores or amino acid variability is observed at sites
where mutations are selected for primary or secondary INSTI resistance.
Subtype-specific resistance mutations to INSTIs: Among HIV-1 subtypes, residues associated
with IN catalytic activity and common INSTIs mutations sites, N155, Q148, Y143 are highly
conserved, however there is variability at secondary resistance mutations sites among different
HIV-1 subtypes (489) (Fig. 16). HIV-1 subtype specific amino acid differences have been
observed near primary or secondary resistance mutations (490).
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Figure 16. HIV-1 IN of different subtypes. Across HIV-1 integrase gene there are a number of
differences in naturally occurring polymorphisms in different HIV-1 subtypes. These
polymorphisms may function as compensatory mutations in specific subtypes which may influence
differential selection of major mutations. HIV-1 integrase sequences of ART naïve patients were
downloaded from HIV-1 sequence database (http://www.HIV-1.lanl.gov/). Alignment, annotation,
and visualization was done in Bioedit (491). Blue represents the three catalytic triad residues of
CCD (D64, D116, and E152), green represents major resistance mutation positions, and red is the
natural polymorphisms naturally occurring between different HIV-1 subtypes. General consensus
of amino acids at a particular position between HIV-1 subtypes is represented by (.).

HIV-1 mutations at position G140 of HIV-1 IN occur more frequently in subtype B than nonsubtype B infected individuals (492) which also increases the frequency of Q148H/K/R mutations
in subtype B viruses (Table 1). This is attributed to the high genetic barrier to the emergence of
G140A/S in non-subtypes compared to subtype B. In subtype B virus, glycine at position 140 is
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coded commonly by GGT or GGC thus requiring a single transition G to A to replace glycine with
serine (G140S) or transversion G to C for the alanine (G140A). In contrast, glycine is commonly
coded by either GGG or GGA in non-B subtypes requires two nucleotide substitutions to change
to codon G140 mutants. In cell culture assays, R263K mutation selected by DTG and EVG is
frequent in HIV-1 subtype B and CRF02_AG, whereas G118R conferring resistance to DTG, RAL
and EVG is common in CRF02 A/G and C subtypes (429). Whereas G118R causes low-level
resistance to RAL in subtypes B and C, there is increased resistance to RAL by G118R in
CRF02_AG in cell culture and patient samples (437,493). E138K mutation which confers
resistance to RAL, EVG, and DTG in presence of Q148 mutations shows increased level resistance
to RAL in CRF02_AG compared subtype B viruses (437) (Table 1). Double mutation
E92Q/N155H in HIV-1 subtype C backbone shows 10-fold more susceptibility to RAL and EVG
compared to the same mutations in subtype B virus (486). On effect of subtype on IN enzyme
activity, H51Y causes significant loss in IN enzyme activity in CRF02_AG and B but not in
subtype C, and E138K leads to >55% reduction in enzyme activity in CRF02-AG but not in
subtype B and C (437). Strand transfer efficiency is restored by addition of E138K+H51Y to
G118R in subtype B but not as much with subtype C and CRF02_AG (437).
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Table 1. The INSTIs associated resistance mutations frequency and impact on
susceptibility in different HIV-1 subtypes
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a

A, C, D, F, G, CRF01, CRF02, CRF01, CRF05, CRF35; b A, C , D, F, G, H, J, CRF01_AE,
CRF02_AG, CRF03, CRF06, CRF09, CRF11, CRF12_BF, CRF13, CRF14_BG, CRF15, CRF18,
CRF19; c A, C, D, F, G, CRF01_AE, CRF02_AG. In bold, major INSTIs DRMs. In brackets, INSTIs for
which there is increased resistance in presence of respective DRMs.

Subtype-specific resistance mutations to PIs: Natural polymorphisms, M36I, V82I, L10I, L63P,
L10V, K20R, and V77I in protease gene of non-subtype HIV-1 in ART naïve patients are known
to reduce susceptibility to PIs in HIV-1 subtype B viruses (487,494). Substitutions at position 36
of HIV-1 protease seem to have differential impact on susceptibility of ART in different subtypes.
I36 appears as an accessory mutation and enhances resistance to ritonavir, ATV, and nelfinavir as
a natural polymorphism in non-B HIV-1 subtypes, specifically subtype C and CRF02_AG (83%)
but appears at only a 6% occurrence in subtype B ART naïve patients (495). In contrast, M36 has
this accessory/secondary resistance effect to PIs in HIV-1 subtype B (496).
Primary DRM, V82A/F/T/S selected by IDV and LPV does appear more frequently in subtype F1
than subtype B HIV-1 infected patients (497). In contrast, D30N results in highly impaired viral
replication in HIV-1 subtype C whereas this D30N is a primary PI resistant mutation in HIV-1
subtype B infected patients receiving a PI-based treatment (498). Lack of DRM D30N in some
subtypes may relate to lack of natural polymorphisms, L63P and V77I in subtype B compared to
non-B subtypes (495) necessary to compensate for D30N fitness loss. Mutation/natural
polymorphism L63P has been shown to compensate loss in viral fitness by the primary PI resistant
mutation, L90M mutation (499) found at lower frequency among subtypes C, F1, and intersubtype
BF compared to subtype B (500–502). Finally, emergence of M89T mutation which causes
phenotypic resistance to ATV, NFV (nelfinavir) and LPV is influenced by presence of
polymorphism M89 in subtypes A, C, and CRF01_AE, and L89 in subtype B viruses (503). The
mutation L89M increases genetic barrier for emergence of L90M and reduces susceptibility to
IDV, RTV and NFV in subtype F though remains susceptible in subtype B viruses with exception
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of IDV (504).

In-vitro assays also reveal possible polymorphisms associate with hyper

susceptibility to PIs. For example, CRF02_AG viruses carrying protease polymorphisms G17E
and I64M confer hypersusceptibility to NFV, ATZ, and IDV inhibition (505). Accessory
mutation/polymorphism I93L is also associated with hypersusceptibility to LPV in subtype C
viruses compared to HIV-1 subtype B viruses (506).
Subtype-specific resistance mutations to NRTIs and NNRTIs: Generally, amino acid substitutions
conferring resistance to NRTIs in subtype B match those of non-subtype B (507). However, there
is more rapid emergence of the K65R in RT coding region in patients infected with subtype C
compared to individuals infected with subtype B, G, and CRF02_AG (508). Lysine 65 of HIV-1
RT confers resistance to TDF, ABC, didanosine (DDI), and d4T and is coded by AAG in subtype
C and AAA in subtype B such that a single versus double transition G to A mutation (respectively)
is necessary for the Arginine. Contrary, K65R is less frequent in subtype A compared to subtype
B and C HIV-1 in patients on ART (509). Otherwise, the frequency of thymidine analog drug
resistance mutations (D67N, K70R, L210W, T215F/Y) is similar in patients infected with HIV-1
subtype A, B and C and receive a thymidine analog (D4T or AZT) in a treatment regimen (509),
though M41L has been found to be more frequent in subtype B than C infected patients (497).
In relation to NNRTI resistance, mutations in HIV-1 pol associated with NVP and EFV, K103N,
V106M and, A98S occur more frequently in those infected with HIV-1 subtype C compared to
subtype B. This was observed in both ART naïve and experienced patients receiving an NNRTIbased treatment regimen (510). Mutation K103N associated with NVP, and EFV, is less frequent
in subtype A and D compared to HIV-1 subtype C (511), and Y181C mutation which reduces
susceptibility to NVP, EFV, etravirine, and rilpivirine shows more prevalence in subtype B and C
compared to subtype A (509). Minority species of K103N or Y181C detected by ultrasensitive
PCR were found in 42% of subtype A/AE compared to 70-87% of subtype C HIV-1 infections
(512). V106M is preferentially selected in subtype C under NVP/EFV therapy compared to V106A
commonly seen in subtype B viruses (399,513). N348I mutation in connection domain of HIV-1
RT reduces susceptibility of NVP, EFV, AZT, and DDI and is commonly associated with M184V
and TAMs in HIV-1 infected patients (514–517). There seem to be decreased susceptibility for
EFV and NVP in subtype A and D viruses than for subtype B and C when N348I mutation is
present (518). Rilpivirine is a second generation NNRTIs with a high genetic barrier to resistance
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in vitro (519) but with reduced susceptibility in presence of E138A/K/Q mutations (520). In HIV1 ART naïve and experienced patients, E138A/K/Q mutations are found at a higher frequency in
HIV-1 subtype C than subtype B infected patients (521).
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Chapter 2

2 HIV-1 treatment, drug resistance and subtypes in Uganda
2.1 Preface
Uganda is one of the countries which has overcome a historical high prevalence of HIV-1 infection
from 30% in 1992 when 18% of population was infected to the current 5.7% reported in 2018
(522,523). Uganda was also one of the first countries in Africa to access/distribute cART and with
Dr. Anthony Fauci, was the primary architect of the U.S. President's Emergency Plan for AIDS
Relief (PEPFAR) treatment plan. Despite the success of NNRTI-based first-line therapy under
PEPFAR and UNAIDS/Global Fund in Uganda, there has been increasing prevalence of HIVDR
leading to the implementation of PI-based second-line and RAL-based third-line treatment
regimens (always with two NRTIs). Uganda has recently surpassed the WHO threshold of >10%
prevalence of pretreatment HIV-1 drug resistance (PDR) to NNRTIs (524). WHO recommends a
change of first-line regimens with PDR prevalence > 10% and Uganda has switched from
NNRTIs+2NRTI for first-line to DTG/3TC/TDF regimen for patients initiating cART (525). DTG
not only prevents the rapid emergence of resistance with first line cART but is also effective in
viruses harboring most DRMs. Uganda is among few countries with a very diverse population of
HIV-1 strains which makes studying HIV-1 subtype dynamics possible. Indeed, HIV-1 subtypes
have been shown to influence rate of replication, pathogenesis, and occurrence of HIVDR in some
HIV-1 infected populations. In this chapter, we describe ART options, HIVDR, and role of HIV1 subtype distribution on treatment outcomes in the Uganda population.

2.2

HIV-1 history in Uganda

For many years, HIV-1 spread in Uganda without knowledge of what exactly was causing the
“slim” body stature in individuals who were immunocompromised. By the time HIV-1 was
recognized as a causative agent for AIDS, the rate of HIV-1 prevalence had already skyrocketed
with over 18% of general population harboring HIV-1. HIV-1 was first recognized in Rakai district
in South west part of Uganda in 1982 by a young resident doctor who was seeing 29 patients
having clinical manifestations including fevers and sweats, oral candidiasis, diarrhea, Kaposi’s
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sarcoma, lymphadenopathy, and genital warts. All these patients had uniform characteristic of
extreme weight loss which was locally referred to as “slim” (3,526). In 1986, 900 cases were
reported in the country (Uganda AIDS control program, 1989). Despite the first HIV-1 cases being
described in 1982, HIV-1 epidemic in Uganda likely originated in 1960 (1950-1968) for subtype
A1 and 1973 (1970-1977) for subtype D in regions of Masaka (South-West of country) and then
spread to the Kampala capital region (527). The 1970s-1980s was likely the period of exponential
growth and by 1985, HIV-1 prevalence was reported to be 11% among population of pregnant
women (528) and 18% in the general population. By 1992, HIV-1 prevalence in pregnant women
receiving antenatal care had risen to 30% and 3% in urban and rural areas, respectively. Through
public sensitization and behavioral changes including reduction of casual sex patterns and use of
condoms, there was a sharp decrease in HIV-1 prevalence among pregnant women from 30% in
1992, to 21% in 1998 and 6% in 2000 (523). The rate of HIV-1 in adults has been steady over the
last few years with prevalence of 7% in 2001, 6.5% in 2009, and most recently 6.8% in 2019
(529,530).

2.3

ART treatment in Uganda

The government of Uganda in collaboration with UNAIDS launched a two-year pilot program,
Drug Access Initiative (DAI) in 1997 with mandate of improving HIV-1/AIDS care access for
individuals living with HIV-1. The initiation of DAI program allowed over 912 HIV-1 infected
individuals to access ART through the program (531,532). However, the extremely high annual
cost of HIV-1 drugs to the tune of US $ 12,000 in 1997 to about US $7,200 in 1999 for first-line
regimen was a huge stumbling block to the program (531). The ART program in Uganda only
changed trends of HIV-1 infections after importation of generic drugs by the Joint Clinical
Research Centre (JCRC) in 2000 which allowed patients to access ART at an end-user price of US
$ 31/month for generic ARVs (AZT/3TC/NVP) produced by Cipla in India breaking the
inequitable international TRIPS agreement (531,532). This allowed more patients access ART
with some economic means. Despite the multinational pharmaceutical companies signing an
agreement to lower the cost of ART for developing countries in May 2000, the most significant
reductions in cost of ART coincided with importation of generic drugs from Cipla by JCRC in
October 2000. Indeed, the number of HIV infected patients with access to generic ART at JCRC
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increased from 912 in 2000 to 3,400 in 2002 (532). Further progress was made with initiation of
PEPFAR program in 2004. By 2005, 75% of HIV-1 infected patients were receiving ART in
Uganda (533). JCRC being one of major PEPFAR grantee, 19,000 HIV-1 infected patients were
receiving ART in the first 18 months of PEPFAR including 2,000 orphans and pregnant women
(533). JCRC kept playing a critical role with over 60,000 HIV-1 infected patients receiving
treatment through the JCRC by the mid-2000s and nearly 200,000 through clinics across the
country. In 2017, the Uganda government adopted 2015 WHO recommendation of “test and treat”
which entailed initiating ART for all individuals testing HIV-1 positive, irrespective of their CD4
count or clinical stage.
First-line regimens in Uganda: In 1997-2000, cART consisted of three affordable choices for
patients with high personal incomes: 2 NRTIs + either NNRTI or PI; or 2NRTIs + hydroxyurea
(the latter showing only partial suppression and never used widespread in high income countries).
In 2002, treatment guidelines recommended use of triple therapy of AZT or D4T plus 3TC/NVP
as first line in Uganda despite limited access to this treatment for vast majority of Ugandans (534).
The revised ART guidelines of 2008 recommended first line of AZT/3TC/NVP or EFV in both
adults and children/infants but EFV was not recommended in children <3 years and <13 kgs (526).
By 2008, if an infected individual had access to a clinic and had CD4 cell counts <200/mm3, this
treatment was available for free through the PEPFAR, the Global Fund, or the Clinton Foundation.
Since first roll-out of ART in Uganda in 2002, ART regimen constituted NNRTIs+ NRTIs with a
number of transitions including d4T replacing AZT in 2008 and TDF replacing d4T (or AZT if
still in use) by 2012. D4T and AZT had long since been abandoned by the high income countries
due to mitochondrial toxicity, anemia and peripheral neuropathy (526,531,535). Due to favourable
properties of DTG including high potency, low toxicity, higher genetic barrier to resistance, and
increased circulation of NNRTI resistance, there was a switch in the cART naïve from an NNRTIbased treatment to the TDF/3TC/DTG combination (525). In March 2018, Uganda transitioned
from NNRTIs-based to once-daily fixed dose of TDF/3TC/DTG for all patients initiating ART and
eligible ART experienced patients except women and adolescents of childbearing potential or on
effective contraception (525). In children 3<10 years and less than 35 kg ABC/3TC/LPVr is
recommended (525). The updated 2020 HIV-1 treatment guidelines now recommend initiation of
TDF/3TC/DTG in all adults and adolescents ≥ 30kg including pregnant and breastfeeding women
with use of EFV (400mg) where DTG is contraindicated (536). In children ≥ 20Kg - <30Kg,
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ABC/3TC/DTG is recommended first-line with LPV/r, EFV, RAL, or triple NRTIs use when DTG
is contraindicated (536). A study at one of the HIV-1 treatment specialized centers in Uganda,
shows possible increased prevalence of hyperglycemia in patients who transitioned to DTG though
this group had significantly higher number of older, male, and long-term ART experienced patients
compared to patients who did not transition to DTG (537).
Second-line regimens in Uganda: ART expansion phase starting in 2002, recommended a secondline of AZT or d4T plus DDI/LPV/r (534). The revised cART treatment and care guidelines of
2008 recommended ABC/DDI/LPVr, FTC/LPVr, or AZT(or ABC)/DDI/LPVr as second-line
regimen in adults and children/infants respectively (526). In 2018 national HIV-1 treatment
guidelines recommended second-line of AZT/3TC/ATVr in adults and AZT/3TC/RAL or DTG in
children 3<10 years (525). The 2020 HIV-1 treatment guidelines recommend TDF/3TC/LPV/r
second-line in ≥ 30kg patients failing on DTG-based first-line, TAF or ABC/3TC/LPV/r in
children ≥ 20Kg - <30Kg, and ABC/3TC/LPV/r in children weighing <20Kg (536).
Third-line regimens in Uganda: Viral load of <1000 copies/ml with evidence of >95% adherence
to treatment warrants a switch to third-line regimen under guidance of genotyping test (525). The
choice of third-line regimen is guided by HIV-1 genotype testing, and regimens are selected by
national third-line ART team basing on genotypic profile, available ART options and patient
treatment history (525). Third-line treatment consists of regimens active against resistant viruses
and commonly DRV/r, RAL, and ETR, or two recycled NRTIs are used in these highly treatment
experienced patients. Third-line cART remains the last line of treatment due to inaccessible CCR5
or fusion inhibitors in Uganda. Ugandan children (<18 years) carrying multiple DRMs after failure
on second-line, responded well to RAL-based third-line after ~5 years of follow up (538).

2.4

Distribution of HIV-1 subtypes in Uganda

HIV-1 subtypes A and D account for the majority of HIV-1 infections in Uganda (539,540), with
subtype C (541–543), B (542,544,545), and G (546) only rarely reported in the country. The A/D
unique and stable recombinant forms (URFs and CRFs) account for 9% to 30% of HIV-1 infections
(540,547,548). Subtype C and other CRFs account to <10% of HIV-1 infections in Uganda (540).
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HIV-1 subtype A emerged in Uganda earlier than subtype D (549) and it was shown to have
originated from Congo which then spread from East to West in the country with subtype A now
predominant in HIV-1 infections of Kenya. HIV-1 Subtype D in Uganda is said to have originated
from Tanzania but originated in the Congo Basin like all HIV-1 group M strains. Subtype D now
predominates the Southwest of the country and has had more limited spread to the North and East
(550–552). Consequently, distribution of HIV-1 subtypes vary in different geographical locations
in the country. In central regions of the country-areas of Kampala and Entebbe, subtype A is only
slightly more prevalent than D (50 and 30% respectively) (539,548,553) with subtype A becoming
more prevalent near the Kenyan border; and subtype D reaching a peak in prevalence (>70%) in
the Southern Rakai district (550,554). Despite HIV-1 subtype D being of the highly prevalent HIV1 strains, its prevalence has been steadily decreasing while subtypes A, C, and A/D and A/C URFs
have been increasing in Uganda (555). HIV-1 subtype A is easily spread through personal and
community transmission (556), however, with increased access to more potent cART, the
incidence rates of subtype A will also likely decrease in the population. By using phylogenetic
analyses, HIV-1 transmission dynamics through clusters has been studied through a cohort of HIV1 patients in Southwestern Uganda. In a 7-year (2004-2010) study of 94 participants, 37% of
sequences (partial gag and env) accounted to 13 transmission clusters and revealed a possible high
sexual risk behavior and super transmitters in the community (552). Phylogenetic analysis of 3796
HIV-1 pol sequences from HIV-1 infected patients in Southwestern Uganda, identified 524
clusters and clustering was largely associated with being a female and staying within general
population cohort set up previously to analyze trends in HIV-1 prevalence and incidence, their
determinants and pathogenicity. The clustering dynamics revealed significant viral spread from
general population cohort without viral introduction from outside the cohort (557).

2.5

Role of HIV-1 subtype on body response to infections

In Uganda, HIV-1 subtype is associated with different clinical and disease manifestations. HIV-1
subtype D is associated with faster disease progression than subtype A in a Uganda population
(558). In ART naïve and experienced HIV-1 infected patients, cART failure is more frequent in
subtype D compared to subtype A infected individuals (488). Subtype D infected is also associated
with lower CD4+ T cell count and faster progression to death and AIDS, compared to subtype A
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(539,558). Subtype D also shows significantly lower transmission rate than subtype A among HIV1 discordant couples (556). Increased ability to use both CXCR4 and CCR5 coreceptors during
diseases progression with subtype D (559), contrary to an almost exclusive use of CCR5 by HIV1 subtype A (558,560) may perhaps explain the high virulence of subtype D. HIV-1 infected
Ugandans infected with CCR5 viruses have higher CD4 cell count than CXCR4 or CCR5/CXCR4
viruses (561). However, independent of co-receptor usage, HIV-1 subtype D isolates have higher
replicative fitness in primary human T cells when compared with HIV-1 subtype A isolates and
higher replicative fitness of subtype D HIV-1 directly correlated to the faster rate of disease
progression as measured by a sharper decline of CD4 T cells in blood (562). This faster decline
CD4 T cells was observed without any usage of CXCR4 by subtype D HIV-1.
Subtypes A and D infected Ugandans also have increased CD4+ and CD8+ T cell activation
compared to subtype B infected counterparts (563). CD4 dysfunction characterized by higher
expression of programmed cell death receptor -1 (PD-1) and increased cell apoptosis is more
pronounced with subtype D compared to subtype A in ART naive Ugandans (564). Subtype D
infected patients also exhibit pronounced loss of invariant natural killer T (iNKT) cells whereas
FoxP3+ regulatory T cells (Tregs) loss is more frequent in subtype A infected Ugandans (565). On
contrary, there seem to be no difference in the initial cART response among patients infected with
HIV-1 subtype A, C and D (566).

2.6

HIV-1 drug resistance in Uganda

In Uganda, the high prevalence rates of HIV-1 infections (~5.7%) (567) and frequent use of low
genetic barrier to resistance regimens have led to increased levels of HIVDR. Uganda much more
like the rest of Africa countries, first generation NNRTIs, NVP and EFV have constituted firstline combination (531,568) and difficult to take LPV has frequently been used in second-line
treatment (526). The high prevalence of HIVDR can also be explained by early roll out of ART in
2002 compared to other African countries (534). Overall, over 10% of HIV-1 infected Ugandans
on ART harbor drug resistance variants, and over 15.4% initiate ART already carrying HIV-1
transmitted drug resistance (TDR) (524).
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HIVDR in ART naïve patients and those with previous exposure to ART has been increasing in
Uganda (569). Over the years, the frequencies of HIVDR in patients initiating ART in Uganda has
increased from 0% (2006–2007) (570), to 8.6% (2009–2010) (571) and 15.4% from WHO survey
(2014–2016) (524). This is largely contributed by NNRTIs-associated TDR compared to other
classes of ART. HIV-1 infected patients carrying TDR can achieve viral suppression on first-line
(572), however, escalating TDR beyond 10% threshold, called for substitution of NNRTI
component following WHO treatment guidelines (524). In ART naïve children and > 12 years,
HIVDR to first-line between 2010-2011 was found at 7.7% (573), and 16.9% (574). Among
different patient groups, TDR among fisher folks has been observed between 5-15% for NNRTIs
and <5% for NRTI and PI regimens (575), 3% for NNRTIs among female sex workers (576), and
<5% for NRTI, NNRTI and PR among women attending antenatal care (570).
HIVDR to thymidine (AZT, d4T) and non-thymidine analogues used in first-line regimens has
been observed in 58.8-95% HIV-1 infected Ugandans (540,577). Thymidine associated mutations,
M41L, D67N/G, T215I/F/Y/T, and K219N/K/E/Q, are frequently selected in HIV-1 infected
Ugandans failing on first-line ART (540,577,578). Non-TAM, M184V/I, K65R/K, are the most
prevalent mutation observed in patients failing first-line regimens (540,577,579,580). NNRTIs
associated resistance account to the majority of first-line resistance with 73.2-96% of first-line
failures harboring NNRTIs-associated resistance (540,577,581). The major frequently selected
NNRTIs mutations include, K101E/Q, K103N/S, G190A/S/E/G, and Y181C (540,577–579,582).
NNRTIs major resistance mutations, K103N, G190A, and Y181C have low fitness cost and
therefore frequently observed even after many years after switching to non-NNRTI regimen
(583,584). We have shown previously that over 55% of patients failing PI-based second-line in
Uganda harbor NNRTIs- resistance mutations (540). There has also been a challenge of using NVP
monotherapy to prevent mother to child transmission which may predispose women to HIVDR.
Indeed the risk of HIV-1 resistance after a single-dose NVP has been estimated to be 32% among
Ugandan women (585,586). Starting babies with prior exposure to single dose NVP to NNRTIs
(due to lack of pediatric PI formulations) further exposes them to NNRTIs resistance. HIVDR has
been observed in over 35.7% of children in prevent mother to child transmission program in
Uganda (573). In some cases, children failing first-line and some with pre-exposure to single dose
NVP, all have been found to harbour NRTI and NNRTIs resistance (587) and impact of HIVDR
in children < 3 years is stronger and has been associated with VF and acquired drug resistance
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(574). Children failing first-line and harboring common M184V, K65R/N, and K103N mutations
may respond well on boosted LPV containing second-line regimens (588). At first-line failure,
CD4 cell count at baseline <250 cells/ul and viral load > 100,000 copies/ml have been shown as
independent predictors of HIVDR at 12 months in HIV-1 infected Ugandans (554,577). The type
of NRTI+ NNRTIs-first-line regimen has been associated with accumulation of TAMS and
K103N, and poor adherence predicts emergence of K103N and reduced virological response to PIbased regimens in Ugandan children (588). Starting HIV-1 patients on AZT containing first-line
compared to TDF, and ART duration of >82 weeks have been shown to be independent predictors
of acquired HIVDR (589).
Following two consecutive viral load of <1000 copies/ml with 3-6 months apart and adherence
support after first viral load test, patients failing on first-line are switched to PI-based second-line,
regimens (525). The boosted LPV has been commonly used in second-line combination until
recently when the country switched to boosted ATV and 2 NRTIs (525). PIs have higher genetic
barrier to resistance compared to NNRTIs or NRTIs. In patients failing PI-based second-line, PI
resistance has not or nearly observed (578,581) but also detected at 18.5% (590), and 19.4% (579)
in Ugandan patients. Major PIs mutations, V82A, I54A, M46I/L are frequently observed in
patients failing PIs-based second line in the Uganda (540,579,590). In patients failing second-line
and carrying PI-resistance, DRV remains the only active part of PI cocktail for third-line treatment
(579). PI resistance at first-line failure is very low in children (<12 years) and over 20% fail
second-line but lacking PI resistance (580). PI resistance has also been shown to be rare in children
(<20 years) failing second-line (588). Sub-optimal adherence and less weight have been associated
with HIV-1 treatment failure of second-line in Ugandan children (<12 years) (580).
Data on HIVDR to third-line regimens in Uganda is very limited. In patients failing RAL-based
third-line, over 48% of patients carry RAL/EVG associated primary DRMs (540). About 5% of
patients failing RAL-based third-line regimens carry DTG-associated DRMs and 2-10% harbor
secondary mutations against INSTIs. Among major DRMs against INSTIs, N155H mutation is
most frequently selected and Q148R/K least selected INSTIs associated mutation in HIV-1
infected Ugandans failing third-line regimens (540). In INSTIs naïve HIV-1 patients, major
INSTIs mutations, Y143H, and Q148R only are observed at low frequency (1.1-1.6%) (578). HIV1 infected patients from 4 African countries including Uganda and initiated on RAL-intensified
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first-line regimen, 9% were found with RAL/EVG resistance but no high-level DTG resistance
(591). Primary INSTIs associated DRMs in ART naïve patients in Uganda and other 4 African
countries have been detected only at <20% frequency (592).
Despite higher entropy scores or amino acid variability at sites where INSTIs mutations are
selected for primary or secondary INSTI resistance between subtype B and non-B HIV-1 subtypes,
there is very limited data on prevalence, genotype, and impact on susceptibility to INSTIs by these
DRMs in non-B HIV-1 subtypes. Observations in the subsequent chapters show absence of INSTIs
associated mutations in INSTIs naïve (n=366) but in 47% of patients failing on RAL-based
regimen. Among the 47% with INSTIs DRMs, 4% (2/51) of patients (subtype A and D) had
multiple primary INSTIs DRMs conferring resistance DTG, BIC, and CAB, a unique observation
in both LMICs and HICs. The viruses harboring single RAL/EVG primary INSTIs mutations
(~50%) remained susceptible to DTG, BIC, and CAB with fold-change in EC50 values nearly
equivalent to that of wild-type. We confirmed that subtype A with E138A/G140A/G163R/Q148R
and subtype D with E138K/G140A/S147G/Q148K viruses on RAL-based regimen are highly
resistant to all currently available INSTIs in LMICs. Emergence of INSTIs resistance appears in
part to be subtype specific with even N155H reducing DTG susceptibility more so in subtype A
and D than in subtype B HIV-1. In contrast to commonly observed G140S/Q148H mutations in
subtype B viruses, non-B HIV subtypes commonly carried G140A/Q148KR mutations. The
potential novel resistance mutations to INSTIs, I203M and I208L, did not singly reduce
susceptibility to either RAL or DTG, further analysis is warranted to determine how these novel
mutations influence susceptibility to INSTIs in HIV-1 subtype A and D infected patients.
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3.1

Preface

Currently there are over 37 million people infected with HIV-1 worldwide and over 35 million
people have died due to HIV-1 related complications. Since the introduction of the first ART
regimen, AZT in 1987, there have been tremendous progress in different ART regimens to the tune
of 40 different regimens available today. In the due course, more potent ART regimens with better
tolerability, safety, and activity with resistant viruses have been made accessible. This achievement
has to the great extent been realized in HICs which have capabilities to get access to these better,
high-cost drugs. INSTIs are the latest class of ART in this category of drugs with high potency
and yet good safety profile.
Dolutegravir, one of the second generation INSTIs, was approved in 2013 by FDA but Uganda
much more like other LMICs could only have DTG widely accessible in late in 2018. DTG was
introduced in Uganda in form of a triple combination of DTG/3TC/ABC in 2019. Yet still, data
on DTG susceptibility in subtype A, D, C and recombinant viruses commonly circulating in
Uganda is not available. The study presented herein, tacked this challenge by screening for DTG,
RAL and EVG associated DRMs in HIV-1 infected individuals on different lines of ART in
Uganda. I selected this cohort of patients, carried out laboratory assays, and completed the
statistical analyses for the study.
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3.2

Abstract

Objectives: To screen for drug resistance and possible treatment with Dolutegravir (DTG) in
treatment naïve patients and those experiencing virologic failure during first, second, and third line
combined antiretroviral therapy (cART) in Uganda.
Design: Samples from 417 patients in Uganda were analyzed for predicted drug resistance upon
failing a first (N=158), second (N=121), or third line (all 51 involving Raltegravir [RAL])
treatment regimen.
Method: HIV-1 pol gene was amplified and sequenced from plasma samples. Drug susceptibility
was interpreted using the Stanford HIV-1 database algorithm and SCUEAL was used for HIV-1
subtyping.
Results: Frequency of resistance to nucleoside reverse transcriptase inhibitors (NRTI) (95%) and
non-NRTI (96%) was high in first-line treatment failures. Despite lack of NNRTI-based treatment
for years, NNRTI resistance remained stable in 55% of patients failing second line or third line
treatment and was also at 10% in treatment naïve Ugandans. DTG resistance (n=366) was not
observed in treatment naïve or individuals failing first and second line cART and only found in
two patients failing third line cART while 47% of the latter had RAL and Elvitegravir (EVG)
resistant HIV-1. Secondary mutations associated with DTG resistance were found in 2% to 10%
of patients failing third line cART.
Conclusion: Of fourteen drugs currently available for cART in Uganda, resistance was readily
observed to all antiretroviral drugs (except for DTG) in Ugandan patients failing first-, second-, or
even third-line treatment regimens. The high NNRTI resistance in first line treatment in Uganda
even among treatment naïve patients, calls for the use of DTG to reach the UNAIDS 90:90:90
goals.
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3.3

Introduction

By 2016, there were 36.7 million people living with HIV-1 infection worldwide, and 1.8 million
new infections diagnosed in the same year (593). Uganda is among the countries with the highest
burden of HIV-1 infections, with approximately 1.5 million (7.1%) people living with HIV1/AIDS and 57% of them receiving combined antiretroviral therapy (cART)(594). Unfortunately,
due to various sociological and economic factors, HIV-1 drug resistance has been rapidly emerging
in patients receiving cART such that HIV-1 drug resistant variants are now responsible for at least
9% of the new infections(488).
In Uganda, as most of sub-Saharan Africa, over 57% of patients have access to TDF- and EFVbased first line regimen recommended by the World Health Organization (WHO), while less than
50% of patients are receiving the DTG- and DRV-based first-line regimens recommended by the
International Antiviral Society – USA(595). However, rapid emergence of HIV-1 drug resistance
to first line B1a rated treatment regimens argues for increasing access to more effective cART,
which may lead to better treatment outcomes, lower adverse events/drug toxicity, and higher
barriers for drug resistance. DTG, a second-generation Integrase Strand Transfer Inhibitor
(INSTI), Elvitegravir/cobicistat (EVG/cobi) or Raltegravir (RAL) are three “backbone” INSTIs
recommended for first line treatment regimens in combination with tenofovir disoproxil
fumarate/emtricitabine (FTC) (or with tenofovir alafenamide/FTC when combined with
EVG/cobi)(596). DTG/abacavir/lamivudine is also employed if the patients are screened to
exclude those with an HLA B57 allele. Rilpivirine along with the latter NRTIs are used for new
first line treatment regimens. Despite these preferences for treatment in HICs, at the JCRC in
Uganda, currently less than 1% of the 60,000+ patients receive this first line cART recommended
by the CDC for HICs.
Equally important, in vivo DTG resistance has rarely been observed even in those few patients
showing virological failure in NRTI-experienced but INSTIs-naïve patients(435). In vitro studies
characterizing the DTG-associated R263K mutation in subtype B, C, and CRF02_AG HIV-1
strains, showed early emergence of R263K in subtypes B and CRF02_AG, whereas the G118R
substitution was only observed in subtype C and CRF02_AG (429). It is possible that HIV-1
strains from different subtypes may explore distinct paths, selecting for different mutations, to
escape DTG pressure. Moreover, while resistance to EVG and RAL comes at high fitness cost
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(597), the DTG-resistant R263K mutation is even slower to emerge and more debilitating to HIV1 replication. The R263K mutation observed in clinical and in vitro studies, and secondary
mutations such as H51Y, M50I and E138K observed in cell culture studies, do emerge during DTG
treatment but appear unable to restore replication capacity of the virus (434,598,599). DTG can
also inhibit most HIV-1 isolates resistant to RAL and EVG which relates to its success in RALexperienced patients in the VIKING-3 study (318).
Despite the strong safety profile and success of DTG in both first and second line treatments, its
use in LMICs has been minimal. DTG has been extensively tested in patients infected with subtype
B, with no difference on DTG susceptibility been observed in non-B subtype HIV-1 strains in
dose-escalating/selection experiments (600). However, little is known about DTG treatment
outcomes in patients infected with subtype A and D HIV-1 primarily found in Uganda (601).
In this study, we evaluated the possible treatment with DTG in cART to treat HIV-1 infected
Ugandan individuals based on the current drug resistance profile in treatment naïve and highly
treatment experience patients. Drug susceptibility was predicted in 417 plasma samples from
treatment naïve individuals (N) (n=87), first-line failures (FF) (n=158), second-line failures (SF)
(n=121) or third line/RAL-based antiretroviral failures (RF) (n=51). Our results did not predict
DTG resistance in HIV-1 infected treatment-naïve patients, nor from individuals failing different
cART regimens, highlighting the suitability of DTG-based therapies to treat HIV-1 infected
patients in Uganda at any stage of the disease.
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3.4

Materials and methods

Samples for the study
This was a retrospective study that assessed the prevalence and impact of DTG associated
mutations in patients failing on different treatment regimens. Samples were collected from the
WHO, CAP, and NIH-VQA-accredited Center For AIDS Research (CFAR) Laboratory of the
Joint Clinical Research Center (JCRC) in Kampala, Uganda. The JCRC is one of the first HIV-1
treatment centers in the country to roll out cART and currently the only site licensed to provide
INSTIs in the country. The patient database in the CFAR laboratory was used to access the patient
demographics, medical, and treatment history of the study samples. A total of 440 plasma samples
were collected from patients receiving routine treatment care at the JCRC and with virological
failure, defined by a viral load above 1,000 copies/mL and/or CD4+ T-cell counts below 250
cells/mm3. These virological failures included plasma samples from 90 N, 165 FF, 125 SF, and 60
RF patients. Antiretroviral therapy (ART) naïve samples came from the Pan-African Studies to
Evaluate Resistance (PASER) network (602), the Monitoring Antiretroviral Resistance in Children
(MARCH) observational cohort study (603), and the Hormonal Contraception and HIV-1 Genital
Shedding and Disease Progression among Women with Primary HIV-1 Infection (GS) study (604).
Forty two of 165 FF samples came from the Europe-Africa Research Network for Evaluation of
Second-line Therapy (EARNEST) trial (605). The rest of the samples were patient samples
collected during routine Sanger genotyping testing at the JCRC. Ethical clearance was obtained
from the IRBs at the JCRC and UHCMC/CWRU (EM-10-07 and 10-05-35)
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RNA extraction and PCR amplification
Viral RNA was extracted from 440 plasma samples using a QIAamp viral RNA Mini Kit (Qiagen)
according to the manufacturer’s instructions. Reverse transcription of the full-length HIV-1
integrase (IN)-coding region from extracted viral RNA and amplification was done with the sense
primer RTA9F (5′-TATGGGGAAAGACTCCTAAATTTA-3′) and antisense primer 3Vif (5′AGCTAGTGTCCATTCATTG-3′) using a Superscript III single RT-PCR system with Platinum
Taq DNA polymerase kit (Thermo Fisher Scientific) as per manufacturer’s instructions. Nested
PCR

was

done

using

the

sense

primer

INTFEXT1

(5′-

AGAAGTAAACATAGTAACAGACTCACA-3′) and antisense Vif 3 reverse 1 primer (5′GTCCTGCTTGATATTCACACC -3′) using a Platinum Taq kit (Thermo Fisher Scientific) as per
manufacturer’s instructions to generate amplicon of 1433 base pairs. Amplification of protease
(PR) and reverse transcriptase (RT) regions was done as previously described (488). The amplicon
was purified using ExoSAP-IT enzyme (Thermo Fisher Scientific) and quantified using a Qubit
fluorometer (Thermo Fisher Scientific).
Cycle sequencing and sequence analysis
The HIV-1 IN as well as the PR and RT coding regions were amplified and analyzed on a Sanger
sequencing platform. Briefly, quantified and purified PCR product was sequenced with primers
spanning the full length of the IN gene (1-288 amino acids): Vif 3 reverse1 (5′GTCCTGCTTGATATTCACACC-3′), INTREXT (5′-AATCCTCATCCTGTCTAC -3′), and
INTFEXT1 (5′-AGAAGTAAACATAGTAACAGACTCACA-3′). PCR product was sequenced
with ABI Big dye terminator (v3.1) (Thermo Fisher Scientific) according to manufacturer’s
instructions on ABI 3730xl sequencing platform (Life Technologies, Carlsbad, California, USA).
A total of 417 samples (N = 87, FF = 158, SF = 121, and RF= 51) were amplified and sequenced
successfully for the IN gene (Fig. 17, Table 2).
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Figure 17. The workflow chart of the patient numbers and their respective groups. FF
consisted of patients who were on NNRTI-based combination therapy, SF had PI-based
combination, RF had RAL backbone and N had not been exposed to ART. Abbreviations: INSTIs,
Integrase Strand Transfer Inhibitors, RT, reverse transcriptase, PR, protease.

Sequences were analyzed using RECall (beta v3.02) program as recommended by the WHO(606).
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Table 2: Clinical and virological characteristics of the patients in the study
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The HIV-1 subtype was predicted using SCUEAL subtype classification algorithm. Viral loads were
assayed using Abbott m2000sp/rt or Roche COBAS Amplicor Monitor ultrasensitive tests, v1.5. a The total
number of patients tested for INSTIs resistance in each patient group. bDescription of the ART combinations
in the study, and the number of patients taking that combination. ND, not determined. Other, the number
of ART combinations which were less prescribed i.e., only one patient for each of these ART drug
combinations: (3TC, TDF, NVP) (AZT, D4T, 3TC, NVP) (3TC, EFV, LPVr) (3TC, EFV, ATVr) (ABC,
DDI, LPVr) (TDF, 3TC, ATVr) (EFV, DDI, LPVr) (EFV, RAL, DRVr) (TDF,3TC, RAL, ETR) (TDF,
FTC, RAL, DRVr) (RAL, ETR, LPVr). cThe average number of patient viral loads (copies/ml x 105), ND,
not determined. dThe percentage of patients with HIV-1 unique circulating recombinant forms (CRFs);
A1/C, A1/AE, D/U, J/A1,C/G, AE/D, A1/U, A3/U and CRF35. Until the time ATVr was available and
incorporated into national treatment guidelines, LPVr was infrequently provided as second line
monotherapy if resistance patient had drug resistance to 3TC and AZT.

Stanford resistance predictions were obtained using a Python client, SierraPy 0.1.2, to automate
transactions with the Stanford HIV-1db Sierra web service algorithm v8.3 (607).
Subtype classification
The resulting JSON files were converted into CSV files using an in-house R script. SCUEAL was
used for HIV-1 subtype classification and recombination detection (608). This algorithm maps
sequences to a phylogeny of subtype reference sequences by maximum likelihood to classify
subtypes and detect recombination. Sequences with two or more recombination breakpoints with
multiple subtype or sub-subtype (e.g., A1, A2) parents are labeled "complex" recombinants.
Amino acid polymorphisms were extracted by pairwise alignment of the consensus sequence to
the HXB2 reference integrase gene sequence using an in-house Python script. Insertions relative
to this reference were discarded and the aligned sequences were translated into amino acids with
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a HXB2 coordinate system. We excluded circulating recombinant forms (CRFs) from the
phylogenetic analysis and aligned all the data using MAFFT v7.305b(609), including the HIV-1
subtype reference sequences of HIV-1 subtypes A1, A2, C and D. We manually adjusted the
resulting alignment using AliView v1.19-beta-3(610). A phylogenetic tree was reconstructed by
maximum Likelihood using PHYML v20160207 with the default parametric bootstrap support
analysis(611). The General Time Reversible model incorporating invariant sites and a gamma
distribution for rate variation across sites (GTR+I+G) was selected using the Akaike Information
Criterion (AIC) using jModeltest v2.1.10(612). The tree was visualized and manually annotated in
FigTree (A. Rambaut,

http://tree.bio.ed.ac.uk/software/ figtree) and Archaeopteryx v0.9920

beta(613).
Statistical analysis
Statistical analyses were performed using GraphPad Prism 7.03 (GraphPad Software, La Jolla,
CA) using one-way analysis of variance (ANOVA) unless otherwise specified.
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3.5

Results

Based on sequencing of the PR, RT and IN-coding regions, HIV-1 subtype distributions did not
significantly differ among the four groups (N, FF, SF, and RF). Subtype A virus was the
predominant subtype found in nearly half of patients in each group followed by subtype D, and C.
Our observations are consistent with our previous study on Uganda HIV-1 subtype distribution in
the last 10 years (488) (Fig. 18). As previously described (488), a higher proportion of patients
failing treatment appeared to be infected with subtype D, but this was not statistically significant
(Fig. 18). No subtype C infections were identified in the RAL treated group, most likely due to
the smaller sample size. AD recombinants were observed at higher frequency in the naïve than
treatment failure populations whereas complex recombinants/CRFs comprised the remaining 1319% (Fig. 18).
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Figure 18. HIV-1 subtype classification of reverse transcriptase, protease, and Integrase
regions. (A) The bar graph (Right) and phylogenetic tree (Left) describe the HIV-1 subtype
classification of the IN gene (percentages) of ART naïve patients, FF, SF and RF. (B) The bar
graph (Right) and phylogenetic tree (Left) of HIV-1 subtype classification of RT, and PR regions
of N, FF, SF, and RF. Subtype descriptions are embedded in the figure. An in-house Python script
was used to label tips with subtype classifications from SCUEAL. A maximum likelihood
phylogenetic tree was reconstructed from the alignment using PHYML v20160207 with the default
parametric bootstrap estimation of branch supports given the data. The tree was visualized and
manually annotated in FigTree (available at: http://tree.bio.ed.ac.uk/software/figtree) and
Archaeopteryx v0.9920 beta.

On average, 10% of the treatment naïve patients were infected with HIV-1 variants harboring
primary resistance mutations to at least one NRTI or NNRTI (Fig. 19, Fig. 20). This treatment
naïve group was recruited from 2007-2011 during chronic disease and tested for HIV-1 drug
resistance genotype (602,603,605).
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Figure 19.Drug resistance predictions based on pol sequences of treatment naïve, first, and
second line treatment failures or in patients receiving raltegravir. Genotypic resistance/drug
susceptibility prediction was performed on 400 HIV-1 pol sequences from Uganda using the HIV1db genotypic resistance interpretation algorithm from Stanford University. Panels A, B, C, and
D show the level of drug resistance in N, FF, SF, and RF respectively. The first bar in each patient
group represents total drug resistance in that group, and the first bar in each drug class represent
total drug resistance in that respective drug class. The rest of description of level of drug resistance
is embedded in the figure.
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A 10% incidence of drug resistance in chronically infected patients from 2007-2011 is likely an
underestimate of current rates of transmitted drug resistance HIV-1 in the treatment naïve
population. Recruitment of these patients during chronic disease likely resulted in a loss of drug
resistance and reversion to wild type HIV-1 following initial infections with a drug resistant HIV1 variant. A recent WHO report 2017 shows pretreatment HIV-1 drug resistance to EFV/NVP in
15.4% of the HIV-1 positive population in Uganda (524).
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Figure 20. HIV-1 genotypic resistance interpretation based on Sanger sequencing. Amino
acid substitutions was used with HIV-1db program Genotypic resistance interpretation algorithm
from Stanford university HIV-1 drug resistance database (https://HIV-1db.stanford.edu) to predict
the levels of susceptibility to PR, RT and INSTIs. A susceptible genotype is shown in green,
intermediate and high-level resistance is shown in yellow and red respectively. Abbreviations:
ABC (abacavir), AZT (zidovudine), D4T (stavudine), DDI (didanosine), FTC (emitricabine), 3TC
(lamivudine), TDF(tenofovir), EFV(efavirenz), ETR (etravirine), NVP (nevirapine), RPV
(rilpivirine), ATVr (atazanavir/r), DRVr (darunavir/r), FPVr (fosamprenavir/r), IDVr (indinavir/r),
LPVr (lopinavir/r), NFV (nelfinavir), SQVr (saquinavir/r), TPVr (titranavir/r), DTG
(dolutegravir), EVG (elvitravir), RAL (raltegravir).
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A slightly higher frequency of NNRTI over NRTI resistance was observed in our treatment naïve
population, which may be due to higher fitness costs of NRTI over NNRTI resistant mutations and
faster reversion to wild type HIV-1(614,615). Finally, no PI or INSTI resistance was observed in
the naïve patients from 2007-2011, which reflects very limited use of these treatments in Uganda
during this time period.
Following first-and second-line treatment failures, 97.8% and 81.9% of the HIV-1 sequences
showed resistance to at least one ART drug, respectively (Fig. 19). Resistance and presence of
drug resistant mutations was mainly observed in the NRTI and NNRTI drug classes following first
line treatment failures due to exclusive use of these drug classes on cART initiation (Figure 19,
Table 3). Due to complete absence of PI treatment in the first line treatment regimens, the PR
coding region was not sequenced upon treatment failure.
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Table 3. Frequency of mutations associated with reduced susceptibility to protease, reverse
transcriptase, and integrase strand transfer inhibitors.
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a

The number of primary resistance mutations in protease region of HIV-1 found in the study patients.
Primary resistant mutations which confer resistance to NRTIs. cPrimary resistant mutations which result

b
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in resistance to NNRTIs. dPrimary resistant mutations which confer resistance to INSTIs. n.d, drug resistant
mutations not determined. Others, drug resistant mutations with one frequency in each patient group.

However, previous studies in Uganda have confirmed the near absence of PR resistant mutations
in first line treatment regimens involving two NRTIs and an NNRTI (578). PIs typically
lopinavir/ritonavir (LPVr) or atazanavir/ritonavir (ATVr) were prescribed in nearly all second line
treatments, hence the appearance of PI resistance upon failure. Despite the absence of NNRTIs in
second- or third-line treatment with RAL, NNRTI resistance remained and was still the most
common in these patients found in 75.5% and 49.0% patients respectively.

Once PIs are

administered, PIs are typically retained in the regimen even upon treatment failure and emergence
of PI resistant mutations. As a consequence, we have little to no data on the potential loss or
reversion of PI resistant mutations, except that PI resistance is still less frequent than NNRTI or
NRTI resistance in newly infected or treatment naïve patients.
Unlike NNRTI, NRTI, and PI resistance, major drug resistance mutations (DRMs) to INSTIs were
noticeably absent in N, FF, and SF, i.e., Y143R/C/H, Q148R/K/H/N, N155H, E92Q, E138A/K/T,
G140S/A/C, S147G, T66A/I/K and R263K conferring resistance to RAL, EVG, and/or DTG.
Nevertheless, we detected some minor IN mutations described as secondary or compensatory
mutations: T97A/T (9.6%), M50I (6.7%), L74M/I (3.1%), E157Q (1.43%), V151I/A (2.0%) and
G163R (2.0%) (Fig. 19, Table 4). L74M was observed in 0.8% of INSTIs naïve patients (N, FF,
SF) and 9.8% of RF.
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Table 4. HIV-1 infected patients failing on RAL-based regimen with primary and/or
secondary (compensatory) INSTI mutations.

Secondary mutations (not included in the table) found in N, FF, and SF, were classified as follows; M50I
was found in 12 (7.5%) of FF, 4 (3.3%) of SF, and 7 (8.0%) of N. L74M found in 1(0.8%) of SF, and 1
(1.1%) of N. T97A was found in 8 (5.0%) of FF, 9 (7.4%) of SF and 7 (8.0%) of N. E157Q was found in
2(1.2%) of FF, and 1 (1.1%) of N. In bold, the major INSTIs primary resistance mutations which confer
resistance to INSTIs. Abbreviations: H, high level resistance, I, intermediate level resistance, L, low level
resistance, S, susceptible genotype. Table 3. Frequency of mutations associated with reduced susceptibility
to protease, reverse transcriptase, and integrase strand transfer inhibitors.

It is a polymorphic accessory mutation selected by RAL and EVG (616) and selected by DTG in
previously RAL treated patients with DTG primary mutations. The M50I polymorphism was
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observed in 6.2% of INSTIs naïve patients and 9.8% of RF, and increases resistance to DTG in
combination with R263K to 5.6-fold in cell culture, though it does not increase the replication
capacity of the virus. E157Q was found in 0.8% of INSTIs naïve and 5.8% of RF. It has been
identified as a compensatory mutation for the N115H mutation, but also tends to increase
susceptibility to DTG. T97A was found in 6.5% of INSTIs naïve and 29.4% of RF. T97A has been
shown to pre-exist in 5%-10% of INSTIs naïve patients infected with subtype A virus.
Additionally, T97A was previously co-selected in the presence of primary INSTIs DRMs by RAL
in many clinical studies (423,617), and by DTG in treatment experienced patients with preexisting
RAL associated resistance mutations (618). As expected, lack of INSTI resistance is attributable
to absence of INSTI treatment in Uganda and most of sub-Saharan Africa. However, previous
reports and data presented herein also indicate that natural polymorphisms conferring resistance
to INSTIs are extremely rare in these subtype A and D isolates, also reported as rare in subtype B
(619). Predicted DTG resistance was also absent in HIV-1 variants from 366 treatment naïve- or
experienced patients (FL and SL treatment failures) (Fig. 19, Fig. 20).
INSTI resistance major mutations Y143R/S (0.9%), Q148K/R (0.47%), N155H (2.1%), E138A/K
(0.7%), G140A (0.47%), T66A/TAIV (0.47%), and S147G (0.25%) (Fig. 19, Table 4) were only
observed in RF.
However, only two patients (DR-206-12, DR-1059-17) in RF had genotypes with potential
resistance to DTG (i.e., G140A, S147G, Q148K, E138K, and G140A, Q148R, E138A, and G163R
respectively). In addition, R263K, the mutation most commonly associated with DTG resistance,
was not observed. Over 47% RF had RAL and EVG resistance but only 23.5% were predicted to
have weak and moderate resistance to DTG

89

3.6

Discussion

The Ministry of Health in Uganda has implemented the WHO “Treat All” recommendation which
states that every person tested HIV-1 positive be started on treatment irrespective of his/her
virological and immunological status. With increasing emergence of drug resistance in treatment
naïve population in LICs (524,615,620,621), and the number of patients on cART increasing, HIV1 drug resistance prevalence will inevitably also rise. More potent antiretroviral drugs, such as
DTG, have shown to be active in treatment-experienced patients. More importantly, resistance to
DTG seems to be infrequent in cART-naïve individuals treated with this integrase inhibitor (622).
The purpose of the study was to screen for drug resistance and possible treatment with DTG in
treatment naïve patients and those experiencing virologic failure during first, second-, and thirdline cART in Uganda. To our knowledge, this is the first study to look at INSTIs associated drug
resistance in both cART naïve and experienced patients in Uganda and most other countries in
sub-Saharan Africa.
Among minor INSTI resistance mutations, T97A mutation was observed in both INSTIs naïve and
RF and has been shown to reduce sensitivity of virus to INSTIs and/or rescue viral fitness in
combination with Y143C/R, Q148+G140S, or N155H. However, a previous study shows T97A
doesn’t significantly reduce susceptibility to INSTI with up to 94% and 97% viral suppression
achievable in HIV-1 patients with preexisting and emerging T97A respectively (623). The
prevalence of the M50I polymorphism observed in INSTI-naïve patients is lower compared to the
10% found in patients infected with HIV-1 subtype B virus, which shows variation in the evolution
of INSTI-associated mutations in different viral subtype populations. A relatively small number
of patients were infected with viruses carrying the E157Q mutation, which has shown to increase
susceptibility to DTG (624). However, the combination of E157Q and R263K increases DTG
resistance by 10-fold (624).
We found neither of the two rare mutations associated with DTG resistance, R263K and G118R.
R263K has been identified in both clinical samples and cell culture assays (429,435) and G118R
in cell culture tests. The major mutation pathways for RAL, Y143R/C, Q148R/K/H and
N155H(419) were not found in INSTIs naïve patients in agreement with previous study done in
treatment naïve patients in South Africa (625). In RF, 18 (35%) of patients had Y143R/S,
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Q148R/K, G140A, E138A, S147G, T66A/TAIV, and N155H INSTI major mutations which could
explain the virological failure observed in these patients.
This study shows that accumulation of INSTIs DRMs at positions, G140, S147, Q148, and E138
after RAL failure can potentially predict the potential loss of susceptibility of the virus to DTG as
seen previously (626). For example, we found two individuals infected with a virus carrying the
Q148K/R resistant mutation, which when present alone moderately reduces RAL and EVG
susceptibility while having a minimal effect on DTG susceptibility; however, in combination with
G140S/A/C and/or E138K/A, it may reduce DTG susceptibility up to 10-fold (607,627). In RF,
N155H had highest frequency 9 (17.6%) compared to other major INSTIs DRMs which may be
due to early selection of this resistant mutation under RAL pressure as observed previously in a
phase II study looking at long term efficacy and safety of RAL in patients with limited treatment
options(628). Among the six major mutations which reduce susceptibility to EVG, T66I, E92Q,
T97A, S147G, Q148K and N155H (424), only substitution E92Q was not selected by the virus in
the study patients which could be due to cross resistance as EVG is currently unavailable in the
country.
Based on our analyses of 417 Ugandan HIV-1 pol sequences, DTG would possibly be effective at
any stage of cART treatment in sub-Saharan Africa. DTG has become the preferred drug for the
majority of new FL or salvage treatments in HICs. In our Ugandan cohort, we did not observe a
higher frequency of mutations conferring DTG or any other primary INSTI resistance mutations.
We observed a high frequency of NNRTI resistance in FF (96.4%), and in patients who remain on
treatment but who have not received NNRTI for years, SF (75.5%) and RF (49.0%). This
observation complements the fact that over 50% of treatment failures in Uganda retain NNRTI
resistant virus and often for years following the last dose of nevirapine (NVP) or efavirenz (EFV).
In contrast, the frequency of NRTI and PI resistance is lower in all of these HIV-1 infected groups
in Uganda. With the UNAIDS/WHO 90:90:90 goals, continued use of NNRTIs (EFV or NVP)
may help increase access to treatment since these drugs are readily available in this setting but may
not impact treatment outcomes due to associated high drug resistance, high pill burden, and poor
tolerability profiles. However, to achieve continued viral suppression in 90% of treated
individuals, we should abandon the continued use of NNRTIs (NVP or EFV) in first line treatment
and strongly advocate for the use of second generations INSTIs, such as DTG or even Bictegravir,
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in first line treatment regimens in lower income countries (LICs), such as Uganda and other East
African countries.
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4.1

Preface

Raltegravir is commonly used as a salvage therapy in most LMICs in combination with darunavir
and NRTIs. Though RAL is sparingly used in Uganda, over 50% of patients failing third line
therapy harbor RAL/EVG associated DRMs with 4% predicted to harbor DTG resistance. DTG
has a higher barrier to resistance profile and for that treatment failure in DTG naïve or experienced
patients is rare. Indeed, from our previous study, DTG resistance was only predicted in patients
with multiple INSTIs associated DRMS failing RAL-based regimen. The prediction was based on
Stanford HIV-1 drug resistance database interpretation and therefore it was necessary to confirm
these results by carrying out phenotypic assays on recombinant viruses from patient-derived HIV1 integrases.
E.N, Y.L, A.M, C.T, P.S performed drug resistance assays and experimentation in this article and
E.N, M.A, A.P, A.S.O, R.M.G, M.E.Q-M performed data analyses. I.N, F.K, C.K recruited all the
patients for this study. E.J.A and M.E.Q-M procured the funding, and E.J.A designed, supervised,
and guided the overall direction of the study as the principal investigator.
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4.2

Abstract

Objectives
Increasing first-line treatment failures in low-and middle-income-countries (LMICs) has led to
increased use of integrase strand-transfer inhibitors (INSTIs) such as dolutegravir (DTG).
However, HIV-1 susceptibility to INSTIs in LMICs especially with previous raltegravir (RAL)
exposure is poorly understood due to infrequent reporting of INSTI failures and testing for INSTI
drug resistant mutations (DRMs).
Methods
A total of 51 non-subtype B HIV-1 infected patients failing third-line treatment regimen (RALbased) in Uganda were initially selected for the study. DRMs were detected using Sanger and deep
sequencing. HIV-1 integrase genes of 13 patients were cloned and replication capacities (RCs) and
phenotypic susceptibilities to DTG, RAL, and elvitegravir (EVG) were determined with TZM-bl
cells. Spearman’s correlation coefficient was used to determine cross resistance between INSTIs.
Results
INSTIs DRMs were detected in 47% of patients. HIV-1 integrase-recombinant virus carrying one
primary INSTI DRM (N155H or Y143R/S) was susceptible to DTG but highly resistant to RAL
and

EVG

(>50-fold).

Two

patients

with

E138A/G140A/Q148R/G163R

or

E138K/G140A/S147G/Q148K displayed highest reported resistance to RAL, EVG, and even
DTG. The former multi DRM virus had wild type RC whereas the latter had lower RCs than wild
type.
Conclusions
In HIV-1 subtype A and D infected patients failing RAL and harboring INSTIs mutation DRMs,
there is high level resistance to EVG and RAL. More routine monitoring of INSTI treatment may
be advised in LMICs considering multiple INSTI DRMs may have accumulated during prolonged
exposure to RAL during virologic failure, leading to high level INSTI resistance, including DTG
resistance.
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4.3

Background

HIV-1 integrase strand transfer inhibitors (INSTIs), the latest class of ART, have changed the HIV1 treatment landscape around the world. The second generation INSTI dolutegravir (DTG) has a
higher genetic barrier to resistance and has proved to be an effective INSTI when used in
combination therapy for treatment-naïve as well as individuals harboring viruses resistant to
raltegravir or elvitegravir (318,444). Under 2018 WHO guidelines, a DTG-based regimen is
preferred for first-line ART for all adults and adolescents except for those women of childbearing
age who wish to become pregnant. DTG is also the preferred second-line drug of choice for those
failing NNRTI-containing treatment regimens (629). For children >4 weeks of age, DTG is favored
for second-line treatments following failure to NNRTIs or PI containing ART (629). Following
FDA approval in 2013, and prior to 2014, DTG was rarely administered in low-income and middleincome countries (LIMCs) but with the rollout of TDF+3TC+DTG at a cost of US $75 annually
per patient-year (630), over 4 million patients are now receiving a DTG- containing regimen (631),
eclipsing the number of patients receiving DTG in the high income countries (HICs). In Uganda,
the focus site of this study, generic DTG is now part of the preferred first-line regimen
(TDF+3TC+DTG) in all adults (525).
RAL performs pivotal role as salvage and pediatric treatment and EVG can be used in ART naïve
patient in Uganda and other LMICs. However, RAL and EVG resistance has been reported but
mostly in HIV-1 subtype B due to early use of INSTIs (632). In addition, there is infrequent
reporting of INSTI failures and testing for INSTI drug resistant mutations in non-B subtypes
especially subtype A and D. Switching patients to salvage treatment in Uganda is done under
discretion of a committee by the ministry of health which rely on resistance predictions from HIV1 drug resistance databases (525). However, there appears to be subtype specificity associated with
resistance to INSTIs with some mutations. For example, substitutions at Q148 of HIV-1 integrase
which confers resistance to RAL, EVG, and cross resistance to DTG appears more in subtype B
than non-B subtypes (633). Thus, it becomes imperative to assess the impact of RAL and EVG
associated mutations in-vitro to further elucidate on impact of these mutations in subtype A and D
integrases.
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Despite the rapid and large scale roll out of DTG in LMICs, there is very limited data on the
susceptibility of non-subtype B HIV-1 to INSTIs (592,633), including cross-resistance to DTG
conferred by raltegravir-resistant variants HIV-1 emerging in non-B HIV-1 subtype infected
patients failing raltegravir-based regimens (633). In addition, increasing spread of HIV-1 non-B
subtypes in regions where subtype B previously predominated such as Europe and America (634–
636), calls for the urgent need for more genotypic drug susceptibility testing for INSTI resistance.
Even with the use of generic DTG for first-line ART in LIMCs, treatment failures to the NNRTIbased and subsequent boosted PI-based regimens are still followed by raltegravir-based ART.
Failure to this third-line treatment in LMICs leaves patients with few options since entry inhibitors,
i.e., enfuvirtide- and maraviroc, are not readily available. In our previous study, we found over
50% of patients failing on raltegravir-based therapy in Uganda harbored raltegravir-associated
DRMs (540).
In this study, non-B HIV-1 integrase (IN) chimeric viruses derived from 11 Ugandan patients
failing a raltegravir-based third-line regimen showed significant resistance to raltegravir and
elvitegravir but remained susceptible to DTG when the “common” raltegravir resistance mutations
were present: N155H, Y143R/S. However, viruses harboring three, or four resistance mutations
(i.e., E138K/A, G140A, S147G, Q148K/R, and G163R) showed high-level resistance to all
INSTIs, and only one had significantly impaired replicative rates.
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4.4

Materials and methods

Samples for the study
Samples were collected from the WHO, College of American pathologist (CAP) and National
Institutes of Health-virology quality assurance (NIH-VQA)-accredited center for AIDS Research
(CFAR) laboratory of the Joint Clinical Research Center (JCRC) in Kampala, Uganda. The patient
database in the CFAR laboratory was used to retrieve the patient demographic, medical, and
treatment histories. A total of 60 plasma samples were collected from patients failing raltegravirbased third-line regimens. Virologic failure was defined by a viral load above 1,000 copies/ml
and/or CD4+ T cell counts below 250 cells/mm3 defined immunological failure. Written consent
was obtained from all patients prior to sample storage. Ethical clearance was obtained from the
IRBs at the JCRC and University hospitals Cleveland medical center/Case Western reserve
university (EM-10-07 and 10-05-35).
RNA extraction and PCR amplification
HIV-1 viral RNA was extracted from plasma using a QIAamp viral RNA Mini Kit (Qiagen) and
HIV-1 IN-coding region amplified using a Superscript III single RT-PCR system (Thermo Fisher
Scientific) as previously described, (540) (Table 5).
Sanger sequencing and sequence analysis
The HIV-1 IN coding regions were amplified and analyzed using Sanger sequencing as previously
described (540). Briefly, a quantified and purified PCR product was sequenced to cover the full
length of the HIV-1 IN (1–288 amino acids) (Table 5). Sequences were exported and analyzed in
RECall (beta v3.02) program as recommended by the WHO (606).
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Table 5. List of primers used in the study

RT, reverse transcription; F, forward; R, reverse

The Stanford HIV-1db Sierra web service algorithm v8.3 was used to predict resistance phenotype.
(637)
Library preparation and deep sequencing
An amplicon-based deep sequencing method was used to detect variants and confirm presence of
DRMs originally identified by Sanger sequencing (Table 5). Briefly, two overlapping PCR
products spanning full-length of HIV-1 IN were purified using (Agencourt AMPure XP; Beckman
Coulter) and quantified using (Quant-iT Picogreen dsDNA assay kit; Thermo scientific).
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Table 6. HIV-1 drug resistance interpretation and subtypes of all study patients
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a,b,c

HIV-1 susceptibility to DTG, EVG, RAL respectively. Sanger and Illumina sequences were predicted
for resistance using Stanford HIV-1 database v8.3 (https://HIV-1db.stanford.edu/HIV-1db/by-sequences/).
DTG, dolutegravir; EVG, elvitegravir; RAL, raltegravir; H, high level resistance; I, intermediate resistance;
L, low level resistance; P, potential resistance; S, susceptible; IN, HIV-1 integrase.

The barcodes were added using Nextera XT index Kit v2 (Illumina) (Table 4) and paired-end
sequencing done on a MiSeq instrument (Illumina). Analysis was performed with MiSeq Reporter
analysis software version 2.6 (Illumina) and drug resistance interpretation was done using Stanford
HIV-1db Sierra web service algorithm v8.3 (637). Samples confirmed by deep sequencing to
harbor INSTIs associated DRMs (n=11) or having no known INSTIs associated DRMs (n=2) were
selected for phenotypic testing on DTG, raltegravir and elvitegravir (Table 6, Table 7).
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Table 7. Virological and clinical characteristics of patients with INSTIs associated
mutations in the study

The HIV-1 subtype was predicted using SCUEAL subtype classification algorithm. Viral loads were
assayed using Abbott m2000sp/rt or Roche COBAS Amplicor Monitor ultrasensitive tests, v1.5. In bold,
major INSTIs resistance mutations a The patients accession numbers tested for INSTI resistance.
b
Description of the ART combinations in the study cThe patient viral loads (copies/ml) dThe predicted
subtype of study patients ethe resistance mutations detected in study patients cART, combined antiretroviral
therapy; ND, not determined; INSTI, integrase strand transfer inhibitor; ATVr, atazanavir/r; DRVr,
darunavir/r; LPVr, lopinavir/r; RAL, raltergravir; 3TC, lamivudine; TDF, tenofovir; FTC, emitricabine.

HIV-1 subtype classification and detection of recombination forms was done using SCUEAL
program (608).
Cells and antiviral compounds
TZM-bl, U87.CD4.CXR4, and HEK293T cell lines were obtained through the AIDS Research and
Reference Reagent program, division of AIDS, NIAID, NIH. TZM-bl cells, and HEK293T were
maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 100 μg/ml penicillinstreptomycin. U87.CD4.CXR4 cells were maintained in DMEM supplemented with 10% FBS,
100 μg/ml penicillin-streptomycin, 300 μg/ml G418, and 1 μg/ml puromycin (Invitrogen,
Carlsbad, CA). All cell lines were subcultured every 3-4 days at 37°C under 5% CO2. The TZMbl cells had reporter luciferase and β-galactocidase reporter genes which can be activated by
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expression of HIV-1 tat. Elvitegravir was obtained from (Gilead Sciences, Inc., Foster City, CA),
raltegravir and DTG (NIH).
Construction of HIV-1 IN chimeric viruses
HIV-1 full length IN PCR products were recombined into near full-length HIV-1
(pREC_NFL_IN/URA3) vector using transfected Saccharomyces cerevisiae MYA-906 cells
(ATCC) based on yeast homologous recombination-gap repair system (638). Plasmids were
extracted from the yeast cells using phenol/chloroform (Thermo Fisher scientific) and transformed
into electrocompetent Escherichia coli Stbl4 cells (Thermo Fisher scientific). Plasmids were
extracted from the bacteria using Qiagen miniprep kits (Hilden, Germany). The presence of
mutation (s) in generated plasmid was confirmed by Sanger sequencing. pREC_NFL_INT
plasmids were cotransfected into HEK 293T cells (3×104 cells/well) along with the complementing
plasmid pCMV_cplt using Fugene 6 reagent (Promega, Madison, WI) (638). Produced
heterodiploid virus particles containing one copy of the pREC_NFL_INT and cplt HIV-1 RNAs
were further propagated on U87.CD4.CXCR4 cells to produce a complete HIV-1 genome.
Following virus propagation, viral RNA was re-sequenced to confirm the presence of the various
DRMs.
INSTIs resistance assays in TZM-bl cells
The susceptibility of patient-derived viruses to DTG, raltegravir and elvitegravir was determined
using short-term resistance assays with TZM-bl cells. Briefly, 20,000 cells were seeded to each
well of 96-well plate and infected with controls, NFL4-3, UG14, UG98, and mutant viruses in
presence of 10-fold dilutions of DTG, raltegravir, or elvitegravir (100 µM to 10-8 µM) and DEAEdextran (1mg/ml). The amount of virus added to each well was normalised to 0.01 MOI based on
infectious titre. After 48 hr incubation at 37°C and 5% CO2, the infectivity of viruses was
quantified using X-gal as previously described (639). The stained colonies were counted using
Cytation 5 plate reader (BioTek USA) and confirmed by manual counting using a fluorescent
microscope. Drug sensitivity curves were generated using nonlinear regression curve fitting
features of GraphPad Prism 8.0 software (GraphPad Software, Inc., San Diego, CA). Drug
resistance was expressed as fold change (FC) in effective concentration 50 (EC50) between
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controls and mutant viruses basing on at least two sets of experiments each performed in
quadruplicates.
X-gal staining assay
The X-gal (5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside) (40 mg/ml) substrate was used to
detect β-galactocidase enzyme expression from infected cells (639). The TZM-bl cells infected for
48 hrs were fixed with glutaraldehyde (0.2%) and formaldehyde (0.8%). The cells were
sequentially stained with potassium ferrocyanide (0.2M), potassium ferricyanide (0.2M),
magnesium chloride (2M), and X-gal substrate, and then incubated for 2 hours at 37°C.
Infectivity assay in TZM-bl cells
Infectivity of HIV-1 IN chimeric mutant viruses were determined using short-term infectivity
assay in TZM-bl cells. Briefly, 20, 000 TZM-bl cells in presence of DEAE-dextran (1mg/ml) were
infected with increasing concentration of either mutant or controls. Cells were fixed, stained, and
β-galactosidase expression was measured using X-gal protocol as described above. The fold
decreases in infectivity were expressed as percentage of relative decrease in area under the curve,
amount of virus needed for TZM-bl cells to produce the maximal level of β- galactosidase in an
infection.
Statistical analyses
Statistical analyses were performed using non-linear regression in GraphPad Prism 8.1.2
(GraphPad Software, La Jolla, CA). The level of cross resistance was analysed using Spearman’s
rank order test.
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4.5

Results

Samples and patient demographics
Samples were obtained from 60 patients failing a third-line raltegravir-based in Uganda. Of them,
51 (85%) were successfully amplified and sequenced by Sanger and deep sequencing (540).
INSTI-associated DRMs were detected in 24/51 (47%) patient samples. Eleven samples with
INSTIs resistance mutations were subsequently selected for phenotypic assays. Of the 11 samples
selected for phenotypic studies, 8 of 11 were obtained from individuals on dual therapy (protease
inhibitor [PI] + raltegravir) while the other 3 were treated with triple therapy (i.e., NRTI + PI +
raltegravir). The average viral load count was 454,669 copies/ml (range 850 -2,293,840) (Table
7). Seven of 11 (64%) viruses were classified as HIV-1 subtype A, 27% subtype D (3/10) and 1
sample had a subtype A/D recombinant (Table 6, Table 7). Two patient IN with no INSTIassociated DRMs, UG98 (subtype D), UG14 (subtype A), as well as NL4-3 HIV-1 (subtype B)
where included in phenotypic assays as reference strains (Table 7).
As previously published, (540) nearly 5% (2/51) of the patients failing a raltegravir-containing
therapy harbored virus with multi-DRMs to INSTIs, i.e the subtype A UG1059 with
E138A/G140A/G163R/Q148R and subtype D UG206 with E138K/G140A/S147G/Q148K. These
were selected for cloning and phenotypic assays along with other 9 with INSTIs DRMs. Whereas
Q148H only emerges in context of G140S mutants in subtype B, the Q148R/K appears associated
with G140A in non-B subtypes. Overall, N155H was the predominant INSTI DRM found in 9 of
51 patients. For this study, three IN regions with only N155H (UG1179, UG11, and UG537) and
two

patients’

IN

containing

N155H

with

secondary

mutations,

L74I/T97A

or

M50L/L74I/V151I/E157Q/G163R (respectively) were cloned for phenotypic analyses (Table 6,
Table 7). Along with these seven, other three had Y143R plus secondary mutations
M50I/L74IM/T97A, (UG35), or T97AT/G163R, (UG481), and Y143S plus T97A (UG1044). One
patient had E138A, T97A, V15IA mutations (Table 6, Table 7).
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N155H and Y143R/S emergence during raltegravir treatment in subtype A and D confer
high level resistance to raltegravir and elvitegravir but not to DTG
The N155H mutation in HIV-1 subtype B confers significant level resistance to both raltegravir
and elvitegravir. In drug susceptibility assays, the three subtype D and circulating recombinant
form A/D patient derived recombinant viruses (UG11, UG537 and UG1179) carrying only N155H
had a 10- to 19-fold decrease in susceptibility to raltegravir, 63- to 78-fold to elvitegravir, but only
1.3-fold change to DTG susceptibility when compared to susceptibility of wild type NL4-3 (Fig.
21, Fig. 22, Fig. 23). Slightly higher levels of resistance were observed with these N155H viruses
when compared to the wild type subtype D or A IN cloned into NL4-3.
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Figure 21.The susceptibility of viruses with drug resistant mutations to INSTIs. The log
values of drug concentrations were plotted against percentage of infections in TZM-bl cells
detected by x-gal assay. The colonies were counted using elispot and they are from 2-3 independent
experiments each run in quadruplets. The change in EC50 relative to wild type (NL4-3) is shown.
Ral: raltegravir, evg: elvitegravir, dtg: dolutegravir.

When L74I and T97A was found in addition to N155H in a subtype A IN, there was no effect on
susceptibility to DTG (FC 1.57-fold change or FC) but increased resistance to raltegravir (FC 39)
and elvitegravir (FC 48) was evident (when compared to the wild type NL4-3).
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Figure 22.The susceptibility of mutants by subtype. The fold change values in EC50 of DTG,
RAL and EVG relative to each subtype was determined in short term infection assay in TZM-bl
cells. Each value represents the mean fold change of EC50 from 2-3 independent experiments each
done in quadruplets.
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Presence of secondary mutations, E157Q, G163R, M50L, L74I and V151I in addition to N155H
in the subtype D integrase resulted in a low 2.8-fold resistance to DTG but high-level resistance to
elvitegravir (FC 70) and raltegravir (FC 56).

Figure 23.The susceptibility of HIV-1 mutants relative to NL4-3 strain. The fold change values
in EC50 of DTG, RAL and EVG relative to NL4-3 was determined in short term infection assay in
TZM-bl cells. EC50 fold changes of wild type A, D relative to NL4-3 are also shown. Each value
represents the mean fold change of EC50 from 2-3 independent experiments each done in
quadruplets.

The Y143R/S mutation only emerged in HIV-1 subtype A infected patients and conferred slightly
higher levels of resistance to raltegravir than to elvitegravir in subtype A HIV-1. The T97A, M50I,
and L74I/M secondary mutations had minimal or no impact on INSTI resistance. Susceptibility to
DTG was not affected by Y143R/S with the other secondary mutations (Fig. 21, Fig. 22, Fig. 23).

110

Multiple INSTI DRMs with secondary mutations confers high level resistance to DTG,
raltegravir and elvitegravir
Q148H/K/R alone typically has minimal effect on DTG susceptibility. In patients failing a
raltegravir-based treatment in Uganda, the Q148R mutation in subtype A HIV-1 was found in
combination with primary INSTI DRMs, E138A, G140A, and in subtype D, a Q148K with E138K,
G140A, and S147G. With the IN from both patients, the chimeric viruses were highly resistant to
elvitegravir, raltegravir (both >1000-fold), and DTG (>100-fold) (Fig. 22, Table 8, Fig. 23).
Table 8. The mean EC50 of different HIV-1 integrase strand transfer inhibitors against
recombinant viruses in the study

DTG, dolutegravir; RAL, raltegravir; EVG, elvitegravir; EC50, effective concentration 50; CI, confidence
interval
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Finally, chimeric virus from HIV-1 subtype A infected patient with secondary mutations T97A,
V151A, and E138A had resistance to elvitegravir (45-fold) and low-level resistance to raltegravir
(12-fold) but wild type sensitivity to DTG (Fig. 21, Fig. 22, Fig. 23).
For all the chimeric viruses studied for drug susceptibility, the IN genes of HIV-1 subtype A and
D infected patients containing INSTI DRMs were cloned into a subtype B backbone. Despite the
concerns with complementation compatibility, the same level of resistance with these IN chimeric
viruses was observed when compared to wild type NL4-3 or the NL4-3 containing the wild type
subtype A and D IN coding regions (Fig. 24).

Figure 24. Effects of IN complementation in an NL4-3 chimeric virus. The correlation of fold
change values relative to subtype A, D, and nfl4-3. Each value represents the fold change of means
from each subtype. Correlation was determined using spearman’s rank order with p=0.001
significant.

INSTI DRMs can impair replicative capacity regardless of subtype
Using TZM-bl cells replication capacity (RC) of these IN chimeric HIV-1 (all with NL4-3
backbone) were compared to wildtype NL4-3, UG14, and UG98 references. All the IN chimeric
HIV-1 with INSTI DRMs had significantly reduced RC compared to the reference wild type
strains. Reduced RC exhibited by the viruses was not simply due to poor complementation
considering the IN of the subtype A and D in a NL4-3 backbone had slightly higher replication
rates than wild type NL4-3. Viruses, UG138-A (N155H; secondary mutations, T97A/L74I,), and
UG481-A (Y143R; secondary mutations, T97A/G163R) had lowest RCs at ~30% of NL4-3 and
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<30% of the subtype A and D references. UG206-D, with four primary DRMs, E138K, G140A,
S147G, and Q148K also had a low RC (29%). However, there was no clear patterns of reduced
replication rates based on any of the primary or secondary DRMs (Fig. 25). UG23-A, UG1044-A,
and UG35-A replicated at 40 to 45% of the references, while UG119-A, UG537-A/D, UG42-D,
and UG11-D were at 50 to 60% of wild type HIV-1s.

Figure 25. Relative viral infectivity of recombinant viruses. The viral infectivity of resistant
mutants compared to controls and wildtype was determined using short-term infection assay in
TZM-bl cells. Area under the curve was used to measure the relative decrease in infectivity. The
data shown represent means and standard deviation from independent experiments performed in
triplicates.

The other chimeric HIV-1 with four primary DRMs in IN (E138A, G140A, Q148R, G163R) had
the highest RCs (>80% of wild type).
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Cross resistance observed between DTG and elvitegravir
Correlation coefficient of FC values for DTG, raltegravir, and elvitegravir were assessed to
determine the level of cross resistance between the INSTIs. DTG FC values for resistance were
found to correlate with elvitegravir FC values for resistance (P=0.0073, R=0.8), but not with FC
values to raltegravir resistance (P=0.54, R=0.21).
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4.6

Discussion

Resistance to INSTIs is well characterized in HIC with a 12, 7 year, and 6-year history of
employing raltegravir, elvitegravir, and DTG, respectively. The typical 4 major pathways to
INSTIs resistance involve N155H, Q148H/K/R, and Y143R/H/C to raltegravir and elvitegravir,
and R263K to DTG and bictegravir as primary INSTI DRMs. Both in vitro and in vivo selection
of DTG resistance is conferred by either an accumulation of INSTI DRMs or the emergence of
R263K. Both pathways confers low-level DTG resistance, significant reductions in RC, and often
requires the emergence of compensatory mutations, e.g. H51Y with R263K (434).
In this study, we produced 11 chimeric viruses harboring the IN genes of Ugandan patients failing
third-line raltegravir-based treatment and with known DRMs. Chimeric IN HIV-1 produced with
single DRMs resulted in significant resistance to elvitegravir and raltegravir and 43 to 68%
decrease in RC. Even these single DRMs with compensatory/secondary mutations emerging in
subtype A and D IN do not confer cross resistance to DTG. HIV-1 containing IN of two patients,
UG1059 and UG206 with three and four DRMs (respectively) showed high-level resistance to
elvitegravir and raltegravir and over 100-fold cross resistance to DTG. The level of INSTI
resistance by these two patient derived viruses are among the highest ever recorded with
phenotypic tests. Although the subtype D UG206 had a 70% reduction in RC, the RC for UG1059
was not significantly different from wild type.
Few studies have assessed phenotypic INSTI resistance using the IN derived from INSTI failures
in Uganda or in Sub Saharan Africa. One study describes resistance to INSTIs, even DTG in
subtype A, B, C, D, F, G, CRF01, CRF02, and other CRFs related to Q148H/K/R resistance
pathway but these Q148H/K/R were infrequent in this cohort when compared to INSTI failures in
subtype B infected patients (633,640,641). There are, however, several genotypic studies
describing common INSTI DRMs in untreated and in INSTI treated patients of Sub-Saharan
Africa. For nearly 10 years raltegravir-based treatment has been recommended by WHO for thirdline regimens (642) and as such is rarely used in treatment within LIMCs. In just 4 years, generic
DTG and TDF/3TC/DTG is now accessible to 3.9 million HIV-1 infected individuals in subSaharan Africa and other developing countries (629,631). This important roll out of DTG was
briefly interrupted with a report suggesting tetragenic effect in babies born from mothers who start
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DTG treatment from the time of conception (643). Nonetheless, there has been no extensive screen
for susceptibility of African non-subtype B HIV-1 to DTG and especially not with HIV-1 derived
from those failing a raltegravir-based regimen. This study suggests that 5% of raltegravir failures
may harbor DTG resistant HIV-1. Even this frequency of DTG cross resistance in raltegravir
failures in subtype A and D infected individuals could be a cause of concern. Furthermore, a recent
study by our team suggests that 28% of raltegravir failures harbor raltegravir / elvitegravir resistant
viruses with previously uncharacterised INSTI DRMs related to subtype A and D (reference
submitted for now). Half of these new INSTI-resistant genotypes in subtype A and D HIV-1
displayed cross resistance to DTG.
HIV-1 IN mutation N155H is selected early under raltegravir pressure (644). We have previously
shown predominant selection of N155H (17.6%) in HIV-1 patients failing third-line raltegravir based regimen in Uganda (540), and thus, understanding the susceptibility of viruses with single
N155H is important in assessing if DTG could be utilized in a fourth-line regimen given the limited
availability of other salvage drugs like enfuvirtide or maraviroc in Uganda. In our study, three
viruses with a single N155H mutation were susceptible to DTG (FC, 1.6-2.4) two of these
comparable to N155H in subtype B HIV-1 (FC, 1.2) (319). Given the low-level phenotypic
resistance associated with DTG failure in subtype B infected individuals, even our modest 2.4-fold
decreased susceptibility with N155H to DTG may predict potential treatment failure with DTGcontaining ART use as fourth-line treatment in Uganda.
Prolonged exposure to INSTI following treatment failure can lead to an accumulation of primary
DRMs and compensatory secondary mutations to increase INSTI resistance and/or restore viral
fitness (645). Achieving viral suppression with DTG in patients failing raltegravir or elvitegravir
is reduced with each added primary INSTI DRM (G140H/A/S, E138A/K/T) in association with
substitutions at Q148, as seen in VIKING-3 study (318). Viral suppression with DTG was also
reduced with INSTIs mutations, E138K, G140A, S147G, Q148R and T97A in a subtype C
infected, raltegravir-experienced patient from Botswana (646). However, this accumulation of
INSTI DRMs is extremely rare in HICs due in part to frequent patient visits, viral load monitoring,
and drug resistance testing. In Uganda like many other LIMCs, less frequent clinic visits and viral
load testing, intermittent adherence, and limited drug resistant testing could contribute to multiDRM viruses with high-level INSTI resistance. Two of 18 patients with raltegravir resistance in
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this Ugandan cohort had E138A, G140A, Q148R, and G163R in a subtype A virus and E138K,
G140A, S147G, Q148K in subtype D. The presence of these four primary INSTI resistance
mutations within IN has never been observed in subtype B infected patients, naïve to or failing
INSTIs (421). A combination of two primary INSTI DRMs (Q148H, G140S) with secondary
mutations, T97A, L74M conferred resistance to DTG in subtype B viruses (647). The loss of RC
observed with UG206 could as well be compensated by emergence of secondary mutations to
support active infection in presence of drug. Thus, the frequent appearance of multi-DRM HIV-1
in subtype A (as with UG1059) and subtype D (with UG206) upon INSTI treatment failure could
have devasting consequences for future roll out of DTG. Hopefully, a 11% frequency of multiDRM will not persist with larger cohorts on raltegravir-based treatment in sub-Saharan Africa.
Conclusions
In this study, we show that INSTIs resistant viruses in the majority of patients in Uganda failing
raltegravir-based third-line treatment remain susceptible to DTG and have impaired RC. However,
accumulation of primary INSTI DRMs mutations leads to high level resistance to all INSTIs
currently available in LMICs.
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5.1

Preface

Accumulation of primary HIV integrase mutations in ART experienced patients infected failing
RAL leads to high-level resistance to DTG, RAL, and EVG. However, we have shown previously
that DTG remains active against viruses with single primary mutation or combination of secondary
mutations. N155H within IN may confer higher resistance to DTG in subtype A and D compared
to subtype B viruses. BIC is newly approved second generation INSTI that is becoming available
in LMICs, and CAB INSTI is in phase III clinical trial as daily oral and long acting parenteral
nanosuspension for monthly or quarterly administration. CAB and BIC have activity against many
resistant HIV strains to EVG and RAL and some resistant variants to DTG. Due to wide roll out
of INSTIs in LMICs, the number of patients failing INSTIs will also likely increase limiting the
available ART options. Therefore, to ascertain possibility of switching ART experienced patients
to BIC or CAB, we carried out drug susceptibility assays in-vitro and tested the level of resistance
conferred by a diverse group of INSTIs DRMs.
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5.2

Abstract

Objectives
The second-generation integrase strand transfer inhibitor (INSTI) bictegravir (BIC) is becoming
accessible in low- and middle-income countries (LMICs), and another INSTI (cabotegravir, CAB)
has recently been approved as long-acting injectable. Data on BIC and CAB susceptibility in
raltegravir (RAL)-experienced HIV-1 subtype A and D infected patients carrying drug resistance
mutations (DRMs) remains very scarce in LMICs.
Patients and methods
HIV-1 integrase (IN) recombinant viruses from eight patients failing RAL-based third-line therapy
in Uganda were genotypically and phenotypically tested for susceptibility to BIC and CAB. Ability
of these viruses to integrate into human genomes was assessed in MT-4 cells.
Results
HIV-1 IN-recombinant viruses harboring single primary mutations (N155H or Y143R/S) or in
combination with secondary INSTI mutations, T97A, M50I, L74IM, E157Q, G163R, or V151I
were susceptible to both BIC and CAB. However, combinations of primary INSTI-resistance
mutations such as E138A/G140A/G163R/Q148R or E138K/G140A/S147G/Q148K led to
decreased susceptibility to both CAB (fold change in EC50 values from 429 to 1,000x) and BIC
(60 to 100x), exhibiting a high degree of cross resistance. However, these same IN-recombinant
viruses showed impaired integration capacity (14% to 48%) relative to the wild type HIV-1 NL43 strain in the absence of drug.
Conclusions
Though not currently widely accessible in most LMICs, BIC and CAB offer a valid alternative to
HIV-infected individuals harboring subtype A and D HIV-1 variants with reduced susceptibility
to first generation INSTIs but previous exposure to RAL may reduce efficacy more so with CAB.

120

5.3

Introduction

HIV-1 drug resistance remains a global threat, even in the era of second-generation HIV-1 strand
transfer integrase inhibitors (INSTIs). In low- and middle-income countries (LMICs), the
increasing prevalence of HIV-1 drug resistance in the treatment naïve population has required the
reduced use of a first-line non-nucleoside reverse transcriptase inhibitors (NNRTI)-based
combined

antiretroviral

therapy

(cART),

such

as

efavirenz

or

nevirapine,

to

a

tenofovir/lamivudine/dolutegravir regimen (629). Nevertheless, prolonged virological failure is
common in LMICs due to limited virological monitoring of HIV-infected individuals, leading to
accumulation of even INSTI-resistance mutations and reduced susceptibility to dolutegravir
(DTG), raltegravir (RAL), and elvitegravir (646,648,649).
Bictegravir (BIC, formally GS-9883) and cabotegravir (CAB, formally S/GSK 1265744 or GSK
744), both structural analogues of DTG, are the latest second generation INSTIs. Two clinical
trials in ART-naïve individuals and two trials in virologically suppressed patients (321,457,650)
led to approval of BIC in 2018 by FDA as a fixed-dose combination of BIC/FTC/TAF in cART
naïve and suppressed patients (<50 copies/ml) with no history of drug resistance. BIC is a potent
unboosted once-daily INSTI with a higher in vitro barrier to resistance than RAL and EVG, and
with limited drug-drug interactions. Its structure has a distinct oxazepane ring attached to a metal
chelating scaffold (Fig. 1), which increases flexibility allowing for more adaptability in presence
of drug resistance mutations (651). CAB is another analog of DTG from a class of carbamoyl
pyridones that has recently been approved by FDA and European Union as long-acting injectable,
CAB/rilpivirine for use in HIV patients with undetectable viral loads, stable on current cART, and
no drug resistance (652–654). The unique physicochemical and pharmacokinetic properties of the
CAB formulation allows its use as a single-daily tablet or long-acting nanosuspension for monthly
or quarterly via subcutaneous or intramuscular administration. CAB was recently approved as a
fixed-dose long-acting injectable combination of CAB plus the NNRTI rilpivirine after successful
clinical trials in HIV infected individuals (324,655).
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Figure 26. The chemical structures of different INSTIs. 1) Elvitegravir, 2) Raltegravir, 3)
dolutegravir, 4) cabotegravir, and 5) bictegravir. The coplanar oxygen atoms are highlighted in red
and green circle highlights extended linker a common feature to all second generation INSTIs.

BIC has shown broad activity in vitro as an INSTI against recombinant viruses and clinical isolates
carrying primary mutations associated with resistance to RAL and elvitegravir (459,656).
However, mutations at position Q148 of the HIV-1 integrase (IN) confer a wide range of resistance
to BIC in vitro when combined with other amino acid substitutions (657). Selection of the Q148R
mutation was observed in two patients on either oral or long injectable CAB in the LATTE clinical
trials (655,658); however, CAB has shown activity against viruses harboring T66I, Y143R,
N155H, E92Q, Q148H/K/R and G140S/Q148H/K/R (<7-fold) (463).
By mid-2020, transition to generic DTG-based first line had been implemented in 100 LMICs,
however, the distribution of DTG at large scale in LMICs has coincided with the emergence of
SARS-CoV-2, responsible for the COVID-19 pandemic (659,660). Unfortunately, this may lead
to increasing emergence of INSTI-resistance mutations associated with poor therapy adherence
due to reduced access to pharmacies and healthcare providers, or disruptions in the distribution of
antiretroviral drugs (661). Currently, patients failing third-line RAL-based regimens can only be
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switched to optimized dosage of DTG. Twice-daily DTG dosage of 50mg or 100mg may rescue
viral suppression in patients carrying resistance mutations at residue G140 and Q148 of IN
(318,662). However, some cART experienced patients infected with subtype B or non B HIV-1
strains with multiple DRMs are already resistant to DTG (646,648,649,657). With prevailing
challenge of access to more potent antiretrovirals options in LMICs, it becomes very crucial to
assess susceptibility of viruses harboring diverse INSTI-associated mutations to BIC and CAB
(663).
In this study, non-B IN recombinant viruses derived from eight Ugandan patients failing RALcontaining regimens and carrying single or multiple primary INSTIs mutations with or without
secondary INSTIs mutations, were phenotypically tested for susceptibility to CAB and BIC.
Although patient-derived IN-recombinant viruses carrying single primary INSTI mutations (or in
combination with secondary INSTI mutations) were susceptible to BIC and CAB, viruses
harboring multiple primary INSTI-resistance mutations (i.e., E138A/G140A/G163R/Q148R and
E138K/G140A/S147G/Q148K) led to reduced susceptibility to both novel INSTIs.
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5.4

Methods

Clinical samples
The study patients n=8 failing RAL-based third-line therapy with INSTIs-resistance mutations
were part of a cohort of n=51 HIV-1 infected patients failing RAL-based third line at the Joint
Clinical Research Center (JCRC) in Kampala, Uganda as described previously (540,649). JCRC
was the first center to provide generic cART in Uganda starting in early 2000 (531,533) and has
since provided HIV-1 treatment to over 200,000 HIV-1 patients in Uganda and other African
countries since 1990. Samples of patients with virological failure detected during routine checkups
are sent to Case Western Reserve University -Center for AIDS Research (CFAR) laboratories at
JCRC for sanger HIV-1 genotyping tests (488). The CFAR laboratory is a World Health
Organization (WHO), College of American Pathologist (CAP), and National Institutes of Healthvirology quality assurance (NIH-VQA)-accredited laboratory. HIV-1 patients who provided
written consent and were experiencing virological or immunological failure described as plasma
HIV-1 RNA load >1,000 copies/ml and/or CD4+ T cell counts below 250 cells/mm3 were included
in the study. Ethical clearance was obtained from the IRBs at the JCRC and University Hospitals
Cleveland Medical Center/Case Western Reserve University (EM-10-07 and 10-05-35).
RNA extraction and PCR amplification
Plasma samples from all eight patients were used to extract HIV-1 viral RNA (QIAamp viral RNA
Mini Kit, Qiagen) and the IN-coding region was amplified using a Superscript III single RT-PCR
system (Thermo Fisher Scientific) as previously described (540).
Sanger sequencing analysis
Purified and quantified IN amplicons were cycle sequenced using Big Dye Terminator v3.1
(Thermo Fisher scientific) and analyzed as previously described (540). Briefly, PCR products were
sequenced on an ABI 3730XL to cover the full length of the IN (288 amino acids). Raw sequences
were exported and analyzed in RECall (beta v3.02) program as recommended by the WHO (606).
To check for presence of DRMs, analyzed sequences were exported to Stanford HIV-1db Sierra
web service algorithm v8.3 (637).
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Library preparation and deep sequencing
To confirm the presence of drug resistance mutations originally identified by Sanger sequencing,
an amplicon-based deep sequencing method was used as previously described (540). Briefly, two
overlapping PCR products spanning full-length of INT were purified using (Agencourt AMPure
XP; Beckman Coulter) and quantified using (Quant-iT Picogreen dsDNA assay kit; Thermo
scientific). The barcodes were added using Nextera XT index Kit v2 (Illumina) and paired-end
sequencing done on a MiSeq instrument (Illumina). Analysis was performed with MiSeq Reporter
analysis software version 2.6 (Illumina) and drug resistance interpretation was done using the
Stanford HIV-1db Sierra web service algorithm v8.3 (637).
Cells and antiviral compounds
TZM-bl, U87.CD4.CXR4, MT4, and HEK293T cell lines were obtained through the AIDS
Research and Reference Reagent Program, division of AIDS, NIAID, NIH. TZM-bl cells, and
HEK293T were maintained in DMEM supplemented with 10% FBS, 100 μg/ml penicillinstreptomycin. U87.CD4.CXR4 cells were maintained in DMEM supplemented with 10% FBS,
100 μg/ml penicillin-streptomycin, 300 μg/ml G418, and 1 μg/ml puromycin (Invitrogen,
Carlsbad, CA). MT4 cells were maintained in RPMI supplemented with 10% FBS. All cell lines
were sub-cultured every 3 to 4 days at 37°C under 5% CO2. CAB and BIC were purchased from
Selleck chemicals (Houston, TX).
Construction of HIV-1 integrase recombinant viruses
Full-length

IN-

PCR

products

were

recombined

into

near

full-length

HIV-1

(pREC_NFL_IN/URA3) vector using transfected Saccharomyces cerevisiae MYA-906 cells
(ATCC) based on the yeast homologous recombination-gap repair system as previously described
(638). Briefly, plasmids were extracted from the yeast cells using phenol/chloroform (Thermo
Fisher scienfific) and transformed into electrocompetent Escherichia coli Stbl4 cells (Thermo
Fisher scienfific). Plasmids were then extracted from the bacteria using Qiagen Miniprep kit
(Hilden, Germany). The presence of mutation(s) in the generated plasmids was confirmed by
Sanger sequencing. pREC_NFL_IN plasmids were co-transfected into HEK293T cells (3×104
cells/well) along with the complementing plasmid pCMV_cplt using Fugene 6 reagent (Promega,
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Madison, WI) (638). Produced heterodiploid virus particles containing one copy of the
pREC_NFL_IN and cplt HIV-1 RNAs were further propagated on U87.CD4.CXCR4 cells to
produce a complete HIV-1 genome. Following virus propagation, HIV-1 RNA was RT-PCR
amplified and Sanger sequenced to confirm the presence of the different DRMs.

Virus titration
The titers of the IN-recombinant viruses were measured using short-term infectivity assays in
TZM-bl cells using Galacto-Star chemiluminescent reporter gene assay (Thermo Fisher
Scientific), which measures expression of the β galactosidase enzyme under HIV-1 Tat expression.
Briefly, 20,000 TZM-bl cells were seeded in the presence of polybrene (1mg/ml) to each well of
96-well plate. The cells were infected with 3-fold serially diluted virus and cultured in 37°C and
5% CO2 incubator for 48 hrs. The cells were washed with 200µl of 1X PBS and lysed with 10µl
of lysis buffer for 10 mins. To the cell lysate, 100µl of reaction buffer and Galacton-star substrate
was added and incubated for 1 hr at room temperature. The expression of β-galactocidase enzyme
was measured on Cytation 5 plate reader (BioTek USA).
INSTI susceptibility assay
The susceptibility of patient-derived IN-recombinant viruses to BIC and CAB was determined
using short-term resistance assays based on TZM-bl cells. Briefly, 20,000 cells were seeded to
each well of 96-well plate and infected with the IN-recombinant viruses, or three control HIV-1
strains (i.e., subtype B NL4-3, subtype A UG14, and subtype D UG98) in the presence of 10-fold
dilutions of BIC and CAB (100 µM to 10-8 µM) and polybrene (1mg/ml), at an MOI of 0.05 IU/ml
in quadruplicate. After 48 hr incubation at 37°C and 5% CO2, virus replication was quantified
using Galacto-Star chemiluminescent reporter gene assay as described above. Drug dose response
curves were generated using nonlinear regression curve fitting features of GraphPad Prism 8.0
software (GraphPad Software, Inc., San Diego, CA). Drug resistance was expressed as fold change
(FC) in effective concentration 50 (EC50) between HIV-1 controls and IN-recombinant viruses.
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HIV-1 integration assay
The relative HIV-1 integration into cellular DNA was determined by carrying out Alu-gag qPCR
as previously described (428),(664), with some modifications. Briefly, 30,000 MT-4 cells were
infected with normalized viruses (MOI of 0.05 IU/ml) in the presence of 1mg/ml polybrene.

Figure 27. The Alu-Gag PCR workflow. In the first round of PCR, primer Alu forward aligns to
the alu repeats which exist randomly in human genome. The reverse primer, Gag reverse aligns at
U5 of 5′ end of HIV genome. In the second round of PCR, LTR (R) forward primer aligns at R
and reverse primer LTR (U5) at U5 of 5′ end of HIV genome to produce 129bp product that is
quantified by qPCR machine.

The HIV-1 protease inhibitor darunavir (1µM) was added to allow one round of infection and cells
were cultured in 37°C and 5% CO2 incubator for 72 hours. Genomic DNA was extracted using
DNeasy Blood and Tissue kit (Qiagen) and normalized using β-globin gene using primers
described previously. The DNA was amplified using Alu-Gag PCR with first round PCR primers,
Alu Forward (5′ GCC TCC CAA ACT GCT GGGATT ACA G-3′) and HIV-1 Gag reverse (5′
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GTT CCT GCT ATG TCA CTT CC-3′) and kinetic PCR primers, LTR (R) forward, (5′-TTA AGC
CTC AATAAA GCT TGC C-3′), LTR (U5) reverse, (5′-GTT CGG GCG CCA CTG CTA GA-3′)
and probe (5′-FAM-CCA GAG TCA CACAAC AGA GGG GCA CA-TAMRA-3′) previously
described (664). The first round PCR was done using platinum taq DNA polymerase High fidelity
(ThermoFisher scientific) and reaction mix consisting of 10X High fidelity PCR buffer, 50mM
Mgcl2, 10mM dNTP mix, 20µM of each primer and water. The PCR gram was done as follows:
initial denaturation at 94°C for 2 mins, denaturation at 94°C for 15 secs, annealing at 55°C for 15
secs, extension at 68°C for 3 mins and final extension at 68°C for 7 mins. The kinetic PCR was
done using TaqMan Fast advanced master mix (ThermoFisher scientific), 20µM of each primer
and probe, water, and template. QuantStudio real time system (ThermoFisher scientific) was used
under the following conditions, UNG incubation at 50°C for 2 mins, polymerase activation at 95°C
for 10 mins, denaturation at 95°C for 15 secs and annealing/extension at 60°C for 1 min. The
relative HIV-1 integration was quantified using a standard curve generated by dilution series of
DNA from infected MT-4 cells (dilution using DNA from uninfected cells).
Global occurrence of Q148H/K/R mutations
To assess global occurrence of Q148H/K/R mutations and associated INSTIs primary resistance
mutations in patients failing RAL, we analysed all the available HIV-1 INSTI-associated mutations
from the Drug Resistance HIV Stanford Database (https://hivdb.stanford.edu/). All sequence data
with original reference, patient identifier, isolate name, accession number, and treatment history
was retrieved for the analysis. The search was conducted on August 28, 2020 and search terms
used were, “integrase, raltegravir, HIV-1 and subtypes.”
Statistical analyses
Statistical analyses were performed using non-linear regression in GraphPad Prism 8.1.2
(GraphPad Software, La Jolla, CA). The level of cross resistance between INSTIs was analyzed
using Spearman’s rank order test. The means of EC50 for BIC, CAB, DTG, RAL, and elvitegravir,
were compared using one-way ANOVA and p-values <0.05 were considered statistically
significant.
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5.5

Results

Individuals failing ART with INSTI-associated mutations
We previously described a cohort of sixty HIV-1-infected patients failing RAL-based third-line
regimen in Uganda (540). From this group of individuals, we identified eight patients carrying
HIV-1 strains with a variety of mutations associated with resistance to INSTIs (the most common
being N155H), as well as two patients infected with HIV-1 strains lacking INSTI-associated
mutations (Table 9). The patients median age was 30.5 years [Interquartile range (IQR), 26.2536.25 years] and the median plasma HIV-1 RNA load was 85,091 copies/ml with (IQR, 3687.5570,480 copies/ml). As expected, most patients were infected with subtype A HIV-1 strains
(62.5%), followed by subtype D (25%) and recombinant A/D (12.5%). Five of the eight patients
were treated with RAL/LPV/RTV, while the other three individuals were RAL/DRV/RTV,
RAL/TDF/3TC/LPV/RTV, and RAL/TDF/FTC/DRV/RTV-experienced (Table 9).
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Table 9. The clinical characteristics of study patients

The HIV-1 subtype was predicted using SCUEAL subtype classification algorithm. Viral loads were
assayed using Abbott m2000sp/rt or Roche COBAS Amplicor Monitor ultrasensitive tests, v1.5. In bold,
major INSTIs resistance mutations. Abbreviations: cART, combined antiretroviral therapy; ND, not
determined; INSTI, integrase strand transfer inhibitor; DRVr, darunavir/ritonavir; LPVr,
lopinavir/ritonavir; RAL, raltergravir; 3TC, lamivudine; TDF, tenofovir; FTC, emitricabine

BIC and CAB retain activity in presence of single N155H or Y143R and added secondary
mutations.
In this study, IN recombinant viruses carrying diverse INSTIs-associated resistance mutations
from patient-derived IN (n=8) were tested for their susceptibility to BIC and CAB (Table 9). The
RAL and elvitegravir -resistant mutant N155H remained susceptible to both BIC (1-2.3-fold) and
CAB (1.3-6.3-fold), and emergence of secondary mutations, E157Q, G163R, M50L, L74I, and
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V151I in context of N155H, did not affect susceptibility to BIC (0.8-fold) and CAB (1.3-fold)
respectively (Table 10, Fig.28, and Fig.29). Viruses carrying the primary mutation to RAL, Y143R
in combination with secondary mutations T97AT, G163R, M50I, and L74IM remained susceptible
to BIC (FC, 1.2-1.3) and CAB (1.7-2.6).
Table 10. The mean EC50 and fold-change in EC50 of recombinant viruses

The EC50 and 95% CI for EC50 was determined using nonlinear regression analysis in GraphPad prism. The
nfl4-3 was used as wild type in the assays. Abbreviations: BIC, bictegravir; CAB, cabotegravir; EC50, 50%
effective concentration; CI, confidence interval. The fold-change values are relative to NL4-3 wild type.

The mutation E138A selected by RAL, elvitegravir, and DTG did not reduce susceptibility to
either BIC (0.8-fold) or CAB (3.3-fold) in presence of secondary mutations T97A and V151A
(Table 10, Fig.28, and Fig.29).
Combination of multiple primary INSTI-associated mutations leads to high-level resistance
to both BIC and CAB.
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Prolonged virological failure on same HIV-1 regimen can result in accumulation of HIV-1 drug
resistance mutations in a patient viral population (665). Severe reduced susceptibility to DTG
(>100-fold) was previously shown with IN-recombinant virus UG1059 carrying the primary
E138A, G140A, Q148R mutations as well as the secondary mutation G163R (649).
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Figure 28. The EC50 (nM) and fold-change in EC50 of recombinant viruses by subtype. The
susceptibility of IN-recombinant viruses, UG537 (with mutation N155H), UG1179 (N155H),
UG481 (Y143R, T97AT, G163R), UG23 (E138A, T97A, V151A), UG42 (N155H, E157Q,
G163R, M50L, L74I, V151I), UG35 (Y143R, T97A, M50I, L74IM), UG1059 (E138A, G140A,
Q148R, G163R), and UG206 (E138K, G140A, Q148K, S147G) to BIC and CAB was determined
using TZM-bl cells. The mean EC50 (nM) values from independent experiments run in
quadruplicates were used to determine fold-change in EC50 (nM) of recombinant viruses harboring
INSTIs-resistance mutations relative to subtype B, A, and D references (panels A, B, and C). The
error bars represent ± SD in EC50 values between replicates of independent experiments. The
horizontal line represents fold-change of 1.

In context of BIC and CAB, UG1059 showed a decreased susceptibility to BIC (60-fold), and
>100-fold to CAB.

Figure 29. The susceptibility of recombinant viruses to CAB and BIC. The susceptibility of
recombinant viruses to INSTIs, BIC and CAB was determined using short-term infectivity assay
in TZM-bl cells. Each experiment was done in quadruplicates. The change in EC50 (nM) of
recombinant viruses harboring INSTIs- resistance mutations was determined in reference to NL43 wild type. Panel A- UG206, B- UG1059, C- UG537, D- UG42, E- UG35, and F- UG481, drug
susceptibility to BIC (left panel) and CAB (right panel) respectively.

Interestingly, the subtype D virus UG206 also resistant to DTG, carrying E138K, G140A, Q148K,
and S147G mutations, was even more resistant to BIC and CAB (>100-fold and >1,000-fold)
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respectively (Table 10, Fig.28, Fig.29, and Fig.30). The NL4-3 alone or subtype B HIV-1 carrying
a wild type subtype A or D IN coding region showed no difference in susceptibility to BIC and
DTG with EC50 values previously reported for wild type HIV-1. (458,463) Overall, BIC showed
more potency against viruses carrying various INSTIs-associated resistant mutations compared to
CAB (p=0.03). IN-recombinant viruses carrying multiple primary INSTIs- resistance mutations
showed substantial reduced susceptibility to both BIC and CAB but EC50 values for BIC were
significantly lower compared to CAB for both UG206 (p=0.003) and UG1059 (p=0.0016; Fig. 29
A-B).

Figure 30. The fold-change (FC) in EC50 of recombinant viruses. A) the FC in EC50 (nM) of
recombinant viruses UG206 relative to wild type NL4-3 for BIC, CAB, DTG, RAL, and EVG. B)
the FC in EC50 of recombinant virus UG1059 relative to wild type NL4-3 for BIC, CAB, DTG,
RAL, and EVG. C) the FC in EC50 (nM) of BIC and CAB for recombinant virus UG206, D)
UG1059. The FC in EC50 (nM) of recombinant viruses harboring INSTIs-resistance mutations
relative to wild type NL4-3 were determined in short infection assay in TZM-bl cells. The mean
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EC50 of CAB and BIC were compared using nonparametric two-tailed t-test, p=0.005 was
considered statistically significant.

Both BIC and CAB are second generation INSTIs targeting IN gene for inhibition of HIV-1
replication. To determine degree of cross resistance between BIC and CAB for different viral
genotypes tested, log FC in EC50 values for BIC resistance were correlated with log FC in EC50
values for CAB resistance. Significant cross resistance was observed as shown by strong
correlation coefficient, r= 0.995, p= 0.0001, and slope, 0.69 between BIC and CAB (Fig. 30).

Figure 31. The correlation of fold change values in EC50 between BIC and CAB for the same
patient sample. The correlation of resistance between BIC and CAB was determined by spear
man’s correlation coefficient. The fold change (FC) values are relative to NL4-3 wild type.

IN-recombinant viruses carrying single or multiple primary INSTIs-resistance mutations
exhibit impaired integration capacity into cellular DNA.
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HIV-1 integration into host chromatin strongly favors active transcription sites (231). To test
impact INSTIs-resistance mutations may have on integration, we quantified the relative amounts
of viral integration using a quantitative Alu-gag qPCR (Fig. 32) as described previously. (664)
Viruses UG35 and UG42 carrying the primary N155H or Y143R mutations with additional
secondary mutations showed only 25%-29% of the capacity to integrate into the host genome
compared to wild type NL4-3 or NL4-3 carrying the wild type subtype A or D IN. Presence of a
single N155H mutation in the UG537 or UG1179 viruses led to a 50% reduction in integration.
The UG1059 virus carrying mutations E138A, G140A, Q148R, and secondary G163R had the
lowest capacity of integration with only 14% compared to wild type NL4-3 (Fig. 32).

Figure 32. The relative integration capacity of recombinant viruses harboring diverse
INSTIs associated DRMs. The ability of recombinant viruses to integrate into host chromatin was
determined in MT-4 cells using Alu-gag assay and percentage of integration by mutant relative to
NL4-3 was determined.
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Prevalence of Q148HRK mutations in RAL failing patients infected with subtype B and nonB HIV-1 isolates
Viruses, UG1059 and UG206 with high-level resistance to both BIC and CAB carry Q148K/R
with additional E138A, G140A, G163R and E138K, G140A, and S147G INSTI-associated
mutations, respectively (Table 10, Figs.28, Fig.29, and Fig.30). However, this combination of
INSTI resistance mutations have not be previously reported which prompted us to assess global
prevalence of Q148HRK and other mutations in subtype B and non-subtype B infected individuals
failing RAL (Table 11, Fig 33). We used Stanford HIV database (https://hivdb.stanford.edu/) to
analyse HIV-1 INSTIs-resistance mutations from HIV-1 infected patients failing on RAL
(n=1,653).
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Table 11. Prevalence of Q148HKR and associated primary mutations in patients failing on
raltegravir.

INSTIs associated resistance mutations in patients failing on RAL containing regimens were retrieved
from Stanford HIV drug resistance database (https://hivdb.stanford.edu/). a HIV-1 subtype A, C, D, F, G,
H, J, K, CRF01_AE, CRF02_AG, CRF12_BF, CRF05_DF, CRF47_BF, CRF06_cpx, CRF11_cpx,
CRF09_cpx. b Q148HKR and associated primary mutations observed once in patient database: S147G,
Q148R; T66TK, G140GS, Q148QR; E138EK, S147G, Q148R; E138K, Y143YCHR, Q148QR; E138EA,
S147SG, Q148QR, N155NH; G140S, Q148H, V151VA; G140GS, Y143YR, Q148QH, N155NH; and
E92EQ, G140GS, Y143YR, Q148QR, N155NH.

HIV-1 subtype B comprised the majority of sequences carrying Q148HRK (87%, 1442/1653)
while non-B HIV-1 subtypes represented 13% of sequences (211/1653). The single Q148HRK or
in combination with other primary mutations was found in 29% (419/1442) of HIV-1 subtype B
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but only 5.2% (11/211) of non-B subtypes infected patients failing RAL-based treatments. The
Q148HRK, G140SCA combination was most dominant in HIV-1 subtype B (19.5%) and non-B
subtypes (4.9%), with Q148HRK, E138AKT, G140SCA combination occurring in (3.7%) of
subtype B and (1%) of non-B HIV-1 subtypes infected patients. The combination of Q148HRK
and N155H are uncommon in all HIV-1 derived INs from patients failing RAL (1.8%) regardless
of subtypes (Table 11, Fig 33).

Figure 33. The prevalence of Q148HRK and associated primary INSTIs-resistance
mutations in HIV-1 subtype B and non-B subtype viruses in patients failing RAL-based
regimens. The number of HIV-1 infected patients failing on RAL with single Q148HKR with or
without other primary INSTIs mutations was assessed from HIV drug resistance database by
Stanford University (https://hivdb.stanford.edu/).

Our detection of these multiple INSTI resistance mutations in two HIV-1 infected individuals
would appear to be a chance and rare discovery. However, it is important to point out that our IN
sequences represents 51 of 71 of subtype A and D sequences in the Stanford HIV database and 51
of 211 of all non-subtype B sequences from individuals failing any INSTI-based treatment.
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5.6

Discussion

Increased prevalence of drug resistance in the treatment naïve HIV infected population of many
LMICs has led to switch from the administration of two NRTIs + an NNRTI (efavirenz or
nevirapine) to the TDF/3TC/DTG regimen for individuals initiating cART. Current WHO
guidelines also recommend switch of patients on first line with no history of INSTI treatment to
TDF/3TC (or FTC)/DTG (666). Despite wide roll out of DTG in LMICs, there is increasing casereports of DTG failure in patients started on DTG-based regimens, and in INSTIs experienced
patients carrying mutations including Q148HKR (318,649).
The recently approved second generation INSTI BIC is available as a part of single-fixed dose
formulation of TAF/FTC/BIC (Biktarvy). This TAF/FTC/BIC treatment is indicated in ART naïve
and virologically suppressed patients (viral load <50 copies/ml) with no history of treatment failure
and drug resistance (667). As previously reported with DTG (308,319,649), BIC also shows potent
inhibition of a broad range of drug resistant viruses in vitro. (668,669) Before recent CAB approval
as long-acting injectable, CAB was tested in combination with rilpivirine in both ART naïve and
virologically suppressed patients as oral or long acting injectable in the LATTE 1, LATTE 2,
ATLAS and FLAIR clinical trials. In LATTE 1 and 2, INSTIs associated Q148R mutation
emerged while in the FLAIR study, G140R, Q148R, E138A/T/K, and ATLAS, N155H mutation
were observed in patients with virological failure (289,655,658,670).
In this study, we tested the HIV inhibition profiles of CAB and BIC using virus carrying patientderived subtype A and D INs. Recombinant viruses carrying either single primary INSTI resistance
mutations (N155H, Y143R, E138A) remained susceptible to both BIC and CAB. We have
previously shown that N155H as a predominant INSTIs-resistance mutation (17.6%) in HIV-1
patients failing third-line RAL-based regimen in Uganda (540). Viruses carrying N155H in
subtype A or D IN were susceptible to BIC (1-2.3-fold), comparable to that observed with HIV-1
subtype B virus (1-fold) (668). In HIV-1 infected patient failing RAL, Q148HRK mutation
emerges later in the course of infection replacing N155H mutation of higher replication fitness but
exhibiting lower resistance to RAL (671). In our study, subtype A recombinant virus carrying
E138A, G140A, Q148R, and G163R mutations and subtype D virus carrying E138K, G140A,
Q148K, and S147G mutations showed high level resistance to both CAB and BIC. In the studies
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presented herein, the triple and quadruple INSTI resistance mutations emerged in two different
patients infected with subtype A and D HIV-1 (respectively) and failing a RAL-based treatment
regimen. The high level cross resistance to BIC and CAB by this patient-derived HIV-1 has been
confirmed with the same set of mutations in a study screening for BIC and CAB using a subtype
B HIV-1 with these mutations introduced in vitro (459). Despite high level resistance to both drugs
by the RAL selected primary mutations, Q148KR, G140A, E138KA and S147G, the fold-change
cross resistance to CAB was more pronounced. BIC, compared to CAB appears to be better
accommodated in the binding pocket of IN even with these mutations, possibly due to the
oxazepane ring attached to metal chelating scaffold of BIC (651). The superiority of BIC compared
to CAB to inhibit viral replication in viruses carrying substitutions at G140 and Q148 has also
been reported in studies of mainly subtype B viruses (457,459,647).
Multiple INSTIs-resistance mutations (>3) emerging in HIV-1 infected patient is rare but its
detection during RAL failure is not surprising in highly cART experienced patients, especially if
RAL failure is prolonged due to limited virological monitoring common in LMICs (646,648).
Despite increasing reporting of patients failing INSTIs with multiple primary mutations in non-B
HIV-1 subtypes, we found most occurrence of Q148HKR and associated primary mutations to be
in subtype B viruses. This may be associated with early use of INSTIs in high income countries
where subtype B virus is predominant. The HIV-1 genotypes with Q148HKR in association with
multiple INSTIs primary mutations is currently < 3% in Uganda and 5.2% in non-B HIV-1
subtypes which encourages use of BIC and CAB, but increased INSTIs resistance surveillance will
be required as INSTIs become accessible in LMICs.
IN-catalyzed integration into cellular DNA is a two-step process of 3′-processing and strand
transfer process and is required for viral replication and infectivity (672). IN-resistance mutations
including N155H and E138K and added mutations reduce efficiencies of 3′ processing and strand
transfer activities which impairs HIV-1 integration capacity (437,440). We find that all INrecombinant viruses tested exhibited <50% capacity to integrate into cellular DNA which may
explain our previous observation of loss of replication fitness associated with these viruses (649).
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Conclusions
Emergence of multiple INSTIs-resistance mutations after prolonged virological failure on RAL
presents a huge threat to the efficacy of BIC, CAB, and DTG regimens, the latter previously
reported. (649) BIC and CAB retain potency in patients carrying most single primary INSTI
resistance mutations with or without secondary mutations. However, with common use of RALbased regimens for third line treatments, failure to a prolonged RAL-based treatment as well as
spread of RAL resistance viruses carry multiple INSTI resistance mutations could impact the use
of these second generation INSTIs. Given the infrequent use of drug resistance genotyping in
almost all LMICs, we have not determined the prevalence of the specific INSTI drug resistance
genotypes in both individuals failing INSTI treatment or in treatment naïve population.
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6.1

Preface

Based on our previous studies, only about 5% of HIV-1 infected patients in Uganda have drug
resistance mutations (DRMs) which could impact efficacy of dolutegravir (DTG) especially when
used as salvage therapy. Contrary, over 50% of patients failing raltegravir (RAL)-based regimen
have resistant viruses to RAL and elvitegravir (EVG). In addition, around 38% of patients failing
RAL-based regimen lack any DRM associated with reduced RAL susceptibility. These patients
still fail on treatment which could be related to poor adherence and/or due to a novel resistant
mutation(s) currently unrecognized in HIV-1 drug resistance interpretation algorithms.
Support vector machine (SVM) analysis can be used to identify association between groups of
population sharing specific traits. SVM was employed to identify novel resistance pathways to
RAL resistance in patients found not to harbor any putative DRMs using deep sequencing data.
After generation of plasmids with these candidate mutations, recombinant viruses were made and
tested for susceptibility on RAL and DTG. In the chapter presented herein, Dr. Mariano Avino the
lead author for the manuscript carried out computational analysis for the deep sequencing data. I
recruited the patients for the study, carried out all the laboratory assays, and analyzed Sanger
sequencing and NGS data for the study.
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6.2

Abstract

The global HIV-1 pandemic comprises many genetically divergent subtypes. Most of our
understanding of drug resistance in HIV-1 derives from subtype B, which predominates in North
America and Western Europe. However, about 90% of the pandemic represents non-subtype B
infections. Here, we use deep sequencing to analyze HIV-1 from infected individuals in Uganda
who were either treatment-naive or who experienced virologic failure on ART without the expected
patterns of drug resistance. Our objective was to detect potentially novel associations between
mutations in HIV-1 integrase and treatment outcomes in Uganda, where most infections are
subtypes A or D. We retrieved a total of 380 arcHIV-1ed plasma samples from patients at the Joint
Clinical Research Centre (Kampala), of which 328 were integrase inhibitor- naive and 52 were
RAL-based treatment failures. Next, we developed a bioinformatic pipeline for alignment and
variant calling of the deep sequence data obtained from these samples from a MiSeq platform
(Illumina). To detect associations between within-patient polymorphisms and treatment outcomes,
we used a support vector machine (SVM) for feature selection with multiple imputation to account
for partial reads and low-quality base calls. We subsequently introduced the I203M, I208L
mutations through site-directed mutagenesis, and used patient-derived integrases carrying I208L
or I203M and I208L to evaluate susceptibility of these mutants to INSTIs in vitro. Recombinant
viruses with mutations, I203M, I208L or I203M and I208L were generated and phenotypically tested
to determine susceptibility to RAL and DTG in TZM-bl cells. Novel resistance mutations, I208L,
I203M or I203M and I208L identified by SVM did not show reduced susceptibility to RAL or
DTG compared to wild-type virus with 1.3-1.8-fold and 1.1-1.4-fold observed, respectively.

Author summary
There are many different types of HIV-1 around the world. Most of the research on how HIV-1
can become resistant to drug treatment has focused on the type (B) that is the most common in
high-income countries. However, about 90% of infections around the world are caused by a type
other than B. We used next-generation sequencing to analyze samples of HIV-1 from patients
in Uganda (mostly infected by types A and D) for whom drug treatment failed to work, and
whose infections did not fit the classic pattern of adaptation based on B. Next, we used machine
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learning to detect mutations in these virus populations that could explain the treatment
outcomes. Finally, we experimentally added two candidate mutations identified by our analysis
to a laboratory strain of HIV-1 and confirmed that they conferred drug resistance to the virus.
Our study reveals new pathways that other types of HIV-1 may use to evolve resistance to drugs
that make up the current recommended treatment for newly diagnosed individuals
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6.3

Introduction

There are currently six classes of antiretroviral drugs approved for treatment of HIV-1 infection,
with protease inhibitors (PIs) and nucleoside and non-nucleoside reverse transcriptase inhibitors
(NRTIs and NNRTIs) in most widespread use (673). Integrase strand transfer inhibitors (INSTIs)
are a more recent class of antiretroviral drugs targeting the virus-encoded integrase (IN) protein,
which is responsible for inserting complementary DNA derived from the viral RNA genome into
the genome of the host cell (674). INSTIs are increasingly being used for individuals in low and
middle-income countries (LMICs) for whom first- and second-line antiretroviral treatment (ART)
regimens have failed, due to the emergence of drug resistance mutations (DRMs) to the PIs, NRTIs
and/or NNRTIs that comprise these regimens (642). With the exception of boosted PIs, there is
typically a greater genetic barrier for HIV-1 to develop resistance to second-generation INSTIs,
such as dolutegravir (DTG) and bictegravir (BIC), relative to other drugs (671,675). Even so, there
are multiple well-characterized mutations conferring major and accessory resistance to INSTIs
(676), where we employ the Stanford HIV-1 Drug Resistance (HIV-1db) guidelines for
categorizing DRMs (677). Most DRMs with major effects cause some level of cross-resistance
to all drugs in this class— DTG, BIC, raltegravir (RAL) and elvitegravir (EVG) — with higherlevel resistance to RAL and EVG compared to DTG and BIC.

Until recently, HIV-1 drug resistance studies have generally focused on individuals receiving ART
in high income countries. The expansion of ART to over 18 million worldwide has turned
attention to finding affordable methods for scaling up treatment monitoring and drug resistance
testing. With the high volume of tests, some LMICs have adopted drug resistance genotyping
by next generation sequencing (NGS) technologies (678,679), in place of the more common but
less scaleable Sanger sequencing approaches (680). In addition to the ability to multiplex large
numbers of patient samples into a single run (681), NGS has an added advantage of deep
sequencing — where the same region of the virus genome is covered by sequences from hundreds
or thousands of individual viruses in the sample — making it possible to reproducibly identify
minority HIV-1 variants below the detection threshold of Sanger sequencing (682). Despite their
low frequencies within patients, these minority variants have clinical significance as they can
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anticipate the emergence of drug resistance and treatment failure (683). Deep sequencing
analysis of clinical HIV-1 samples in LMICs also provides a unique opportunity to identify
potentially new HIV-1 polymorphisms associated with drug resistance in diverse HIV-1 strains
(684–686). These opportunities also present significant bioinformatic challenges. Enormous
amounts of sequence data must be processed accurately and efficiently, where sequencing error
rates still exceed conventional Sanger methods (687). The task of identifying novel associations
between treatment outcomes and minority variants in diverse HIV-1 populations remains an open
problem, and research has focused largely on HIV-1 coreceptor tropism (688,689) in populations
predominantly affected by subtype B. .

The global diversity of HIV-1 is structured into four phylogenetic groups, denoted by letters MP (690). The vast majority of infections worldwide are caused by group M viruses, which are
further separated into subtypes that have distinct geographic distributions, possibly owing to early
‘founder effects’ in sub-Saharan Africa (691). The majority of research on DRMs has historically
been carried out on HIV-1 subtype B, owing in part to the predominance of this subtype in North
America and western Europe — this subtype represents only about 10% of the global HIV-1 pandemic (692,693). Fortuitously, clinical outcomes on first- and second-line ART appear to be
largely independent of HIV-1 subtype (483,484,694). However, several studies (reviewed in (695)
have shown that non-subtype B infections can accumulate DRMs in response to treatment along
mutational pathways that are distinct from subtype B. For example, a novel DRM in HIV-1 RT
(V106M) has been reported to confer resistance to the NNRTI efavirenz (EFV) that is
characteristic of HIV-1 subtype C (513). More recently, investigators determined that the HIV-1
integrase mutation G118R confers a high level of resistance to RAL in the circulating recombinant
form CRF02 AG, where the glycine is highly conserved across subtypes (493). According to that
study, G118R had only been previously observed in cell culture on exposure to another secondgeneration INSTI (MK- 2048).

Historically, Uganda has had one of the highest burdens of HIV-1/AIDS in the world, with an
estimated 1.3 million people living with HIV-1. The majority of infections in Uganda are caused
by HIV-1 subtypes A and D, followed by A/D inter-subtype recombinants and subtype C (696).
With increasing access to ART, the transmission of DRMs is becoming increasingly common with
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an estimated 5% to 9% of treatment- naive individuals carrying at least one primary DRM (488).
The majority of individuals starting ART in Uganda are prescribed a first-line regimen based on
EFV, tenofovir (TDF) and a second NRTI, whereas almost no one had received the World Health
Organization-recommended (666) INSTI + 2 NRTIs initial regimen that is more common for firstline therapy in higher income settings (540,697). DTG was recently introduced into new first line
treatment regimens across sub-Saharan Africa, but treatment with any INSTI still represents less
than 1% of active first line treatments in LMICs (698). In most LMICs, INSTIs have generally been
reserved for those requiring a third-line treatment regimen, with RAL-based regimens being quite
successful in treatment-experienced individuals with multidrug-resistant HIV-1 (628,699,700).
Several mutational pathways reducing susceptibility to RAL have been described, including the
major DRMs T66K, Y143R, Q148H/K/R, and N155H in HIV-1 integrase (433,617,671,701).
Notably, all of these studies were carried out in predominantly (≥ 90%) HIV-1 subtype B cohorts
or in vitro with a subtype B laboratory clone.

Here, we describe a bioinformatic approach to detect potential novel DRMs from NGS data sets
that include all within-host polymorphisms above a frequency of 1%. We have applied this method
to HIV-1 NGS data from a cohort of individuals with HIV-1 non-subtype B infections in Uganda,
of whom a subset had experienced treatment failure on RAL-containing salvage regimens.
Addition- ally, we have experimentally verified the resistance effects of the novel DRMs predicted
by our bioinformatic analysis by drug susceptibility assays in vitro, and characterized these
mutations in structural models of HIV-1 integrase.
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6.4

Methods

Data collection
The study samples were collected from the Center for AIDS Research Laboratory at the Joint
Clinical Research Centre (JCRC) in Kampala, Uganda (540). Written informed consent was provided by all study participants. Ethical approval was obtained from JCRC and University Hospitals
Cleveland Medical Center/Case Western Reserve University Institutional Review Boards (EM10- 07 and 10-05-35). All investigations have been conducted according to the principles
expressed in the Declaration of Helsinki. Patient samples were assigned to one of four categories
based on treatment history and clinical outcome records in the JCRC database: treatment- naive,
first-line treatment failures, second-line treatment failures, and treatment failures on RAL-based
salvage regimens (RAL failure). Treatment failure was defined by the presence of either a viral
load above 1,000 copies/mL and/or a CD4 cell count below 250 cells/mm3 in the period following
treatment initiation. Although current definitions of treatment failure tend to focus on viral load
measurements, we retained the criterion based on CD4 cell counts for consistency with historical
practice in this treatment population.
RNA extraction and PCR amplification
For each sample, viral RNA was extracted from 200µL of plasma using a QIAamp viral RNA Mini
Kit (Qiagen) according to the manufacturer’s instructions. Reverse transcription of the full-length
HIV-1 integrase (IN)-coding region from extracted viral RNA and amplification was performed
with the sense primer RTA9F (5-TATGGGGAAAGACTCCTAAATTTA-3) and antisense primer
3Vif (5-AGCTAGTGTCCATTCATTG-3) using a Superscript III single RT-PCR system with Platinum Taq DNA polymerase kit (Thermo Fisher Scientific) as per the manufacturer’s instructions.
The complementary DNA product was purified using a Quant-iT Picogreen dsDNA assay kit
(Thermo Fisher Scientific) and quantified using a Qubit fluorometer (Thermo Fisher Scientific).
The region encoding integrase was amplified in two parts by nested PCR using the following sets
of primers: (1) sense primer INTF1B (5’-AGGTCTATCTGGCATGGGTACC -3’) and antisense
primer INTR1B (5’-GATTGTAGGGAATTCCAAATTCCTGCT-3’);

(2) sense primer

INTF2B2 (5’-CAGGAATTTGGAATTCCCTACAATCCCC-3’) and antisense primer INFR2B4
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(5’-TGTC TATAAAACCATCCCCTAGCTTTCCC-3’).
Library preparation and deep sequencing
Two overlapping IN-PCR regions corresponding to the 288 amino acids of HIV-1 IN were
sequenced with the MiSeq NGS platform (Illumina). The amplicons were purified with Agencourt
AMPure XP (Beckman Coulter) and quantified using the Quant-iT Picogreen dsDNA assay kit
(Thermo Fisher Scientific), prior to adding adapters using the Nextera XT sample prep kit (Illumina) with dual indexing for a maximum of 384 unique tags. The resulting libraries were
quantified, normalized and pooled for paired-end sequencing (2×300 nt) on the Illumina MiSeq
platform. Signal processing, base calling and structural variant analysis were performed with the
MiSeq Re- porter Software (version 2.6, Illumina). We deposited the unprocessed FASTQ data in
the National Center for Biotechnology Information (NCBI) Short Read ArcHIV-1e (BioProject
accession number PRJNA554675).

Site directed mutagenesis of I203M and I208L
The I203M and I208L mutations were created in HIV-1 INT gene from pREC-NFL (NL4-3)
back- bone using in-house site directed mutagenesis protocol. Briefly, the HIV-1 IN coding regions
were

amplified

with

the

following

primers:

Vif

3

reverse

1

(5′-

GTCCTGCTTGATATTCACACC-3′); INTREXT (5′-AATCCTCATCCTGTCTAC-3′); and
INTFEXT1 (5′-AGAAGTAAACATAGTAACAGACTCACA-3′). The I203M mutation was
created using sense primer 5′-gcaggggaaaga atagtagacATGatagcaacagacatacaaac-3′ and the
antisense primer 5′-gtttgtatgtctgttgctatCATgtctac tattctttcccctgc-3′); I208L was created using the
sense primer 5′-gaatagtagacataatagcaacagacTTG caaactaaagaattacaaaaa-3′ and antisense primer
5′-tttttgtaattctttagtttgCAAgtctgttgctattatgtctactatt c-3′. The presence of the mutation in the
plasmid and the propagated virus was confirmed by PCR followed by Sanger sequencing.
Cells and antiviral compounds
TZM-bl, U87.CD4.CXR4 and HEQ293T cell lines were obtained through the AIDS Research and
Reference Reagent Program (Division of AIDS, National Institute of Allergy and Infectious
Diseases, U.S.) (702). All cell lines were maintained in Dulbecco modified Eagle medium
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(DMEM) supplemented with 10% fetal bovine serum (FBS) and 100 µg/ml penicillinstreptomycin. In addition, U87.CD4.CXR4 cells were maintained in the presence of 300 µg/ml
G418 (an amino- glycoside antibiotic) and 1 µg/ml puromycin (Invitrogen, Carlsbad, CA). All
cell lines were sub- cultured every 3-4 days at 37◦C under 5% CO2. The TZM-bl cells contained
reporter luciferase and β -galactocidase reporter genes that were activated by expression of HIV1 tat. DTG and RAL were provided by Gilead Sciences (Foster City, CA, USA).
Construction of HIV-1 INT chimeric viruses
HIV-1 full length integrase PCR products were cloned into pREC NFL IN/URA3 vector and Saccharomyces cerevisiae MYA-906 cells (ATCC) using the yeast homologous recombination-gap
repair system (638). Following homologous recombination, plasmids were extracted from the
yeast cells and transformed into electrocompetent Escherichia coli Stbl4 cells (Invitrogen).
Plasmids were extracted using Qiagen miniprep kits and plasmid DNA was quantified using a
NanoDrop spectrophotometer (Thermo Scientific). The presence of the mutation in the generated
plas- mid was confirmed by sequencing. Chimeric pREC NFL INT plasmids were co-transfected
into HEK293T cells (3 ×104 cells/well) along with the complementing plasmid pCMV cplt using
Fu- gene 6 reagent (Promega, Madison, WI) as described previously (638). Virus was then
propagated on U87.CD4.CXCR4 cells as described (638).
Drug susceptibility assay in TZM-bl cells
HIV-1 susceptibility to DTG and RAL was determined using TZM-bl cells. Briefly, 20,000 cells
per well were exposed to wildtype (WT), and mutant HIV-1 in presence of 10-fold dilutions of
DTG or RAL (100 µM to 10−7 µM) and polybrene (1mg/ml) in 96-well tissue culture plates
(Corning). The amount of virus added to each well was normalised to a multiplicity of infection
(MOI) of 0.05 based on the infectious titer. After 48 hr incubation at 37°C and 5% CO2, the
infectivity of viruses was quantified using Galacto-Star chemiluminescent reporter gene assay
and detection was done using Cytation 5 plate reader (BioTek USA). The fold changes in the
effective concentrations for 50% inhibition (EC50) and standard errors of the mean (SEM) were
calculated based on two sets of experiments, each performed in quadruplicate. Drug sensitivity
curves were generated using nonlinear regression curve fitting features of GraphPad Prism 8.0
software (GraphPad Soft- ware, Inc., San Diego, CA). Drug resistance is presented as fold change
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in EC50 between WT and mutant viruses.
Sequence analysis
We processed the FASTQ files generated by the Illumina MiSeq platform using a customized
version of the MiCall pipeline (https://github.com/PoonLab/MiCall-Lite) (687). First, the
pipeline extracts the empirical φ X174 error rates from the ‘ErrorMetricsOut’ binary InterOp file
associated with the MiSeq run, and then censors bases in the FASTQ files associated with
problematic cycle-tile combinations with error rates exceeding a cutoff of 7.5%. Next, the
program cutadapt (version 1.11) (703) was used to filter the FASTQ read data for Illumina adapter
sequences. The pipeline subsequently used the alignment program Bowtie2 (version 2.2.6) (704)
to map the paired- end read data to the full-length sequence encoding HIV-1 integrase of the HXB2
reference genome (Genbank accession K03455). This preliminary mapping stage was followed
by the iterative re- mapping of reads from the original FASTQ files to new reference sequences,
which were progressively updated with the plurality consensus of reads that were successfully
mapped in the previous iteration (687). A mapping quality score cutoff of Q = 20 was applied at
this stage to filter ambiguously mapped reads. The primary outputs of the pipeline included the
sample-specific nucleotide consensus sequence, coverage maps, and the matrix of amino acid
frequencies in the coordinate system of the HXB2 reference; insertions relative to this reference
coordinate system were written to a separate output file.
We used a Python script to filter the amino acid frequency matrices generated by the pipeline
described above, using a minimum coverage threshold of at least 1,000 mapped reads per amino
acid. First, any matrix corresponding to a pair of FASTQ files was discarded if the overall number
of reads mapped to the sample-specific consensus sequence was below this threshold. Next, any
individual amino acid position below this coverage threshold was coded as missing data in the
remaining frequency matrices. Additionally, any sites with discordant amino acid frequencies
within the overlapping region of the two amplicons — i.e., where the frequency of an amino acid
exceeded the threshold in one amplicon but not the other — was also coded as missing data. Next,
the script converted the amino acid frequency data for each sample into a long binary vector that
indicated whether each of the 20 amino acids was observed above a frequency threshold of 1% at
every position in the integrase gene; these outputs are herein denoted the low-threshold (LT) data
set. This dichotomization step was repeated at a frequency threshold at 20% to produce the high154

threshold (HT) data set. Hence, the amino acid frequency data from the aligned short reads were
encoded into two presence-absence matrices, each comprising 20 × 288 = 5, 760 variables.
(columns) and one row for every pair of FASTQ files. Similar dichotomization approaches
(e.g.,sparse binary encoding (688) have previously been used for feature selection analyses
involving amino acid polymorphisms (688,705). All subsequent analyses were replicated across
these two data sets.
Data imputation
A substantial number of patient samples (Supplementary Table S1) were sequenced more than
once on the MiSeq platform to take advantage of the large number of index combinations and
sequencing yield of this instrument. In other words, the number of rows in the presence-absence
matrix produced by the previous step was greater than the number of patient samples. To
incorporate the entire data collection without unnecessarily and arbitrarily discarding or pooling
repeated measurements, we randomly down-sampled redundant rows to obtain a reduced
presence-absence matrix with one row per sample and repeated this procedure to yield 10
replicate matrices. All subsequent analyses were replicated across these matrices.
The next stage of our analysis employed a support vector machine (SVM) classifier to identify
putative associations between amino acid polymorphisms and RAL failure. Although extensions
of SVMs have recently been developed to handle missing data (706), the prevailing approach is
to use a generic method to impute missing values prior to the SVM analysis. We used multivariate
imputation by chained equations as implemented in the R package mice (707). Based on the overall
proportion of missing observations in our data sets (3.2% for the LT data set and 2.9% for the HT
data set), the recommended minimum number of imputations was 3 (708). We decided to generate
5 imputed data sets for each of the 10 normalised data sets from the previous section. Further, we
duplicated this approach for the LT and HT data sets for a total of 5 × 10 × 2 = 100 imputed data
sets. To speed up the multivariate imputation, we used the quickpred variable selection procedure
implemented in the mice package to filter the data for potentially significant predictors based on
a simple correlation statistic. We excluded sites with an absolute correlation with the group labels
below 50% and output the remaining variables to a preliminary predictor matrix. Each imputation
was run for 20 iterations instead of the default 5 iterations, and convergence was visually assessed
using the trace line plots of estimates against iteration numbers. To increase the robustness of
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results from the SVM analysis, we filtered amino acid features with non-zero weights (based on
their incorporation into support vectors) by a minimum frequency of 80% across imputations, i.e.,
at least 40 out of 50.
SVM analysis
The preceding imputation step yielded 100 large presence-absence matrices encoding the observed
HIV-1 integrase amino acid polymorphisms across baseline and treatment failure samples. We
analyzed each imputed data matrix with a support vector machine (SVM) in which the samples
which was encoded by +1 and −1, respectively, as stipulated by the soft-margin linear SVM model
were mapped to a high-dimensional feature space based on the presence or absence of amino acids,
(709)[52]. Our samples were recategorized into two groups of outcomes (labels): samples from
patients who experienced treatment failure on a RAL-based regimen (abbreviated to ‘RAL
failure’); and samples from treatment-naive patients and patients who experienced treatment failure
on first- and second-line regimens without integrase inhibitors (‘RAL naive’). An SVM attempts
to locate the hyperplane, defined by a subset of data points (the support vectors), that most
effectively separates the training data into the two groups. We performed an SVM analysis with the
svm.fs function from the R package penalizedSVM (710) using an L1-norm penalty. Compared to
an unpenalized SVM, this penalty function aggressively zeroes-out the coefficients associated
with features that are less informative for classifying the data, and thereby provides a framework
for feature selection (711). To calibrate the λ tuning parameter of the SVM model, which controls
the severity of penalizing data points that cross the margin of the hyperplane, we used a discrete
grid search to determine the optimal λ with minimal misclassification error by 5-fold crossvalidation (712). After training and cross-validation, we generated the final SVM model for the
entire data set using the optimized λ parameter. For each of the 100 data sets, we extracted the
average feature weights and counts from the SVM results.
To corroborate the assignments of the most positive or negative feature weights to specific amino
acids per treatment group, we calculated the odds ratios to quantify the statistical associations
between the amino acid and outcomes (group labels). We calculated odds ratios and 95%
confidence intervals by unconditional maximum likelihood estimation (Wald method) as
implemented in the R package epitools, adding a fixed n = 0.5 value to every single cell of its
contingency table to avoid a division by zero error (Haldane-Anscombe correction (713).
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Subsequently, we averaged the results for each feature across all 100 data sets. Additional details
on the sequence processing and SVM analysis are provided as Supplementary Text S1.
Drug resistance prediction
To obtain resistance predictions from the sequence data from the IN coding region, we generated
a consensus sequence at a polymorphism threshold of 20%, such that any position with two or
more nucleotide frequencies above this threshold was encoded as an ambiguous base using the
corresponding IUPAC symbol. Further, we censored all positions with fewer than 50 mapped
reads as missing data – this threshold was less stringent than the minimum number of mapped
reads (1000) required for positions to be carried over to the SVM analysis, because the objective of
the latter was to detect associations with polymorphisms at a minimum frequency of 1%. Since a
minimum of 10 mapped reads (1% × 1000) was required to be interpreted as a real polymorphism,
the same number of mapped reads was required to influence the consensus sequence at a cutoff of
20% (50 reads × 20% = 10 reads). Drug resistance prediction scores on the resulting consensus
sequences were obtained for RAL using the Stanford HIV-1db algorithm version 8.4 (updated
2017- 06-16) (677).
Subtype and phylogenetic analysis
We used the same consensus sequences generated for drug resistance prediction to predict subtypes
and reconstruct the phylogeny. We used the SCUEAL algorithm in HyPhy (608) to generate subtype
classifications and detect inter- and intra-subtype recombination. Next, we excluded predicted
recombinant sequences and sequences that were classified as circulating recombinant forms
(CRFs), and generated a multiple sequence alignment from the remaining sequences using
MUSCLE (version 3.8.425) (714). This alignment also incorporated the HIV-1 reference
sequences curated by the Los Alamos National Laboratory (LANL) HIV-1 Sequence Database
(http://www.HIV-1.lanl.gov) for subtypes A1, C, D and G, where this selection of references was
based on subtyping results from this study population. The alignment was manually inspected
and refined in AliView (version 1.19-beta-3) (610). We used jModelTest (version 2.1.10) (612)
to select the most effective nucleotide substitution model based on the Akaike Information
Criterion (AIC). Finally, we used PhyML (version 20160207) (715) to reconstruct a phylogenetic
tree by maximum likelihood un- der the AIC-selected model with the default bootstrap support
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analysis (1,000 replicates). The tree was visualized and manually annotated for subtypes in
FigTree (version 1.4.2, A. Rambaut, http://tree.bio.ed.ac.uk/software/figtree).
Structural analysis
The α-helix that connects the catalytic core domain (CCD) to the C-terminal domain (CTD) of
the HIV-1 integrase protein is not resolved in the available DNA bound three-dimensional (3D)
structure (PDB ID 5U1C). We therefore modelled the coordinates of the missing α-helix region
(a total of 22 amino acids derived from PDB ID 1EX4) into one monomer (chain A) of the
original structure (PDB ID 5U1C) using the program MODELLER (version 9.21) (716) to create
an extended structure (PDB ID 5U1C extended). Using the extended structure as template, we
built structural models of the I203M, I208L and combined I203M and I208L mutations
respectively. The protein refinement program 3Drefine was used for energy minimization and
optimization of all models (717). Furthermore, we used the molecular structure visualization
program PyMOL (version 1.7.2.1, http://pymol.org; Schrödinger, LLC) to visualize the sites where
the I203M and I208L mutations are located on the 3D structure (PDB IDs 5U1C, 5U1C extended
and 2B4J) of the HIV-1 integrase protein (91).
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6.5

Results

Data collection
We obtained plasma samples for a total of 380 patients receiving treatment for HIV-1 infection at
the Joint Clinical Research Center in Kampala, Uganda, for genotypic drug resistance testing by
deep sequencing on the Illumina MiSeq platform. Of the 328 samples from INSTI-naive
individuals (RAL naive), 85 samples were categorized as treatment-naive, 127 as first-line
treatment failures, and 116 as second-line treatment failures. The remaining 52 samples (14% of
total) were obtained from individuals who had experienced treatment failures on raltegravir-based
salvage regimens (RAL failure). From these samples, we generated a total of n = 524 paired FASTQ
files with a mean of 83,185 reads per pair. Using the MiCall pipeline (687), which iteratively
re-maps read data to update sample-specific reference sequences, we mapped an average of 81,189
reads (97.6% of the raw totals) to the HIV-1 IN coding region from each sample. This pipeline
enforced a number of coverage and quality filtering criteria (see Methods), including a minimum
requirement of 1,000 read coverage per amino acid position. Consequently, we discarded n = 7
FASTQ files due to insufficient numbers of reads that mapped to the HIV-1 reference.
The φ X174 control error rates associated with the two MiSeq runs used for these sequencing
experiments displayed the typical exponential decay with increasing cycle number, starting at a
median of 0.44% (interquartile range, IQR: 0.32%, 0.96%) and ending at 9.2% (6.7%, 15.6%;
Supplementary Figure S1). The overall median error rate was 1.5% (0.49%, 3.7%), which was
consistent with previously reported error rates for this platform. Out of a total of 22,800 tile-cycle
combinations, 2,095 and 3,360 combinations with an error rate exceeding 7.5% from the respective
runs were excluded from further analysis. These combinations were concentrated in the last 100
cycles of the second reads (80.3% and 74.6%). The median sequence length after mapping with
soft clips was 498 (IQR 325, 525) nt, indicating that the majority of the dropped base calls due to
bad tile-cycles could be compensated by high quality base calls in the first reads at the paired-end
read merger step of the pipeline.
A key challenge in detecting genetic associations in deep sequencing data from rapidly-evolving
pathogens like HIV-1 is that polymorphisms can be observed at many, if not most, sites.
Hypothetically, there exists a frequency threshold that optimally separates polymorphisms caused
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by sequencing errors from actual variants with potential clinical significance. Because it was not
feasible to replicate all downstream analyses for an exhaustive sample of frequency thresholds,
we proceeded with 1% (low threshold, LT) and 20% (high threshold, HT) to dichotomize the
amino acid frequency data into binary presence/absence values. These values were chosen on the
basis of prior information on the expected error rate for this sequencing platform (687) and the
detection limit of Sanger sequencing (680,682), respectively.

After excluding reads with low map quality scores and censoring low quality or discordant base
calls, we obtained a mean coverage of 18,907 and 19,076 reads per amino acid site for LT and HT
data sets, respectively. We restricted our subsequent analyses to amino acid polymorphisms,
excluding variation due to insertions, deletions, and premature stop codons. On average, we
observed 10−4 insertions and 8 ×10−5 deletions per nucleotide, which was within the expected
range of indel error rates for this sequencing platform (718). Ambiguous amino acid
polymorphisms due to low base quality or incomplete coverage affected a small fraction of the
data sets (3.2% and 2.9% for the LT and HT data, respectively). These ambiguities were encoded
as missing data and handled through multiple imputation.

Sequence subtyping

Subtyping analysis of the majority consensus sequences derived from the NGS samples confirmed
that the majority of samples were assigned to HIV-1 subtypes A (n = 159, 49.7%) and D (n = 70,
21.3%) as expected for this study population in Uganda. An additional n = 28 (8.4%) samples
were predicted to be A/D recombinants, and n = 16 (4.2%) samples were predicted to be subtype C. The remaining samples were assigned to other inter-subtype recombinants or could not
be confidently assigned to a known subtype or circulating recombinant form. We found no
significant association between predicted HIV-1 subtypes and RAL-based treatment failure
(Fisher’s exact test, P =0.5). Variation among sequences was best explained by the general time
reversible model of nucleotide substitution with invariant sites and a gamma distribution to model
rate variation across sites (GTR+I+G). We reconstructed a maximum likelihood phylogeny under
this model to verify the subtype predictions from SCUEAL relative to curated HIV-1 subtype
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reference sequences, where sequences assigned to subtypes A, C and D comprised monophyletic
clades with high bootstrap support values (>85%).

Drug susceptibility by genotyping
Applying the Stanford HIV-1db algorithm to the NGS consensus sequences to predict resistance
to RAL, we confirmed that less than one-third of RAL-based treatment failures (shortened to
‘RAL failures’) manifested the classical RAL resistance pathways (540). The complete
breakdowns of resistance prediction scores by HIV-1 subtype in the RAL naive and RAL failure
groups are summarized in Fig. 34. Out of 52 consensus sequences from RAL failure samples,
only 14 samples (26.9%) were predicted to have high-level resistance to RAL (score ≥ 60). One
of these samples (score 120) harbored the major RAL resistance mutation G140A (in 99.12% of
reads) in combination with the accessory mutation E138K (99.1%).

Figure 34. Distribution of RAL resistance predictions on sample consensus sequences by
HIV-1 subtype and treatment outcomes. Resistance prediction scores were obtained by the
Stanford HIV-1db algorithm [7]. The study population was split into RAL naive (left, n=328)
and RAL failure (right, n = 52) patients; accordingly, these plots are on different scales. Each
stacked barplot stratifies patients by predicted HIV-1 subtype and categorizes the prediction
scores into high-level (60+, red), intermediate (30-59, orange), low-level (15-29, yellow) and
potential low-level resistance (10-14, light green), and RAL susceptible (below 10, dark green).
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An additional 10 samples carried the major mutation N155H at frequencies between 94.2% and
99.7%, and two samples carried the major RAL resistance mutation T66K (at 93.8% and 62.7%,
respectively). Finally, two samples with high RAL resistance scores in this group carried the
major mutation Q148R in combination with accessory mutation G163R. This relative lack of
expected mutational pathways in the RAL failure group, quantified by the low number of patient
samples with resistance prediction scores in the susceptible to low-level resistance range (Fig.
22), motivated a more comprehensive analysis of HIV-1 integrase polymorphisms in the deep
sequencing data.
Support vector machine analyses
A key challenge in detecting genetic associations in deep sequence data from rapidly-evolving
infections like HIV-1 is that potentially any amino acid may appear at any position. We followed
the sparse binary encoding approach in (688) so that every sample was represented by a total of 5,760
binary variables for 20 amino acids at 288 positions in the HIV-1 integrase reference. This is an
unwieldy number of predictor variables for conventional association tests like logistic regression.
Support vector machines (SVMs (719) were developed to handle this sort of scenario, where the
number of observed cases is vastly exceeded by the number of predictor variables, and have been
employed in a number of studies of HIV-1 variation (720,721).
We used penalized SVMs to select features (polymorphisms) that most effectively separated
patient samples into RAL naive and RAL failure categories. Our results are summarized by the
mean feature weights (the relative contributions of different polymorphisms to the separation of
labels) for the low (1%) and high (20%) amino acid frequency threshold (LT and HT) data sets,
respectively. Figs. 35A (for LT) and 35B (for HT) display these results in comparison to the mean
univariate odds ratios (ORs) for polymorphisms selected by the SVM analyses to provide more
intuitive measures of association. To account for variation induced by missing data, we excluded
features that were selected in fewer than 40 out of 50 imputed matrices for both LT and HT data
sets, which disproportionately affected features with average weights close to zero.
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Figure 35. Summary of results from support vector machine analyses. (top) Feature weights
and odds ratios for selected polymorphisms in the LT (A) and HT (B) databases. Each point
corresponds to an amino acid polymorphism (feature) selected by support vectors. To reduce
clutter and identify features robust to missing data, we removed all features selected in fewer than
40 out of 50 imputations. The x-axis corresponds to feature weights, and the y-axis represents the
log-transformed mean odds ratio (OR) for each feature against the labels. Vertical lines indicate
the empirical 95% confidence interval in ORs. Points are coloured grey if this interval spans 1
(not significant) and otherwise according to mutation categorization, if any, by the Stanford HIV1 Drug Resistance Database (see inset legend). (bottom) Positive weight selected from the SVM
analysis and greater than one Odd ratio polymorphisms for the LT (C) and HT (D) data sets. The
HIV-1 integrase reference coordinates are marked along the x-axis, and log-transformed OR
mean and C.I. along the y-axis.
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In general, we observed strong positive correlations between the SVM feature weights and
mean ORs for the LT (Spearman’s ρ = 0.59, P < 2.2 × 10−16) and HT (ρ =0.68, P < 2.2 × 10−16)
data sets.
To identify the most promising features from these results, we filtered the features that were
selected in at least 40 imputations and where the mean lower 95% confidence limit in odds ratios
was greater than 1. In total, we recorded 663 features selected by support vectors, of which 83
(12.5%) were reproducibly selected in at least 40 imputed matrices. Although the known major
RAL resistance mutations T66K (722) and Q148R (723) had positive mean feature weights, they
appeared in only 13 out of 50 imputed data sets. Only the major mutation N155H (724) was selected
in a majority of imputations (all 50) with the fourth highest mean weight. An additional 8 features
were known accessory or minor RAL resistance mutations (T66A (725), L74M (726), T97A
(671), V151I (616), N155D (727), E157Q (728), G163R (616) and R263K (729); with the
exception of R263K, all were assigned positive weights (Supplementary Table S2). Only G163R,
V151I and T97A were selected in a majority (>80%) of analyses, and in fact were selected for
all 50 imputed matrices. Overall, our filtering criteria selected the following polymorphisms in
descending order of weight: G163R, V165I, N155H, V151I, I203M, T97A, K211N, A129S,
D288E, K240R, Q148K, I135F, C65R, I208L and T218S.
The relative locations of these polymorphisms are summarized in Fig. 35C. For instance, we
observed a cluster of 6 selected polymorphisms within the interval IN 198 to 218, which is distal
to both the integrase active site and RAL binding site.
The higher frequency threshold (<20%) for the HT data set substantially reduced the effective
number of amino acid polymorphisms; as a result, there were few features selected in the support
vectors (n = 299). Applying the same criteria as above to identify the most significant features
yielded the following six substitutions (in decreasing order of weight): N155H, G163R, T97A,
I208L, I203M and G134N (Fig. 35D). Of these features, only the primary mutation N155H and
secondary mutations T97A and G163R have been previously described.

I203M and I208L alone or together do not confer resistance to INSTIs in vitro
Based on these SVM analyses, we selected the novel substitutions I203M and I208L for further
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investigation, as they appeared in both lists of the most significant features from the LT and HT
data sets. Figure 36 contrasts the intra-host frequencies of I203M and I208L in the context of
known major RAL mutations, as defined by the Stanford HIV-1 Drug Resistance Database. These
frequency distributions revealed four distinct clusters of mutations among n = 30 (58%) patients
failing a RAL-based treatment regimen and carrying at least one of these polymorphisms.

Figure 36. Summary of intra-host frequencies for known major RAL mutations and two
candidate mutations I203M and I208L. Samples from n = 30 RAL failures patients carrying at
least one of these mutations are each represented by a set of barplots representing mutation
frequencies on the right. The height of each bar is proportional to 1+log10(p) for p ranging from
1% to 100% (see legend in bottom-left). The vertical ordering of samples was determined by a
hierarchical clustering analysis, with the corresponding dendrogram displayed on the left.
Vertical bars have been added on the left to highlight the subsequent specific pathways.
Two clusters of patients in this RAL failure group carried one of two known major RAL resistance
mutations Q148K/R or N155H. There were no patient samples containing the polymorphism
Q148H. A third cluster comprised samples carrying the mutation I208L, and a fourth carried
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I203M and/or I208L to the exclusion of all known major RAL resistance mutations with the
exception of Q148K/R. This pattern suggests that I203M and I208L may comprise novel
mutational pathways for RAL resistance.

To experimentally validate the predicted effects on resistance to RAL and other INSTIs, the
I203M and I208L mutations were placed in the IN of the subtype B laboratory strain NL4-3 (NL43_I203M and NL4-3_I208L). Wild type NL4-3, NL4-3_I203M and NL4-3_I208L were
propagated and then used in INSTI susceptibility assays as described in the Materials and
Methods. I203M or I208L did not impact susceptibility of NL4-3 to RAL or DTG as shown in
Figure 37A and B. It is important to note that these two mutations as associated with RAL failure
was defined by SVM analyses on Ugandan cohort infected with subtype A and D. As such, we
cloned into NL4-3 the HIV-1 subtype A IN from patient DR.110.13 with both I208L and I203M
(DR.110.13_I203M+I208L) and from patient DR.372.15 with only I208L (DR.372.15_I208L).
These viruses were compared for INSTI susceptibility in TZMbl cells as described. Even in a
subtype A IN coding region, the I203M+I208L or I208L did not alter RAL or DTG susceptibility
compared to the wild type NL4-3 (Fig.37A and B).

Figure 37. Drug susceptibility assays on the effects of I203M and I208L on INSTI resistance.
The top row of plots correspond to raltegravir drug susceptibility curves for NL4-3 (wildtype, in
black) and mutants I203M, I208L, or I203M and I208L in either subtype B or A backbone.
Similarly, the second row of plots correspond to the dolutegravir drug susceptibility curves for
NL4-3 (wildtype, in black) and mutants I203M, I208L, or I203M and I208L in either subtype B
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or A backbone. Each point for curves in A-D corresponds to the mean and error bars represent
the standard error of at least four replicate assays
I203M and I208L are natural polymorphisms
To assess whether I203M and I208L mutations are present as natural polymorphisms in the
general population, we queried the Stanford HIV-1 Drug Resistance Database (HIV-1db; last
accessed February 21, 2019) for all available HIV-1 IN sequences (n = 17, 605) from INSTI naive
and experienced patients and evaluated the frequencies of these variants in subtypes A, B and D
(Table 12). This database comprised n = 1, 248 records from RAL-experienced individuals, of
which only n =129 were infected with a non-B subtype — in comparison, our study would
contribute an additional n = 52 sequences, about 40% of the current number. The frequencies of
I203M and I208L in the RAL-naive category in the HIV-1db database were 5.9% and 5.0%,
respectively, suggesting these two mutations are natural polymorphisms that circulate at low
frequencies (> 0.5%).
Table 12. Frequencies of I203M, I208L and RAL INSTI major mutations in HIV-1 IN
stratified by treatment according to Stanford HIV-1 Drug Resistance Database whereas
reported RAL-experienced individuals breakdown is reported

T66K coverage was 16,027 for naive, I203M and I208L coverage was 15,997 for naive and 1573 for
experienced patients. Other major combinations include: G140A/C/S + Y143C/H/R (9 INI),
G140A/C/S + N155H (19 INI), G140A/C/S + Y143C/H/R + Q148H/K/R (9 INI), G140A/C/S +
Q148H/K/R + N155H (21 INI), G140A/C/S + Y143C/H/R + Q148H/K/R + N155H (2 INI),
Y143C/H/R + Q148H/K/R (10 INI), Y143C/H/R + N155H (26 INI), Y143C/H/R + Q148H/K/R +
N155H (2 INI), Q148H/K/R + N155H (27 INI), T66K + G140A/C/S + Q148H/K/R (1 INI), INI =
INSTI-experienced, RAL = Raltegravir. Fisher’s exact tests (experienced vs. naive, RAL- vs. nonRAL-experienced): * = P < 0:05; ** = P < 0:01; *** = P < 0:001.
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We noticed only slight but statistically significant increases in these frequencies in association
with the RAL-experienced category in HIV-1db (Table 12).
Table 13. Frequencies of I203M and I208L polymorphisms in HIV-1 IN stratified by
treatment for this study cohort and by minor allele frequency.

Low threshold = 1% (LT) and high threshold = 20% (HT). Fisher’s exact tests (experienced vs. naive):
* = P < 0:05; ** = P < 0:01; *** = P < 0:001

Although we observed more substantial increases in association with the RAL failure category in
our study population (Table 13), this is not directly comparable to the RAL experienced category
in the HIV-1db database that comprises an unknown proportion of treatment failures. In addition,
we also collected the frequencies of the known major RAL resistance mutations in HIV-1db.
These mutations were almost always observed with INSTI-experienced patients, being almost
absent in INSTI naive patients (Table 12).

Structural analysis
Based on their location in the primary sequence, I203M and I208L maps near the C-terminal base
of the α-helix connecting the C-terminal domain (CTD) to the catalytic core domain (CCD) of
HIV-1 integrase in the unliganded structure (91). Figure 38A displays the structure of HIV-1
integrase complexed with viral and host DNA (PDB ID 5U1C) and in which only the I203M
position could be mapped. However, as discussed in the methods section, a model of HIV-1
integrase was constructed to create an extension of this structure (5U1C extended), such that when
superimposed on the original structure (PDB ID 5U1C), the I208L position was roughly mapped.
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Figure 38. Structural mapping of the novel amino acid replacements. (A) a cryo-electron
microscope structure (PDB ID 5U1C) of integrase protein (lightteal) in complex with host and
viral DNA. The modelled extended structure (palecyan) is superimposed on chain A to show the
missing a-helix where the I208L mutation is located (B) a crystal structure of integrase protein
CCD (shown as a green cartoon) bound to the human LEDGEF protein (shown as sticks) (C) the
modelled I203M mutant structure (limegreen) of HIV-1 integrase superimposed on the modelled
extended wild type structure (greencyan) (D) the modelled I208L mutant structure (aquamarine)
of HIV-1 integrase superimposed on the modelled extended wild type structure (greencyan) (E)
the modelled I203M and I208M mutant structure (lime) of HIV-1 integrase superimposed on the
modelled extended wild type structure (greencyan). All catalytic active site residues are colored
purple while the novel mutation sites are colored blue (I203M) and red (I208L) respectively. The
known major RAL major resistance mutation sites were colored as follows: T66 (cyan), Y143
(lightgreen), Q148 (green), 155 (orange). These images were generated with PyMOL [81].
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From both structures, the I203M and I208L residues are distally located from the catalytic active
site of HIV-1 DNA processing, the binding site for most INSTI, as well as the location of most drug
resistance mutations (all the known major RAL mutations are also shown in the structure in Fig.
38A). Structural mapping shows that the I203M and I208L mutations were on the opposite side
of the C-terminal domain engaged in LEDGEF binding (reference) (Fig. 38B).

Structural modeling of the I203M mutation in HIV-1 integrase shows a conformational change in
the α-helix connecting the CCD to the CTD (Figure 38C). Similarly, the structural model having
both the I203M and I208L mutations also show a conformational change the α-helix connecting
the CCD to the CTD (Fig. 36E). On the other hand, structural modeling of the I208L mutation in
HIV-1 integrase shows very little to no conformational changes (Fig. 38D). These residues are
closer to the C-terminal domain of HIV-1 integrase that may help coordinate binding to both host
and viral DNA (95,730,731).
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6.6

Discussion

The majority of our knowledge on drug resistance mutations in HIV-1 comes from studies of
subtype B, even though this subtype represents only a small proportion of infections worldwide.
In a previous study (540), we observed an absence of known DRMs associated with RAL resistance
in half of the HIV-1-infected Ugandans failing a third line RAL-based treatment. This absence
could be attributed to either complete non-adherence, or a failure to detect resistance-associated
polymorphisms below the threshold of detection of Sanger sequencing (about 20% (682). Based
on an initial viral load decrease and adherence tracking during this third line regimen, complete
non-adherence resulting in a return of wild type HIV-1 was unlikely for all n = 51 patients
(540).
Though we cannot retrospectively quantify the extent and impact of drug non-adherence, we can
explore the possibility of unique, uncharacterized mutations associated with INSTI resistance with
NGS-based genotyping.
Based on previous assay cutoff analyses, the Illumina MiSeq platform is capable of reproducibly
detecting mutations at a lower frequency threshold of about 1% (684–686), which confers a
substantially improved sensitivity over conventional Sanger sequencing. Setting a frequency
threshold of 1% is only meaningful if a sufficient number of virus genomes from the plasma
sample are represented in the sequencing library. For instance, if the input number of templates
is fewer than 100, then any variant detected at a frequency of 1% or less is likely the result of
sequencing error. Our study population comprised patients either sampled prior to initiating ART
or following treatment failure. In previous work, we have reported that plasma viral loads averaged
about 5.4 log10 copies/mL at baseline (732). Although drug resistance testing in Uganda is
requested for patients failing treatment above 1,000 copies/mL, the majority of requests were
obtained when viral loads exceed 10,000 copies/mL (averaging 4.8 log10 copies/mL for first-line
treatment failure, and >5.0 log10 copies/mL for RAL-based/third-line treatment failure)
(540,696).
Our most conservative estimates are that about one-sixth of the viral RNA from 200µL of plasma
was transferred from the sample extraction to the RT-PCR reaction mixture, and that about onehalf was converted to cDNA. Given that half of the reaction mixture was used for PCR amplification
and sequencing, we would expect at least 850 templates on average to be available for NGS. To
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evaluate the effect of template resampling on our ability to measure variant frequencies, we can
simulate the sampling process assuming that extraction and aliquoting is sampling uniformly at
random without replacement, and that sequencing post-amplification is sampling uniformly at
random with replacement. For instance, we predict that a variant found in 500 copies/mL (0.5% of
the plasma sample) has a 0.03% probability of being sampled to a frequency of 1% or greater under our experimental conditions (2.5% and 97.5% quantiles = 0.26%, 0.77%; N = 106 replicates).
Conversely, a variant in 1500 copies/mL (1.5%) would be sampled at 1% or less with probability
0.93%. We further note that our multiple imputation across repeated NGS of the same samples
would have averaged out some sampling variation.
Our NGS analysis of RAL naive and treatment failure samples confirms results from our previous
study (540), including the absence of previously identified DRMs in about half of RAL failure
cases. The SVM analysis of these data also identified a number of potentially novel mutations
associated with reduced sensitivity to RAL. Because this classifier evaluates features by selecting
data points (the support vectors) to anchor the hyperplane separating labels, some of these features
may be associated by chance with RAL failures due to their linkage to features with direct effects.
Consequently, we carried out a post hoc odds ratio analysis to evaluate the significance of
univariate associations between each feature selected by the SVM and the labels (virologic control
versus RAL failure). The combined analyses recovered several known major and accessory
mutations conferring resistance to RAL. For instance, we found a highly significant association
between the major mutation N155H and patients failing RAL treatment (724), and this mutation
was significantly linked with accessory mutations such as V151I (616). A limitation of our SVM
analysis was that we selected two frequency thresholds to dichotomize amino acid polymorphisms
into binary variables. Although it is possible to directly apply the SVM classifier to continuous
variables, dichotomizing the observed frequencies into presence/absence states was necessary to
make the analysis computationally feasible. We selected the two frequency thresholds (1% and
20%) to span the range bounded by the lower limits of detection for the Illumina MiSeq (687)
and Sanger sequencing (682), respectively. Additionally, the selection of 1% for dichotomizing
HIV-1 deep sequence data has also been empirically validated in a recent whole-genome deep
sequencing study of HIV-1 (733) and employed in a genome-wide association study of HIV-1
drug resistance (734).
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Our SVM analyses identified a cluster of amino acid polymorphisms associated with RAL failure
in the α helix domain, including the mutations I203M and I208L. With this new information, we
could map the majority of RAL failure samples to four largely independent mutational pathways
characterized respectively by I203M, I208L, Q148/R, and N155H (Fig. 29). I203M has
previously appeared on lists of INSTI resistance mutations in the earlier literature (735,736)[85–
87]. Furthermore, I203M was previously characterized as a minor or accessory mutation with no
evidence of directly reducing susceptibility, and has also been characterized as a natural
polymorphism that is observed a substantial frequencies in un- treated individuals (729). In
contrast, we have found almost no previous mention of I208L in the HIV-1 drug resistance
literature.
We subsequently introduced the I203M, I208L mutations through site-directed mutagenesis, and
used patient-derived viruses carrying I208L or I203M and I208L to evaluate susceptibility of
these mutants to INSTIs in vitro. Our results indicate that these mutations in IN do not confer
resistance to RAL or DTG (Fig. 30). However, these mutations could act as secondary mutations
to mutations outside HIV-1 integrase gene. Resistance mutations in the HIV-1 3’ polypurine tract,
a conserved motif that primes the synthesis of plus-strand HIV-1 DNA during reverse
transcription, have been shown to significantly reduce susceptibility of HIV to INSTIs in vitro
(737). In addition, recent studies suggest that mutations conferring INSTI resistance may coevolve with the upstream end of U3 and the downstream end of the U5, i.e. the conserved target
sequence for dinucleotide cleavage. We have recently sequenced the LTR of the same Uganda
patients failing INSTIs to determine possible linkage with the U5 and U3 target sequences with
I203M and I208L. Although there is no evidence to date, there is also the possibility that IN
mutations selected by INSTIs may also impact the efficient of integration into the cellular DNA
by way of enhanced chromosomal DNA cleavage. We now have preliminary data suggesting that
treatment failure with INSTI results in dramatic changed in the targeting of proviral DNA
integration. How this is associated with the selected IN mutations associated with INSTI (as
defined by this SVM analyses) is the subject of further study. Finally, resistance to a drug can
also be manifested by increased replicative fitness even if susceptibility to drug is unaltered. For
example, a 10-fold inhibition can be overcome in terms of viral burden if HIV-1 I203M or I208L
replicates 10X more efficiently than wild type. However, our studies indicate that HIV-1 with
I203M or I208L are less fit than the wild type HIV-1.
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Further experimental work in our laboratory is now directed towards detecting mutations outside
HIV-1 integrase gene and the integration patterns in the host genome. We suspect that that I203M
and I208L are associated with INSTI resistance since these mutations define distinct evolutionary
pathways emerging during INSTI treatment and failure to this treatment. This I203M and I208L
evolutionary pathway emerged in lieu of N115H, Y143H/R, and Q148K/R pathways that
definitely confer RAL resistance.
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7.1

Preface

In this Discussion chapter, I will first outline the slow roll out and need of second generation of
INSTIs in low-to-middle income countries like Uganda. Part of this chapter is published in the
journal, Infectious Diseases of Poverty (2019) but aspect of this topic were also addressed by the
commentary published in Journal of Infectious Diseases (2017). For the article published in
Infectious Diseases of Poverty, I wrote and co-authored the article with Dr. Arts. The article
published in J. Infectious Diseases of Poverty was later presented as a featured article on journal’s
homepage.
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In 2014, the Joint United Nations Programme on HIV/AIDS (UNAIDS) and partners launched
the 90-90-90 targets. The 90-90-90 global targets by UNAIDS calls for 90% of all people living
with human immunodeficiency virus (HIV) to know their status, 90% of all people diagnosed
with HIV infection to be on combined antiretroviral therapy (cART) and 90% of all people
receiving cART to have suppressed the virus by 2020 (738). The world is progressing towards
achieving these targets with most European countries close to 90-90-90 targets (739). Some
countries like Denmark, Iceland, Sweden, Singapore, and the United Kingdom have already
achieved these target while good progress towards the 90-90-90 targets are observed in Eastern
and Southern Africa, Eastern Europe and central Asia (740) while countries in West and Central
Africa are lagging farther behind.
In a recent report by UNAIDS, antiretroviral therapy (ART) was accessible to only 26% of
children and 41% adults in Western and Central Africa, compared to 59% of children and 66%
adults who had access to ART in Eastern and Southern Africa in 2017. There was also almost
50% reduction in number of AIDS related deaths in West and Central Africa compared to Eastern
and Southern Africa (24% vs 42% respectively) (741). LICs carry 90% of global HIV burden,
and though there has been good progress to achieve 90-90-90 targets, pretreatment drug
resistance (PDR), non-adherence, and side effects associated with the current cART pose a great
threat. PDR and transmitted drug resistance (TDR) are on the rise in low-income countries (LICs)
(524,742) and the trend is not likely to change as countries implement World Health Organisation
(WHO) “Treat All” recommendation (743). It has been shown that increase of TDR results in
increased treatment switches (744) and positively correlates with cART roll out.
However, with limited treatment options, LIMCs are facing a dilemma of keeping patients on
treatment regimens that are deemed less optimal in high income countries. Lack of access to
drugs having higher genetic barrier to resistance contributes to the transmission of HIV resistant
virus, and limited virological monitoring affects early detection of drug resistant mutations
(DRMs). In LIMCs, first line (FL) cART commonly consists of two nucleoside reverse
transcriptase inhibitors (NRTIs) and one non-nucleoside reverse transcriptase inhibitors
(NNRTIs) commonly efavirenz (EFV) or nevirapine (NVP), with Lopinavir/Ritonavir (LPV/r)
or Atazanavir/Ritonavir (ATV/r) replacing NNRTI in second line (SL) therapy. More potent

177

drugs, Darunavir (DRV), Raltegravir (RAL), and Etravirine (ETR) are sparingly used and
commonly assessed by patients on salvage therapy and only in a few treatment centres.
Routine viral load monitoring, more potent drugs with fixed dose combinations with higher
genetic barrier to DR and adherence support are among areas of emphasis for rapid scale up and
better care of patients (745). However, these guidelines poor implementation in LMICs due to
lack of access to such drugs. It has been predicted that with no change of current regimens and
TDR increasing beyond 10%, there will be 890 000 new deaths, 450 000 new infections and
increase of cART cost of USD 6.5 billion by 2030 (746). I will discuss cART-based reasons
underlying these challenges and mitigation strategies.
The low genetic barrier to drug resistance
The commonly used NNRTIs in FL, (NVP/EFV), and (LPV/r) based SL therapy in LMICs, have
low genetic barrier to drug resistance compared to second generation NNRTIs, rilpivirine (RPV)
and ETR. High-level resistance between these drugs has been reported (513) which reduces
treatment response more so in patients with TDR. In Uganda for example, where NFV and EFV
are frequently used in first line, over 96% FL failures, 75% SL failures, and 49% RAL failures,
have NNRTIs resistance (540). In LMICs, over two-thirds of patients retain NNRTIs resistance
even many years on second line therapy (540), and Steegen et al. show that ≥ 65% of second line
failures had NNRTI mutation (747). Lack of HIV genotypic tests in most countries impedes early
detection of drug resistant variants. Already HIV drug resistance (HIVDR) in patients failing
LPV/r-based regimen has increased in Africa (748), and the number of patients who need second
line therapy is likely to increase from 0.5–3.0 million in 2020 to 0.8–4.6 million by 2030. From
2012, Tenofovir (TDF) is the primary NRTI for first-line cART after replacing zidovudine and
Stavudine. However, TDF resistance is on rise in LICs with 60% of patients who fail on TDF
based cART having TDF resistance (749) and this could be due to lack of baseline resistance
testing and prescription of TDF with EFV or NVP which have low genetic barrier to resistance.
Side effects of current regimens and poor adherence
Adherence to treatment is critical to a successful treatment response and may be influenced by
cART. It reverses occurrence of mortality, cART related morbidity, hospital visits, and improves
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immunological benefit of using ART. Improved adherence correlates with increased CD4 count
(750) and is the second-best predictor of disease progression (751). Poor adherence may be
associated with development of DRMs which may contribute to virological failure (VF). Studies
have shown that contrary to the belief that people in LICs are naturally non-adherent to treatment,
adherence can also be achieved in LICs (752).
The available cART in LICs is complex and associated with huge pill burden, short, and longterm medication side effects. Adherence was reported to be around 40% in a recent adolescent
study in 23 sub-Saharan Africa countries (753). The study shows non-adherence as a key problem
facing health care service in this region, and it is worsened by counselling services focusing on
outcomes of non-adherence not causes. Short message service and treatment supporters can
improve adherence in Africa (754), however, such strategies should go in hand with availability
of more potent drugs with better safety and tolerability profiles.
Though LPV/r is associated with more adverse gastrointestinal effects than ATV/r or
darunavir/ritonavir (755), it still forms the backbone of majority of second line treatment. It has
recently been shown to increase cardiovascular risks of myocardial infarction and stroke in HIV
infected patients in the US when compared to ATV/r (756). Boosted lopinavir and 2NRTI
combination has been removed from other regimens category because of huge pill burden and
greater toxicity (//aidsinfo.nih.gov/guidelines). HIVDR resulting in virologic failure during
second line treatments in LICs, has been attributed to poor adherence other than LPV/r activity
(615). In addition, the commonly used NNRTI, EFV, is associated with more adverse
gastrointestinal effects and rashes compared to RPV (757).
Pretreatment HIV-1 drug resistance
Globally, over 10.1% of HIV infected patients have baseline DR (758) and it is associated with
reduced treatment response in both HICs (759) and in LICs (760). Whereas prevalence of TDR
remained stable in HICs 2002–2010 at 8%, in LICs, there has been an increase in prevalence with
roll out of cART. In some countries, frequencies of NNRTI and NRTI DRMs in patients initiating
cART increased from 0% (2006–2007) (570), to 8.6% (2009– 2010) (571) and 15.4% (2014–
2016) (524). Despite an estimated prevalence of HIVDR of (7.4%) eight years after roll-out of
cART, the estimated annual increase of PDR in East Africa is 29% and 14% in South Africa and
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largely driven by high NNRTIs resistance (524). This confirms observed positive correlation
between cART roll out and increase of TDR in LICs (761). In a national survey by 11 LICs
countries on PDR, six out of 11 countries had prevalence of 10% and above which calls for
change of first line regimen as per WHO guidelines on HIVDR (524). TDR in LICs is more
common in NNRTIs (4.5%) and NRTIs (4%) than in protease inhibitors (2.8%) (760) unlike in
Europe with less baseline NNRTIs resistance (2.5–2.9%) (762,763). Baseline NNRTIs resistance
has been shown to cause more impact to treatment response (763). In LICs, prevalence of TDR
in children ≤ 12 years was found at 42.7% in those exposed to prevention of mother to child
transmission and 12.7% in unexposed (615). These countries now face the dilemma of
overcoming TDR and this is further complicated by lack of virological monitoring and
inaccessible genotyping test. Access to baseline genotyping test in the START trial (Strategic
Timing of Antiretroviral Treatment trial) was found to be 0.1% in Africa, 1.8% in South America
and 22% in Asia (22%) compared to over 80% in Europe (86.7%), United States (81.3%) and
Australia (89.9%) (758). Moreover, Sanger sequencing commonly used in these countries cannot
detect resistant variants below 20% and yet these variants been associated with treatment failure
(732). Only 22% of patients on cART in middle and LICs get access to virological monitoring
(764). This implies reliance on clinical and immunological monitoring which detect treatment
failure late and this leads to emergence of more complicated DRMs. In children below three
years, the impact of TDR is even stronger than in adults with odds ratio for failure of 15.3 and
has been associated with VF and acquired DR (574).
Strategies to address challenges associated with current cART and ways to make more
potent ART accessible in LICs
The most ART associated challenges in LICs are mainly rooted on HIV drug resistance among
other factors like the scarcity of treatment options for HIV infected patients in LICs more so on
those failing salvage therapy. Several recommendations can be made on how to address these
challenges and improve the lives of people living with HIV in LICs.
Firstly, patent licences should be closely monitored, and local drug manufacturers be encouraged.
Drug price is a major factor contributing to lack of access to these drugs especially due to patent
restrictions. Third line therapy may be 18 times and seven times more expensive than FL and SL
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treatment (765). However, with expired patent licenses and some expiring soon, it’s high time
for stake holders to advocate for voluntary and compulsory licensing among other strategies to
make these drugs more affordable. Basing on data on active pharmaceutical ingredients exported
in and out of India, the cost of treatment of HIV could be as low as USD 90 annually if substantial
generic competition is enforced (766).
HIV integrase inhibitor, DTG has shown superior genetic barrier to resistance 185 and potency
in patients with DRMs to RAL and elvitegravir. Once daily dosage of DTG can be given to
patients initiating cART and those failing RAL-based cART as once or twice daily dosage
depending on presence of integrase strand transfer inhibitors (INSTIs) mutations more so
Q148K/R/H. National Institutes of Health consultation recommends the use of tenofovir
alafenamide fumarate (TAF) which has less bone and kidney toxicity, and DTG, which may help
reduce drug resistance and improve adherence in LICs (767). The compound patent for DTG is
expected to expire in 2026 and with licenses on adults and pediatric formulations available to all
LICs through Medicines Patent Pool and ViiV Healthcare, market competition of local
manufacturers will likely increase access of drug in this setting. The initiative by International
drug purchase facility (UNITAID) to enrol DTG in some LICs of Kenya, Uganda and Nigeria
(768) should be encouraged. Neural tube birth defects in children born to mothers who were
exposed to DTG during pregnancy still raises concern to the safety of using DTG in pregnant
mothers. In a study that compared the birth outcomes between 1729 pregnant women on DTG
based ART and 4359 mothers on EFV in Botswana, found no significant differences in the
individual outcomes of stillbirth, neonatal death, preterm birth, very preterm birth, small for
gestational age, or very small gestational age, and severe side effects between patients on DTG
or EFV based ART (769). In a recent study looking at neural tube defects with DTG treatment in
women who started DTG from the time of conception, 426 (0.94%) infants born from mothers
who were initiated on DTG at conception, had neural birth defects of encephalocele,
myelomeningocele and iniencephaly compared to 11 300 (0.12%) infants born to mothers on
non-DTG regimen at conception (643). In same study, 2812 infants 208 who were born to
mothers who initiated DTG during pregnancy none had neural tube defects. These observations
suggest DTG associated neural tube defects may be dictated by the time of DTG initiation to
pregnant mothers. EFV based combinations may be the best choice for HIV infected pregnant
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women initiating ART but with potential reduction in use of NNRTIs based therapy in LICs,
more research is necessary in area of DTG use and pregnancy. The current statement of WHO on
potential risk of birth defects to infants born of mothers exposed to DTG at a time of inception,
is to initiate pregnant women to EFV based regimen which has confirmed efficacy and safety
profiles. DTG can only be used in childbearing women only when consistent contraception is
guaranteed and where other first line regimens can’t be used (770). To concur with this statement,
a recent study carried across 13 European countries and Thailand investigating association of
initiating EFV based ART during conception or first trimester of pregnancy and birth defects,
found no significant difference in prevalence of birth defects between EFV based and non-EFV
ART based groups (771). There are also reports linking the use of DTG to abnormal weight gain.
In a study assessing weight change in patients switching from EFV/3TC/ emitricabine (FTC) to
an INSTI-based regimen, greatest weight gain was observed in patients switched to
abacavir/3TC/DTG combination (772). Another study reviewing patient data from observational
SCOLTA project which was looking for drug related adverse effects in patients who started a
regimen containing, DTG, RAL, EVG, DRV or ETR, found no difference in body mass index
between patients on INSTIs-based ART and those on non-INSTIs regimens. However,
precautions should be taken when drawing conclusions as these were retrospective observational
studies. Therefore randomised, controlled studies are still needed to validate these observations.
ETR is largely patented in developing countries and with patent restrictions in leading
manufacturing nations of India, China and Brazil, no generic form is available. The patent on
novel compound expires in 2026 which is far beyond 2020 target and therefore more advocacies
required. DRV has high genetic barrier to resistance and is effective in patients with multidrug
resistant viruses (773) and was approved for use in treatment naïve adults in the US and European
Union. No high-level resistance to DRV was observed in national survey of 350 patients failing
second line therapy in South Africa [13]. At least three DRV associated mutations in combination
with multiple protease inhibitor associated mutations are necessary for DRV resistance to occur
(774) as shown in POWER 1 and 2 studies. In Madrid study of 1364 genotypes of cART naïve
and experienced patients for the impact of HIV subtype to DRV and tipranavir, all 29 non-subtype
B cART naïve patients had 100% susceptibility with DRV, and associated DRMs were more
common in HIV subtype B virus than in non-subtype B viruses (P < 0.001) (775). In context that
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majority of patients in LICs fail treatment with multiple DRMs, DRV provides best alternative
for those switching to second line therapy. Despite compound patent on DRV expiring in 2013
and patents on pseudopolymorph and/ or on the combination with ritonavir been granted to most
LICs, it is still not widely available in LICs. Countries should take advantage of availability of
license not to enforce patents on DRV in sub-Saharan Africa and least developed countries to
encourage wide manufacturing of generic forms to increase access.
Secondly, access to single pill formulations, drugs with high genetic barrier to resistance, and
those with promising results in clinical trials, should be made a priority. Indeed, high TDR
prevalence and lack of baseline resistance testing call for robust ART for patients starting on
treatment. RPV approved for treatment of NNRTIs-naïve patients is more tolerable and allows
simplification due to its single pill formulations of TDF/FTC/RPV, and TDF/TAF/RPV which
improves adherence and general response to treatment. ETR is approved for use in NNRTIs
experienced patients and has shown high potency to both wild type and NNRTIs resistant virus
(776). However, the high HIVDR due to Y181C after NVP exposure (777) necessitates genotypic
test before use of ETR as salvage therapy. Doravirine being tested in once daily
doravirine/3TC/TDF combination, is more tolerable, has high efficacy, and activity against
viruses with resistant mutations K103N and Y181C (778). It was non-inferior to EFV with 84%
vs 81% of patients in doravirine and EFV arms achieving undetectable VL after 48 weeks
respectively in phase 3 DRIVE-AHEAD study (779). Cabotegravir in advanced stages of clinical
trials, look promising for its use as long acting injectable with monthly or bimonthly
administration for pre-exposure prophylaxis use and treatment of HIV infection. It has shown
better safety profile and high acceptability in low risk uninfected participants in on-going clinical
trial HPTN 077 (780). Though there is possibility of cross resistance with already approved
INSTIs through Q148 pathway, it still provides better alternative. In addition to minimal side
effects, injectable cabotegravir provides convenience, flexibility, and fitness of patient lifestyles
which improves adherence. Bictegravir when given in a fixed-dose combination with FTC and
TAF, was not inferior to DTG given in DTG/FTC/TAF combination in treatment-naïve patients
after 48 weeks in phase 3 of Study 1490 (781). MK-8591 a long-acting nucleoside reverse
transcriptase translocation inhibitor has shown to be a promising long duration treatment and
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prophylaxis in phase 1b clinical study showing half-life of 2.3 to 56.8 and 78.5 to 128 hours with
patent and triphosphate form (MK-8591-TP) respectively (782).
Thirdly, HIV drug resistance surveillance should be emphasized as HIV drug resistance is one of
indicators of ART program. The impact of HIVDR has been attributed to be 15.6% of AIDS
deaths, 9.4% of new infections and 7.9% of ART costs from 2017 to 2021 (783). Therefore,
monitoring of all three forms of HIVDR, TDR, and PDR, and acquired drug resistance, by putting
in place checkpoints to track emerging and spreading HIVDR becomes very paramount. This
becomes even more crucial at a time when countries are starting all persons infected with HIV
on treatment and wide coverage of prevention of mother to child transmission programs. Much
as prevention of mother to child transmission program has drastically reduced the number of
babies acquiring HIV from their HIV positive mothers to < 10%, HIVDR especially to NNRTIs
has been increasing in children who still become HIV infected through prevention of mother to
child transmission program (Table 13). This is mostly attributed to initiating these children to
first line treatment with NNRTIs component due to lack of recommended protease inhibitors in
these settings. This therefore calls for more support to ART programs to ensure adequate and
reliable supply of child dosage combinations in these countries. It is not uncommon in some of
these settings for clinics to provide children formulations to adults by prescribing high dosage
where there is shortage of adult regimens. This form of practice affects pediatric HIV treatment
programs and may lead to treatment failure in adults.
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Table 14. Prevalence of HIV pretreatment drug resistance in pediatrics and adults in lowincome countries
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Abbreviations: CI: Confidence interval, HIV Human immune deficiency syndrome, PDR Pretreatment
drug resistance, NNRTIs Non-nucleoside reverse transcriptase inhibitors, PMTCT Prevention of
mothers to child transmission. -: not applicable

Much as the global burden of HIVDR especially in LICs is known and mitigation strategies well
stipulated, most of these countries are struggling to implement these strategies due to mostly
inadequate resources and lack of political will by governments in some countries. As a result,
there is insufficient monitoring of emerging drug resistance. The early warning indicators by
WHO for drug resistance provide alternative way of monitoring for emerging drug resistance in
this setting. They include offering optimal 300 treatment and according to the guidelines,
checking for percentage of patients with loss of follow up after 12 months, looking at percentage
of patients retained on ART at 12 months, patients with on time pill pick up/ clinic appointment,
drug stock outs, and looking at patients under viral load monitoring and suppression [56]. Much
as there are challenges in implementing this form of monitoring, it remains the feasible tool to
combat the challenge of rising HIVDR in LICs.
The HIVDR monitoring programs cannot afford not to prioritise population at most risk; girls
and women, men who have sex with other men, sex workers, drug users, and people in fishing
communities; who face a lot of stigma and discrimination. Surveillance on access of HIV services
to these vulnerable groups needs to be emphasized by ensuring that monitoring and evaluation
systems for reporting on implementation are functional. The generic form of DTG has allowed a
rapid roll out of this drug in most LICs. It is expected to change the landscape of HIVDR in LICs
due to its high genetic barrier to resistance, better tolerability, and safety profiles basing on
research commonly done in subtype B viruses. However, more research is still required to access
its efficacy in non-B subtypes since DTG associated drug resistance appears to be HIV subtype
specific. As such, there should be well articulated treatment guidelines and frequent surveillance
of resistance to guide its proper use in ART naïve and highly treatment experienced patients in
LICs.
Conclusions
The availability of more potent ART in LICs is of utmost importance if UNAIDS 2020 and 2030
goals are to be realized and sustained not only in HICs but also in LICs. Countries that have
embraced these targets will have to provide treatment to the increasing numbers of newly infected
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individuals expected to be 323 800 000 annually from 30 million in 2017 to 36.4 million in 2025
[37]. In countries which rolled out cART earlier, the prevalence of TDR increased by 12.3% in
span of four years and will likely keep increasing. With increased drug switches which is
associated with TDR, and acquired drug resistance common in LICs, more potent ART offer
therapeutic and preventive incentives which will reduce treatment costs and increase drug
options. In addition to making these drugs available, governments must address current loopholes
through their jurisdictions as well as addressing lack of political commitment and poor policy
decisions seen in some countries. It’s also imperative to strengthen quality service delivery in
terms of retention of patients to treatment, support for adherence to cART, patient follow up, and
adequate drug stocks to help achieve a free AIDS generation.
Roll out of second generation of INSTIs should be in concert with screening for INSTI
resistance in LIMCs
DTG is increasingly being rolled out in many LMICs though INSTIs still account to only about
1% of active first-line regimens in LMICs (698). Due to cost related factors, INSTIs are sparingly
used in LMICs with RAL-based regimens been used in highly treatment experienced with
multiple non-INSTIs mutations (628,699,700). HIVDR presents a huge challenge for future
treatments to outcome. Over 10-15% of patients will fail on ART each year due to HIVDR in
LMICs. HIVDR to INSTIs has been extensively analyzed and screened in subtype B HIV-1
which predominate infections of HICs. Contrary, HIVDR especially to INSTIs in non-B subtypes
is significantly lacking despite 90% of HIV-1 infections caused by non-B HIV-1 subtypes. To
understand the burden of HIVDR to INSTIs in non-B HIV-1 subtypes, we have screened for
DRMs associated with INSTIs in a cohort of Ugandan patients attending HIV-1 testing and
treatment services at Joint clinical research center (JCRC), Kampala, Uganda. Samples from a
total of 417 ART naïve and patients receiving different lines of ART were tested for presence of
INSTIs associated DRMs. In this cohort, INSTIs associated mutations were not observed in
INSTIs naïve (n=366) but in 47% of patients failing on RAL-based regimen (see chapter one).
Among the 47% with INSTIs DRMs, 4% (2/51) of patients (subtype A and D) harboring multiple
primary INSTIs DRMs conferring resistance DTG, a unique observation in both LMICs and
HICs. Nonetheless, DTG resistance was shown to be rare in LMICs which encourages its use
especially in ART naïve patients. Since 2018, TDF/3TC/DTG is now available in Uganda and
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most other LMICs. Basing on absence of DTG cross resistance in INSTIs naïve patients, DTG
provides best option for patients initiating ART and those failing RAL-based regimen in absence
of multiple INSTIs primary mutations.
INSTIs susceptibility/phenotypic studies have remained elusive in most LMICs including
Uganda. In this settings, national treatment guidelines rely almost exclusively on predictions from
HIV-1 resistance databases including International AIDS Society-USA Drug Resistance
Mutations Group (784) and Stanford HIV-1 drug resistance database (607) and yet our cohort of
patients had unique combination of DRMs not observed previously (421). INSTIs associated
resistance has been shown to be subtype-specific with some mutations preferentially selected in
HIV-1 types B compared to non-B subtypes; for instance, Q148 mutations are more frequent in
HIV-1 subtype B compared to non-B subtypes (492). Therefore, phenotypic assays to ascertain
the level of susceptibility of these patient viruses was critical to understanding INSTI resistance
in Uganda.
We phenotypically tested eleven HIV-1-derived integrases from subtype A, D, and recombinant
A/D infected patients (RAL-failures) for susceptibility to DTG, RAL and EVG. The viruses
harboring single RAL/EVG primary INSTIs mutations (~50%) remained susceptible to DTG
with fold-change in EC50 values nearly equivalent to that of wild-type. This may imply that in
such patients failing RAL-based regimens with single RAL/EVG primary INSTIs mutations,
twice daily DTG in combination with best possible NRTIs, may suppress the virus and improve
treatment

outcomes.

From

this

analysis,

we

confirmed

that

subtype

A

with

E138A/G140A/G163R/Q148R and subtype D with E138K/G140A/S147G/Q148K viruses on
RAL-based regimen are highly resistant to all currently available INSTIs in LMICs. The
complexity of these mutations and level of resistance, >100-fold DTG, and >1000-fold RAL and
EVG has not been observed before neither in subtype B or non-B HIV-1 infected individuals.
These results indicate that prescribing DTG-based combination to patients failing RAL-based
regimens with multiple primary INSTIs DRMs may not be beneficial. Therapeutic strategy of
keeping patients on regimens which sustains DRMs associated with reduced RC may help to
avoid continual immune deterioration especially in settings with limited ART options.
Interestingly, viruses carrying multiple INSTIs primary DRMs showed divergent viral fitness
with

E138K/G140A/S147G/Q148K

showing
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severely

impaired

viral

fitness

and

E138A/G140A/G163R/Q148R having nearly wild type replicative capacity. To maintain active
infection in patients with impaired replicative capacity, the loss could be compensated by
emergence of secondary mutations which restore viral fitness and/ or even increase fitness in
presence of INSTIs (671). It has also been shown that maintaining NRTI such as lamivudine
(3TC) or emitricabine (FTC) in a treatment regimen even with the emergence of associated drug
resistance helps to avoid increased viremia (785) and may even help to stabilize the FTC/3TC
resistant mutation, M184V which has been associated with delayed emergence of mutations
conferring resistance to DTG (455,785).
To further characterise INSTI resistance to different INSTIs in HIV-1 non-B subtypes, we tested
8 patient-derived viruses from our cohort for susceptibility to novel BIC and CAB INSTIs.
Recombinant viruses with HIV-1 IN harboring single or in combination with secondary
mutations remained susceptible to both BIC and CAB. Presence of multiple primary INSTIs
DRMs leads to increased resistance to CAB and BIC. Overall, BIC showed more potency against
viruses carrying various INSTIs-associated resistant mutations compared to CAB (p=0.03).
Though not currently indicated, BIC and CAB offer alternative to patients with single primary
and or in combination with secondary mutations especially in settings with limited HIV-1 drug
options.
Over the years, next generation sequencing has increasingly been used in clinical monitoring of
HIVDR especially in LMICs where treatment failure and interrupted therapy often results in
primary drug resistant viruses fading in the patient’s population below the limit of Sanger
sequencing detection. The role of minority variants remains to be elucidated in HICs, but in
Uganda, low frequency drug resistance variants may account for over 64% of HIV-1 patients
failing first-line and where dominant drug resistant HIV-1 was not detected (732). In our
screening study for INSTIs DRMs, we observed that over 50% of patients failing RAL-based
regimens in Uganda lacked signature INSTIs DRMs, either as dominant in the intrapatient HIV1 population or low frequency variants. Using deep-sequencing and SVM analysis, we identified
I203M and I208L mutations in the HIV-1 IN coding region of subtype A and D infected patients
failing RAL but we failed to confirm that these mutations conferred resistance to RAL and DTG.
From structural analysis, I203 and I208 residues are found in C-terminal domain and quite distal
from the HIV-1 IN active site. The I203M and I208L were not linked to any other IN mutations
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or polymorphisms but new findings suggest that these mutations may have co-evolved with
changes in the HIV-1 IN recognition sequence in the proviral DNA (upstream start of U3 and
downstream end of U5). The combination of the I203M and/or I208L mutations with mutations
in the U3 and U5 sequence may confer resistance to INSTIs by increasing the binding of viral or
host DNA, increased dinucleotide cleavage, and/or increased integration efficiency. It is
important to note that both I203M and/or I208L cause replication fitness loss in subtype A, B, or
D IN coding region within an NL4-3 backbone but we had not yet sequenced and compared the
U3 and U5 LTR sequences nor have we introduced the patient-specific, subtype-specific U3 and
U5 sequences linked with the I203M and/or I208L IN sequences. We are currently exploring
this possibility leading to INSTI resistance and that would confirm the high odds ratio that I203M
and I208L are linked to INSTI resistance in about 1/2 to 1/3rd of the subtype A and D infected
patients failing a RAL-based treatment regimen in Uganda.
In a nutshell, emergence of INSTIs resistance appears in part to be subtype specific with even
N155H reducing DTG susceptibility more so in subtype A and D than in subtype B HIV-1.
Surveillance for INSTIs-associated resistance remains critical in LMICs for early detection of
resistance mutations. Early detection of virological failure, detection of novel INSTIs-DRMs, and
increased HIVDR surveillance remains critical in LMICs to avoid the irreversible and detrimental
effects of HIVDR.
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